

METHODS FOR PROSTATE CANCER DETECTION AND TREATMENT

Cross-Reference to Related Applications

[0001] This application claims priority to, and the benefit of, U.S. Provisional Application No. 62/633,675, filed February 22, 2018, the contents of which is incorporated herein by reference in its entirety.

Sequence Listing

[0002] The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on February 19, 2019, is named "LBIO-005_001WO_SeqList.txt" and is 299 KB in size.

Field of the Invention

[0003] The present invention relates to prostate cancer detection.

Background of the Invention

[0004] Prostate cancer (PCA) is the fourth most commonly diagnosed cancer worldwide and the second most common cancer in men. Although the incidence and prevalence have been decreasing, ~200,000 men will be diagnosed in the USA with PCA annually. Multiple factors including age and family history, genetic susceptibility and ethnicity all contribute to the high incidence of the disease. While 90% of PCA are diagnosed while they are localized (non-disseminated), the clinical behavior of tumors is highly variable and ranges from indolence that can be monitored through watchful waiting or active surveillance (e.g., biomarkers and 6 monthly digital rectal examination) to malignant evolution and androgen-resistant disease, metastatic dissemination and death.

[0005] Multiple risk stratification systems have been developed that combines clinical data and pathological information e.g., Gleason score. These, including the more recently developed next generation tools, are only ~70% accurate for predicting outcome.

[0006] Molecular genetic information is increasingly being used to inform pathology and better subtype cancers. This information has been used as both prognostic tools as well as to stratify patients for different therapeutic interventions. Prostate cancers have been examined and mutations, DNA copy number alterations, rearrangements and gene fusions have all been identified. These may correlate with some pathological features. For example, low-Gleason tumors have few DNA copy number alterations while high grade tumors exhibit significant genome-wide

copy number alterations. Somatic point mutations in contrast are relatively uncommon with the frequency of mutations ranging from 1% (*IDH1*) to 11% (*SPOP*). The most common abnormality is androgen-regulated fusions of *ERG* and other *ETS* family members (~50% of tumors). However, fusion-bearing tumors do not have a significantly different prognosis to fusion-negative tumors after prostatectomy. Androgen receptor variant 7 (*AR-V7*) in contrast is implicated in the progression to castration resistance prostate cancer (CRPC) and is considered potentially useful as a treatment selection biomarker. Overall, however, there is an incomplete understanding of the molecular mechanisms underpinning PCA pathogenesis and an absence of molecular-based biomarkers that can be used to predict sensitivity to therapeutic agents. Consequently, the development of diagnostic methods that more accurately define disease status, identify sensitivity to therapy and can ultimately be used to better monitor disease progression, is critical.

[0007] Surveillance remains a cornerstone approach to monitor PCA and detect recurrence at an early stage. After potentially curative resection, monitoring can be undertaken through measurement of blood biomarkers and/or imaging like CT to detect asymptomatic metastatic disease earlier. The current biomarker used for monitoring is prostate specific antigen (PSA) (also gamma-seminoprotein or kallikrein-3). This glycoprotein enzyme is encoded by the *KLK3* gene and is secreted by epithelial cells in the prostate. It, however, is not a unique indicator of prostate cancer, but may also detect prostatitis or benign prostatic hyperplasia (BPH). Use of PSA in isolation results in either unnecessary biopsies for men without cancer or an under diagnosis of men with significant disease. This is based on the low sensitivity (20-40%) and specificity (70-90%) ranges with a consequent positive predictive value of only 25-40%. The United States Preventive Services Task Force (USPSTF) does not recommend PSA use for prostate cancer. PSA, however, is included in clinical nomograms e.g., the UCSF-CAPRA score for prostate cancer risk, which has some utility in predicting disease free survival after surgery.

[0008] There remains a need for biomarker-based tools to accurately diagnose PCA.

Summary of the Invention

[0009] The present disclosure provides a method for detecting a prostate cancer in a subject in need thereof, the method comprising: determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise

AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, XPC, and a housekeeping gene; normalizing the expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A*, and *XPC*; inputting each normalized expression level into an algorithm to generate a score; comparing the score with a first predetermined cutoff value; and identifying the presence of a prostate cancer in the subject when the score is equal to or greater than the first predetermined cutoff value or identifying the absence of a prostate cancer in the subject when the score is less than the first predetermined cutoff value.

[0010] The present disclosure provides a method for detecting a prostate cancer in a subject in need thereof, the method comprising: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized

expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXVD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; (c) inputting each normalized expression level into an algorithm to generate a score; (d) comparing the score with a first predetermined cutoff value; and (e) producing a report, wherein the report identifies the presence of a prostate cancer in the subject when the score is equal to or greater than the first predetermined cutoff value or identifies the absence of a prostate cancer in the subject when the score is less than the first predetermined cutoff value.

[0011] The present disclosure also provides a method for determining whether a prostate cancer in a subject is stable or progressive, the method comprising: determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXVD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXVD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXVD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; inputting each normalized expression level into an algorithm to generate a score; comparing the score with a first predetermined cutoff value; and identifying that the prostate cancer is progressive when the score is equal to or greater than the first predetermined cutoff value or identifying that the prostate cancer is stable when the score is less than the first predetermined cutoff value.

[0012] The present disclosure provides a method for determining whether a prostate cancer in a subject is stable or progressive, the method comprising: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; (c) inputting each normalized expression level into an algorithm to generate a score; (d) comparing the score with a first predetermined cutoff value; and (e) producing a report, wherein the report identifies that the prostate cancer is progressive when the score is equal to or greater than the first predetermined cutoff value or identifies that the prostate cancer is stable when the score is less than the first predetermined cutoff value.

[0013] The present disclosure also provides a method for determining whether a prostate cancer in a subject is low or high grade, the method comprising: determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*,

C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC; inputting each normalized expression level into an algorithm to generate a score; comparing the score with a first predetermined cutoff value; and identifying that the prostate cancer is high grade when the score is equal to or greater than the first predetermined cutoff value or identifying that the prostate cancer is low grade when the score is less than the first predetermined cutoff value.

[0014] The present disclosure provides a method for determining whether a prostate cancer in a subject is low or high grade, the method comprising: determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; normalizing the expression level of each of AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC; inputting each normalized expression

level into an algorithm to generate a score; comparing the score with a first predetermined cutoff value; and producing a report, wherein the report identifies that the prostate cancer is high grade when the score is equal to or greater than the first predetermined cutoff value or identifies that the prostate cancer is low grade when the score is less than the first predetermined cutoff value.

[0015] The present disclosure also provides a method for determining whether a prostate cancer in a subject is a low Gleason score (≤ 6) prostate cancer or a high Gleason score (≥ 7) prostate cancer, the method comprising: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; (c) inputting each normalized expression level into an algorithm to generate a score; (d) comparing the score with a first predetermined cutoff value; and (e) identifying that the prostate cancer is a high Gleason score prostate cancer when the score is equal to or greater than the first predetermined cutoff value or identifying that the prostate cancer is a low Gleason score prostate cancer when the score is less than the first predetermined cutoff value.

[0016] The present disclosure provides a method for determining whether a prostate cancer in a subject is a low Gleason score (≤ 6) prostate cancer or a high Gleason score (≥ 7) prostate cancer, the method comprising: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect

the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; (c) inputting each normalized expression level into an algorithm to generate a score; (d) comparing the score with a first predetermined cutoff value; and (e) producing a report, wherein the report identifies that the prostate cancer is a high Gleason score prostate cancer when the score is equal to or greater than the first predetermined cutoff value or identifies that the prostate cancer is a low Gleason score prostate cancer when the score is less than the first predetermined cutoff value.

[0017] The present disclosure also provides a method for determining the completeness of surgery in a subject having a prostate cancer, the method comprising: determining the expression level of at least 38 biomarkers from a test sample from the subject after the surgery by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*,

TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC; inputting each normalized expression level into an algorithm to generate a score; comparing the score with a first predetermined cutoff value; and identifying that the prostate cancer is not completely removed when the score is equal to or greater than the first predetermined cutoff value or identifying that the prostate cancer is completely removed when the score is less than the first predetermined cutoff value.

[0018] The present disclosure provides a method for determining the completeness of surgery in a subject having a prostate cancer, the method comprising: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject after the surgery by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; (c) inputting each normalized expression level into an algorithm to generate a score; (d) comparing the score with a first predetermined cutoff value; and (e) producing a report, wherein the report identifies that the prostate cancer is not completely removed when the

score is equal to or greater than the first predetermined cutoff value or identifies that the prostate cancer is completely removed when the score is less than the first predetermined cutoff value.

[0019] The present disclosure also provides a method for differentiating benign prostate hyperplasia from a prostate cancer in a subject having an enlarged prostate, the method comprising: determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; inputting each normalized expression level into an algorithm to generate a score; comparing the score with a first predetermined cutoff value; and identifying the presence of a prostate cancer in the subject when the score is equal to or greater than the first predetermined cutoff value or identifying the presence of benign prostate hyperplasia in the subject when the score is less than the first predetermined cutoff value.

[0020] The present disclosure provides a method for differentiating benign prostate hyperplasia from a prostate cancer in a subject having an enlarged prostate, the method comprising: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*,

SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, XPC, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A*, and *XPC*; (c) inputting each normalized expression level into an algorithm to generate a score; (d) comparing the score with a first predetermined cutoff value; and (e) producing a report, wherein the report identifies the presence of a prostate cancer in the subject when the score is equal to or greater than the first predetermined cutoff value or identifies the presence of benign prostate hyperplasia in the subject when the score is less than the first predetermined cutoff value.

[0021] The present disclosure provides a method for evaluating the response of a subject having a prostate cancer to a first therapy, the method comprising: (1) at a first time point: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN,*

KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC; (c) inputting each normalized expression level into an algorithm to generate a first score; (2) at a second time point, wherein the second time point is after the first time point and after the administration of the first therapy to the subject; (d) determining the expression level of the at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers; (e) normalizing the expression level of each of AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC; (f) inputting each normalized expression level into an algorithm to generate a second score; (3) comparing the first score with the second score; and (4) identifying the subject as responsive to the first therapy when the second score is significantly decreased as compared to the first score or identifying the subject as not responsive to the first therapy when the second score is not significantly decreased as compared to the first score.

[0022] The preceding method can further comprise continuing to administer the first therapy to the subject when the second score is significantly decreased as compared to the first score. The preceding method can further comprise discontinuing administration of the first therapy to the subject when the second score is not significantly decreased as compared to the first score. The preceding method can further comprise administering a second therapy to the subject when the second score is not significantly decreased as compared to the first score.

[0023] The present disclosure provides a method for evaluating the response of a subject having a prostate cancer to a first therapy, the method comprising: (1) at a first time point: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting

the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; (c) inputting each normalized expression level into an algorithm to generate a first score; (2) at a second time point, wherein the second time point is after the first time point and after the administration of the therapy to the subject: (d) determining the expression level of the at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers; (e) normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; (f) inputting each normalized expression level into an algorithm to generate a second score; (3) comparing the first score with the second score; and (4) producing a report, wherein the report identifies that the subject is responsive to the first therapy when the second score is significantly

decreased as compared to the first score or identifies that the subject is not responsive to the first therapy when the second score is not significantly decreased as compared to the first score.

[0024] The preceding method can further comprise continuing to administer the first therapy to the subject when the second score is significantly decreased as compared to the first score. The preceding method can further comprise discontinuing administration of the first therapy to the subject when the second score is not significantly decreased as compared to the first score. The preceding method can further comprise administering a second therapy to the subject when the second score is not significantly decreased as compared to the first score.

[0025] The present disclosure also provides a method for treating a prostate cancer in a subject in need thereof, the method comprising: determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYP7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYP7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYP7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; inputting each normalized expression level into an algorithm to generate a score; comparing the score with a first predetermined cutoff value; and administering at least a first therapy to the subject when the score is equal to or greater than the first predetermined cutoff value or identifies the absence of a prostate cancer in the subject when the score is less than the first predetermined cutoff value.

[0026] In the methods of the present disclosure, the housekeeping gene can be selected from the group consisting of *ALG9*, *SEPN*, *YWHAQ*, *VPS37A*, *PRRC2B*, *DOPEY2*, *NDUFB11*, *ND4*, *MRPL19*, *PSMC4*, *SF3A1*, *PUM1*, *ACTB*, *GAPD*, *GUSB*, *RPLP0*, *TFRC*, *MORF4L1*, *18S*, *PPIA*, *PGK1*, *RPL13A*, *B2M*, *YWHAZ*, *SDHA*, *HPRT1*, *TOX4* and *TPT1*. The housekeeping gene can be *TOX4*.

[0027] In the methods of the present disclosure, a predetermined cutoff value can be at least 33% on a scale of 0-100%, or at least 50% on a scale of 0-100%. A first predetermined cutoff value can be at least 33% on a scale of 0-100%, or at least 50% on a scale of 0-100%.

[0028] The methods of the present disclosure can further comprise administering a therapy to a subject. The methods of the present disclosure can further comprise administering a first therapy to a subject. The methods of the present disclosure can further comprise administering a second therapy to a subject.

[0029] In the methods of the present disclosure, a therapy can comprise active surveillance, radiation therapy, surgery, cryotherapy, hormone therapy, chemotherapy, vaccine treatment, bone-directed treatment, or any combination thereof. A first therapy can comprise active surveillance, radiation therapy, surgery, cryotherapy, hormone therapy, chemotherapy, vaccine treatment, bone-directed treatment, or any combination thereof. A second therapy can comprise active surveillance, radiation therapy, surgery, cryotherapy, hormone therapy, chemotherapy, vaccine treatment, bone-directed treatment, or any combination thereof.

[0030] In some aspects, hormone therapy can comprise androgen suppression therapy. In some aspects, chemotherapy can comprise docetaxel, cabazitaxel, mitoxantrone, estramustine, or a combination thereof. In some aspects, a vaccine treatment can comprise Sipuleucel-T. In some aspects, a bone-directed treatment can comprise a bisphosphonate, denosumab, a corticosteroid, or a combination thereof.

[0031] In the methods of the present disclosure, an algorithm can be XGB, RF, glmnet, cforest, CART, treebag, knn, nnet, SVM-radial, SVM-linear, NB, or mlp. An algorithm can be XGB.

[0032] In the methods of the present disclosure, a first time point can be either prior to or after the administration of a therapy to the subject. A first time point can be either prior to or after the administration of a first therapy to the subject.

[0033] In the methods of the present disclosure, a second score is significantly decreased as compared to the first score when the second score is at least 25% less than the first score.

[0034] The methods of the present disclosure can have a sensitivity of at least 92%. The methods of the present disclosure can have a specificity of at least 95%.

[0035] In the methods of the present disclosure, at least one of the at least 38 biomarkers can be RNA, cDNA, or protein.

[0036] In the methods of the present disclosure, when the biomarker is RNA, the RNA can be reverse transcribed to produce cDNA, and the produced cDNA expression level can be detected.

[0037] In the methods of the present disclosure, the expression level of a biomarker can be detected by forming a complex between the biomarker and a labeled probe or primer.

[0038] In the methods of the present disclosure, when the biomarker is protein, the protein can be detected by forming a complex between the protein and a labeled antibody. The label can be a fluorescent label.

[0039] In the methods of the present disclosure, when the biomarker is RNA or cDNA, the RNA or cDNA can be detected by forming a complex between the RNA or cDNA and a labeled nucleic acid probe or primer. For example, a label can be a fluorescent label. A complex between the RNA or cDNA and the labeled nucleic acid probe or primer can be a hybridization complex.

[0040] In the methods of the present disclosure, a predetermined cutoff value can be derived from a plurality of reference samples obtained from subjects not having or not diagnosed with a neoplastic disease. The neoplastic disease can be prostate cancer.

[0041] In the methods of the present disclosure, a test sample can be blood, serum, plasma, or neoplastic tissue. A reference sample can be blood, serum, plasma, or non-neoplastic tissue.

[0042] In the methods of the present disclosure, a subject can have at least one prostate cancer symptom. In the methods of the present disclosure, a subject can have a predisposition or familial history for developing a prostate cancer.

[0043] In the methods of the present disclosure, a subject can have been previously diagnosed with a prostate cancer and is tested for prostate cancer recurrence.

[0044] In the methods of the present disclosure, a subject can be human.

[0045] Any of the above aspects can be combined with any other aspect.

[0046] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. In the Specification, the singular forms also include the plural unless the context clearly dictates otherwise; as examples, the terms “a,” “an,” and “the” are understood to be singular or

plural and the term “or” is understood to be inclusive. By way of example, “an element” means one or more element. Throughout the specification the word “comprising,” or variations such as “comprises” or “comprising,” will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from the context, all numerical values provided herein are modified by the term “about.”

[0047] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, illustrative methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications cited in this specification are incorporated herein by reference in their entireties.

Brief Description of the Drawings

[0048] FIGs. 1A-1B are graphs showing visualisation of 30 putative marker genes identified by the Random Forest algorithm in the derivation cohort of $n = 595$ tissue samples. (FIG. 1A) Expression in E-GEOD-46691. (FIG. 1B) Expression in E-GEOD-46602.

[0049] FIG. 2 is a scatter plot of average predictive importance vs. Kruskal Wallis p-values. Vertical and horizontal lines represent p-value of 0.05 and median Predictive Importance value respectively.

[0050] FIG. 3 is a graph showing hierarchical clustering of gene expression identified that PCA tumor tissue and control tissue were separately clustered. Gene expression was significantly higher in the PCA tissue.

[0051] FIG. 4 is a graph showing clustering of normalized gene expression separates prostate-derived cell lines into their tissue of origin (i.e., normal, localized, metastatic).

[0052] FIG. 5 is a graph showing gene expression in the control ($n=201$), BPH (prostate hyperplasia, $n=26$) and prostate cancer cases ($n=125$). Identified expression levels were

significantly ($p < 0.0001$) elevated in cases ($63 \pm 19\%$) versus benign prostatic hyperplasia (BPH: $17 \pm 13\%$) and controls ($8 \pm 9\%$).

[0053] FIG. 6 is a graph showing receiver operator curve analysis. The AUROC was 0.97 and the Youden J index was 0.94. The Z-statistic was highly significant (38.9; $p < 0.0001$).

[0054] FIG. 7 is a graph showing the metrics of the ProstaTest for determining PCA ranged 92-99%.

[0055] FIG. 8 is a Probit risk assessment plot that identifies a ProstaTest score >30 was 60% accurate for predicting prostate cancer in a blood sample. This was increased to $>80\%$ at a test scores ≥ 34 . Dotted lines represent the 95% confidence interval.

[0056] FIG. 9 is a graph showing receiver operator curve analysis comparing the ProstaTest with measurements of PSA for predicting high grade ($\geq$ Gleason 7) compared to low grade (Gleason 5+6) tumors. The AUROC was 0.98 and the Youden J index was 0.87 for the ProstaTest. For PSA, the AUROC was 0.64 and the Youden J index was 0.42. The ProstaTest was significantly better than PSA for predicting grade (Z-statistic: 3.05, $p = 0.002$).

[0057] FIG. 10 is a graph showing the effect of surgery on the ProstaTest. Levels prior to surgery are elevated ($80 \pm 18\%$). Surgery reduced levels to $22 \pm 7\%$ ($p < 0.0001$), not different to control levels.

[0058] FIG. 11 is a graph showing the effect of treatment on the ProstaTest. Levels prior to treatment are elevated ($74 \pm 18\%$). In those who responded to hormone therapy, levels were reduced to $18 \pm 7\%$ ($p < 0.0001$). In those requiring chemotherapy, levels were reduced to $27 \pm 10\%$ ($p < 0.001$).

Detailed Description of the Invention

[0059] The details of the invention are set forth in the accompanying description below.

[0060] Described herein are methods to quantitate (score) the circulating prostate cancer molecular signature with high sensitivity and specificity for purposes including, but not limited to, detecting a prostate cancer, determining whether a prostate cancer is stable or progressive, differentiating benign prostate hyperplasia (BPH) from prostate cancer, determining the completeness of surgery, and evaluating the response to a prostate cancer therapy. Specifically, the present invention is based on the discovery that the expression levels of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*,

MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC, normalized by the expression level of a housekeeping gene, are elevated in subjects having prostate cancers as compared to healthy subjects or subjects with BPH.

[0061] Symptoms of prostate cancers include problems urinating, blood in the urine or semen, trouble getting an erection, pain in the hips, back (spine), chest (ribs), or other areas from cancer that has spread to bones, weakness or numbness in the legs or feet, or even loss of bladder or bowel control from cancer pressing on the spinal cord.

[0062] As described in the examples, measurements of circulating prostate cancer transcripts – the ProstaTest – diagnoses prostate cancer and decreases in the ProstaTest score in blood correlates with the efficacy of therapeutic interventions such as surgery and chemotherapy. A targeted gene expression profile of prostate cancer RNA can be isolated from the peripheral blood of patients. The expression profile is evaluated in an algorithm and converted to an output (score). It can diagnose and identify active disease and provide an assessment of treatment responses in conjunction with standard clinical assessment and imaging.

[0063] Accordingly, the present disclosure provides a method for detecting a prostate cancer in a subject in need thereof, the method comprising: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1,*

SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC; (c) inputting each normalized expression level into an algorithm to generate a score; (d) comparing the score with a first predetermined cutoff value; and (e) identifying the presence of a prostate cancer in the subject when the score is equal to or greater than the first predetermined cutoff value or identifying the absence of a prostate cancer in the subject when the score is less than the first predetermined cutoff value.

[0064] In some aspects of the preceding method, step (e) can comprise producing a report, wherein the report identifies the presence of a prostate cancer in the subject when the score is equal to or greater than the first predetermined cutoff value or identifies the absence of a prostate cancer in the subject when the score is less than the first predetermined cutoff value.

[0065] In some aspects of the preceding method, the first predetermined cutoff value can be 33% on a scale of 0-100%.

[0066] In some aspects, the preceding method can further comprise administering to the subject a first therapy. The preceding method can further comprise administering to the subject a first therapy when the score is equal to or greater than the predetermined cutoff value.

[0067] The present disclosure also provides a method for determining whether a prostate cancer in a subject is stable or progressive, the method comprising: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1,*

SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC; (c) inputting each normalized expression level into an algorithm to generate a score; (d) comparing the score with a first predetermined cutoff value; and (e) identifying that the prostate cancer is progressive when the score is equal to or greater than the first predetermined cutoff value or identifying that the prostate cancer is stable when the score is less than the first predetermined cutoff value.

[0068] In some aspects of the preceding method, step (e) can comprise producing a report, wherein the report identifies that the prostate cancer is progressive when the score is equal to or greater than the first predetermined cutoff value or identifies that the prostate cancer is stable when the score is less than the first predetermined cutoff value.

[0069] In some aspects of the preceding method, the first predetermined cutoff value can be 50% on a scale of 0-100%.

[0070] In some aspects, the preceding method can further comprise administering to the subject a first therapy. The preceding method can further comprise administering to the subject a first therapy when the score is equal to or greater than the predetermined cutoff value.

[0071] The present disclosure also provides a method for determining whether a prostate cancer in a subject is low or high grade, the method comprising: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A,*

REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC; (c) inputting each normalized expression level into an algorithm to generate a score; (d) comparing the score with a first predetermined cutoff value; and (e) identifying that the prostate cancer is high grade when the score is equal to or greater than the first predetermined cutoff value or identifying that the prostate cancer is low grade when the score is less than the first predetermined cutoff value.

[0072] In some aspects of the preceding method, step (e) can comprise producing a report, wherein the report identifies that the prostate cancer is high grade when the score is equal to or greater than the first predetermined cutoff value or identifies that the prostate cancer is low grade when the score is less than the first predetermined cutoff value.

[0073] In some aspects of the preceding method, the first predetermined cutoff value can be 50% on a scale of 0-100%.

[0074] In some aspects, the preceding method can further comprise administering to the subject a first therapy. The preceding method can further comprise administering to the subject a first therapy when the score is equal to or greater than the predetermined cutoff value.

[0075] In some aspects, a low grade prostate cancer is a prostate cancer with a Gleason score that is less than or equal to 6. In some aspects, a high grade prostate cancer is a prostate cancer with a Gleason score that is greater than or equal to 7.

[0076] The Gleason Grading System is commonly used in the art as a parameter of prognosis, often used in combination with other prognostic factors or tests, for prostate cancer. Prostate biopsy samples are examined, for example, by microscope, and a Gleason score is determined by a pathologist, based on the architectural pattern of the prostate tumor. The Gleason score is based upon the degree of loss of the normal glandular tissue architecture (i.e. shape, size and differentiation of the glands). The sample is assigned a grade to the most common tumor pattern, and a second grade to the next most common tumor pattern. There may be a primary or most common pattern and then a secondary or second most common pattern which can be identified; alternatively, there may be only a single grade. Gleason patterns are associated with the following features: Pattern 1 - The cancerous prostate closely resembles normal prostate tissue. The glands are small, well- formed, and closely packed; Pattern 2 - The tissue still has well-formed glands, but they are larger and have more tissue between them; Pattern 3 - The tissue still has recognizable glands, but the cells are darker. At high magnification, some of these cells have left the glands and

are beginning to invade the surrounding tissue; Pattern 4 - The tissue has few recognizable glands. Many cells are invading the surrounding tissue; Pattern 5 - The tissue does not have recognizable glands. There are often just sheets of cells throughout the surrounding tissue. The two grades are added together to get a Gleason Score, also known as a Gleason sum.

[0077] The present disclosure also provides a method for determining whether a prostate cancer in a subject is a low Gleason score (≤ 6) prostate cancer or a high Gleason score (≥ 7) prostate cancer, the method comprising: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; (c) inputting each normalized expression level into an algorithm to generate a score; (d) comparing the score with a second predetermined cutoff value; and (e) identifying that the prostate cancer is a high Gleason score prostate cancer when the score is equal to or greater than the first predetermined cutoff value or identifying that the prostate cancer is a low Gleason score prostate cancer when the score is less than the first predetermined cutoff value.

[0078] In some aspects of the preceding method, step (e) can comprise producing a report, wherein the report identifies that the prostate cancer is a high Gleason score prostate cancer when the score is equal to or greater than the first predetermined cutoff value or identifies that the prostate cancer

is a low Gleason score prostate cancer when the score is less than the second predetermined cutoff value,

[0079] In some aspects of the preceding method, the first predetermined cutoff value can be 50% on a scale of 0-100%.

[0080] In some aspects, the preceding method can further comprise administering to the subject a first therapy. The preceding method can further comprise administering to the subject a first therapy when the score is equal to or greater than the predetermined cutoff value.

[0081] The present disclosure also provides a method for determining the completeness of surgery in a subject having a prostate cancer, the method comprising: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject after the surgery by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; (c) inputting each normalized expression level into an algorithm to generate a score; (d) comparing the score with a first predetermined cutoff value; and (e) identifying that the prostate cancer is not completely removed when the score is equal to or greater than the first predetermined cutoff value or identifying that the prostate cancer is completely removed when the score is less than the first predetermined cutoff value.

[0082] In some aspects of the preceding method, step (e) can comprise producing a report, wherein the report identifies that the prostate cancer is not completely removed when the score is equal to

or greater than the first predetermined cutoff value or identifies that the prostate cancer is completely removed when the score is less than the first predetermined cutoff value.

[0083] In some aspects of the preceding method, the first predetermined cutoff value can be 33% on a scale of 0-100%.

[0084] In some aspects, the preceding method can further comprise administering to the subject a first therapy. The preceding method can further comprise administering to the subject a first therapy when the score is equal to or greater than the predetermined cutoff value.

[0085] The present disclosure also provides a method for differentiating benign prostate hyperplasia from a prostate cancer in a subject having an enlarged prostate, the method comprising: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; (c) inputting each normalized expression level into an algorithm to generate a score; (d) comparing the score with a first predetermined cutoff value; and (e) identifying the presence of a prostate cancer in the subject when the score is equal to or greater than the first predetermined cutoff value or identifying the presence of benign prostate hyperplasia in the subject when the score is less than the first predetermined cutoff value.

[0086] In some aspects of the preceding method, step (e) can comprise producing a report, wherein the report identifies the presence of a prostate cancer in the subject when the score is equal to or greater than the first predetermined cutoff value or identifies the presence of benign prostate hyperplasia in the subject when the score is less than the first predetermined cutoff value,

[0087] In some aspects of the preceding method, the first predetermined cutoff value can be 33% on a scale of 0-100%.

[0088] In some aspects, the preceding method can further comprise administering to the subject a first therapy. The preceding method can further comprise administering to the subject a first therapy when the score is equal to or greater than the predetermined cutoff value.

[0089] The present disclosure provides a method for treating a prostate cancer in a subject in need thereof, the method comprising: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; (c) inputting each normalized expression level into an algorithm to generate a score; (d) comparing the score with a first predetermined cutoff value; and (e) administering at least a first therapy to the subject when the score is equal to or greater than the first predetermined cutoff value or identifies the absence of a prostate cancer in the subject when the score is less than the first predetermined cutoff value.

[0090] The present disclosure also provides a method for evaluating the response of a subject having a prostate cancer to a first therapy, the method comprising: (1) at a first time point: (a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXFD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene; (b) normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXFD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXFD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*; (c) inputting each normalized expression level into an algorithm to generate a first score; (2) at a second time point, wherein the second time point is after the first time point and after the administration of the first therapy to the subject: (d) determining the expression level of the at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers; (e) normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXFD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXFD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*,

TRIM29, *UNC45A*, and *XPC*; (f) inputting each normalized expression level into an algorithm to generate a second score; (3) comparing the first score with the second score; and (4) identifying the subject as responsive to the first therapy when the second score is significantly decreased as compared to the first score or identifying the subject as not responsive to the first therapy when the second score is not significantly decreased as compared to the first score.

[0091] In some aspects of the preceding method, step (4) can comprise producing a report, wherein the report identifies that the subject is responsive to the first therapy when the second score is significantly decreased as compared to the first score or identifies that the subject is not responsive to the first therapy when the second score is not significantly decreased as compared to the first score.

[0092] In some aspects, the preceding method can further comprise continuing to administer the first therapy to the subject when the second score is significantly decreased as compared to the first score. The preceding method can further comprise discontinuing administration of the first therapy to the subject when the second score is not significantly decreased as compared to the first score. The preceding method can further comprise administering a second therapy to the subject when the second score is not significantly decreased as compared to the first score.

[0093] In some aspects of the preceding method, the second score is significantly decreased as compared to the first score when the second score is at least about 10% less than the first score, or at least about 20% less than the first score, or at least about 25% less than the first score, or at least about 30% less than the first score, at least about 40% less than the first score, at least about 50% less than the first score, or at least about 60% less than the first score, or at least about 70% less than the first score, or at least about 75% less than the first score, or at least about 80% less than the first score, or at least about 90% less than the first score, or at least about 95% less than the first score or at least about 99% less than the first score. In some aspects, when the second score is not significantly decreased as compared to the first score, the subject is considered to be not responsive to the therapy.

[0094] In some aspects of the preceding method, a first time point can be prior to the administration of a first therapy to the subject. A first time point can be after the administration of a first therapy to the subject.

[0095] In some aspects of the methods of the present disclosure, housekeeping genes include, but are not limited to, *ALG9*, *SEPN*, *YWHAQ*, *VPS37A*, *PRRC2B*, *DOPEY2*, *NDUFB11*, *ND4*,

MRPL19, PSMC4, SF3A1, PUM1, ACTB, GAPD, GUSB, RPLP0, TFRC, MORF4L1, 18S, PPIA, PGK1, RPL13A, B2M, YWHAZ, SDHA, HPRT1, TOX4 and *TPT1*. In some aspects, the housekeeping gene is *TOX4*.

[0096] In some aspects of the methods of the present disclosure, a predetermined cutoff value can be about 33% on a scale of 0-100%. In some aspects of the methods of the present disclosure, a predetermined cutoff value can be about 50% on a scale of 0-100%. A predetermined cutoff value can be about 60% on a scale of 0-100%. A predetermined cutoff value can be about 10%, or about 20%, or about 30%, or about 40%, or about 70%, or about 80%, or about 90% on a scale of 0-100%.

[0097] The methods of the present disclosure can have a sensitivity of at least about 50%, or at least about 60%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 99%. The methods of the present disclosure can have a sensitivity of greater than about 50%, or greater than about 60%, or greater than about 70%, or greater than about 75%, or greater than about 80%, or greater than about 85%, or greater than about 90%, or greater than about 95%, or greater than about 99%.

[0098] The methods of the present disclosure can have a specificity of at least about 50%, or at least about 60%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 99%. The methods of the present disclosure can have a specificity of greater than about 50%, or greater than about 60%, or greater than about 70%, or greater than about 75%, or greater than about 80%, or greater than about 85%, or greater than about 90%, or greater than about 95%, or greater than about 99%.

[0099] The methods of the present disclosure can have an accuracy of at least about 50%, or at least about 60%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 99%. The methods of the present disclosure can have an accuracy of greater than about 50%, or greater than about 60%, or greater than about 70%, or greater than about 75%, or greater than about 80%, or greater than about 85%, or greater than about 90%, or greater than about 95%, or greater than about 99%.

[00100] In some aspects of the methods of the present disclosure, a predetermined cutoff value, for example a first predetermined cutoff value, is derived from a plurality of reference samples obtained from subjects not having or not diagnosed with a neoplastic disease. The plurality of reference samples can be about 2-500, 2-200, 10-100, or 20-80. Each reference sample produces a score using the algorithm, and the first predetermined cutoff value can be, for example, an arithmetic mean of these scores. Each reference sample can be blood, serum, plasma, or non-neoplastic tissue. In some aspects, each reference sample is blood. In some aspects, each reference sample is of the same type as the test sample.

[00101] In some aspects of the methods of the present disclosure, a test sample can comprise any biological fluid obtained from a subject. In some aspects, a test sample comprises blood, serum, plasma, neoplastic tissue or any combination thereof. In some aspects, a test sample comprises blood. In some aspects, a test sample comprises serum. In some aspects, a test sample comprises plasma.

[00102] In some aspects of the methods of the present disclosure, a reference sample can comprise any biological fluid obtained from a subject. In some aspects, a reference sample comprises blood, serum, plasma, neoplastic tissue or any combination thereof. In some aspects, a reference sample comprises blood. In some aspects, a reference sample comprises serum. In some aspects, a reference sample comprises plasma.

[00103] Each of the biomarkers disclosed herein may have one or more transcript variants. The methods disclosed herein can measure the expression level of any one of the transcript variants for each biomarker.

[00104] The expression level can be measured in a number of ways, including, but not limited to: measuring the mRNA encoded by the selected genes; measuring the amount of protein encoded by the selected genes; and measuring the activity of the protein encoded by the selected genes.

[00105] The biomarker can be RNA, cDNA, or protein. When the biomarker is RNA, the RNA can be reverse transcribed to produce cDNA (such as by RT-PCR), and the produced cDNA expression level is detected. The expression level of the biomarker can be detected by forming a complex between the biomarker and a labeled probe or primer. When the biomarker is RNA or cDNA, the RNA or cDNA is detected by forming a complex between the RNA or cDNA and a labeled nucleic acid probe or primer. The complex between the RNA or cDNA and the labeled nucleic acid probe or primer can be a hybridization complex.

[00106] Gene expression can also be detected by microarray analysis. Differential gene expression can also be identified, or confirmed using the microarray technique. Thus, the expression profile biomarkers can be measured in either fresh or fixed tissue, using microarray technology. In this method, polynucleotide sequences of interest (including cDNAs and oligonucleotides) are plated, or arrayed, on a microchip substrate. The arrayed sequences are then hybridized with specific DNA probes from cells or tissues of interest. The source of mRNA typically is total RNA isolated from a biological sample, and corresponding normal tissues or cell lines may be used to determine differential expression.

[00107] In some embodiments of the microarray technique, PCR amplified inserts of cDNA clones are applied to a substrate in a dense array. In some embodiments, at least 10,000 nucleotide sequences are applied to the substrate. The microarrayed genes, immobilized on the microchip at 10,000 elements each, are suitable for hybridization under stringent conditions. Fluorescently labeled cDNA probes may be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from tissues of interest. Labeled cDNA probes applied to the chip hybridize with specificity to each spot of DNA on the array. After stringent washing to remove non-specifically bound probes, the microarray chip is scanned by a device such as, confocal laser microscopy or by another detection method, such as a CCD camera. Quantitation of hybridization of each arrayed element allows for assessment of corresponding mRNA abundance. With dual color fluorescence, separately labeled cDNA probes generated from two sources of RNA are hybridized pair-wise to the array. The relative abundance of the transcripts from the two sources corresponding to each specified gene is thus determined simultaneously. Microarray analysis can be performed by commercially available equipment, following manufacturer's protocols.

[00108] In some embodiments, the biomarkers can be detected in a biological sample using qRT-PCR. The first step in gene expression profiling by RT-PCR is extracting RNA from a biological sample followed by the reverse transcription of the RNA template into cDNA and amplification by a PCR reaction. The reverse transcription reaction step is generally primed using specific primers, random hexamers, or oligo-dT primers, depending on the goal of expression profiling. The two commonly used reverse transcriptases are avilo myeloblastosis virus reverse transcriptase (AMV-RT) and Moloney murine leukemia virus reverse transcriptase (MLV-RT).

[00109] When the biomarker is protein, the protein can be detected by forming a complex between the protein and a labeled antibody. The label can be any label for example a fluorescent label, chemiluminescence label, radioactive label, etc. Exemplary methods for protein detection include, but are not limited to, enzyme immunoassay (EIA), radioimmunoassay (RIA), Western blot analysis and enzyme linked immunoabsorbant assay (ELISA). For example, the biomarker can be detected in an ELISA, in which the biomarker antibody is bound to a solid phase and an enzyme-antibody conjugate is employed to detect and/or quantify biomarker present in a sample. Alternatively, a western blot assay can be used in which solubilized and separated biomarker is bound to nitrocellulose paper. The combination of a highly specific, stable liquid conjugate with a sensitive chromogenic substrate allows rapid and accurate identification of samples.

[00110] In some aspects of the methods of the present disclosure, the methods described herein can have a specificity, sensitivity, and/or accuracy of at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

[00111] In some aspects of the methods of the present disclosure, a labeled probe, a labeled primer, a labeled antibody or a labeled nucleic acid can comprise a fluorescent label.

[00112] Any algorithm that can generate a score for a sample by assessing where that sample value falls onto a prediction model generated using different techniques, e.g., decision trees, can be used in the methods disclosed herein. The algorithm analyzes the data (i.e., expression levels) and then assigns a score. In some embodiments, the algorithm can be a machine-learning algorithm. Exemplary algorithms that can be used in the methods disclosed herein can include, but are not limited to, XGBoost (XGB), Random Forest (RF), glmnet, cforest, Classification and Regression Trees for Machine Learning (CART), treebag, K-Nearest Neighbors (kNN), neural network (nnet), Support Vector Machine radial (SVM-radial), Support Vector Machine linear (SVM-linear), Naïve Bayes (NB), multilayer perceptron (mlp) or any combination thereof.

[00113] In some aspects of the methods of the present disclosure, the algorithm can be XGB (also called XGBoost). XGB is an implementation of gradient boosted decision trees designed for speed and performance.

[00114] In some aspects of the methods of the present disclosure, a therapy, for example a first therapy or a second therapy, can comprise active surveillance, surgery, radiation therapy, cryotherapy, hormone therapy, chemotherapy, vaccine treatment, bone-directed treatment, immunotherapy or any combination thereof.

[00115] In some aspects of the methods of the present disclosure, active surveillance can comprise a doctor visit with a prostate-specific antigen blood test and digital rectal exam about every 6 months. Active surveillance can also comprise prostate biopsies, which may be done every year.

[00116] In some aspects of the methods of the present disclosure, surgery can comprise a radical prostatectomy.

[00117] In some aspects of the methods of the present disclosure, radiation therapy can comprise external beam radiation and brachytherapy.

[00118] Cryotherapy, also referred to as cryosurgery or cryoablation, is the use of very cold temperatures to freeze and kill prostate cancer cells.

[00119] In some aspects of the methods of the present disclosure, hormone therapy can comprise androgen deprivation therapy or androgen suppression therapy. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. Hormone therapy can comprise orchiectomy. Hormone therapy can also comprise administration of a compound that lowers the level of androgens, such as Luteinizing hormone-releasing hormone (LHRH) agonists, LHRH antagonists, and CYP17 inhibitors. Known LHRH agonists include, but are not limited to, leuprolide, goserelin, triptorelin, and histrelin. Known LHRH antagonists include degarelix. Known CYP17 inhibitors include abiraterone. Hormone therapy can also comprise administration of an anti-androgen, such as flutamide, bicalutamide, nilutamide, and enzalutamide. Hormone therapy can also include administration of an androgen-suppressing drug, such as estrogens and ketoconazole.

[00120] In some aspects of the methods of the present disclosure, chemotherapy can comprise docetaxel, cabazitaxel, mitoxantrone, estramustine, or a combination thereof.

[00121] In some aspects of the methods of the present disclosure, vaccine treatment can comprise Sipuleucel-T.

[00122] If the cancer has grown outside the prostate, preventing or slowing the spread of the cancer to the bones is a major goal of treatment. Bone-directed treatment can comprise bisphosphonates (e.g., zoledronic acid), denosumab, corticosteroids, external radiation therapy, radiopharmaceuticals (e.g., Strontium-89, Samarium-153, or Radium-223), and pain medicines.

[00123] The response of a subject having a prostate cancer to a therapy can also be evaluated by comparing the scores determined by the same algorithm at different time points of the therapy. For example, the first time point can be prior to or after the administration of the therapy to the subject;

the second time point is after the first time point and after the administration of the therapy to the subject. A first score is generated at the first time point, and a second score is generated at the second time point. When the second score is significantly decreased as compared to the first score, the subject is considered to be responsive to the therapy. In some embodiments, the second score is significantly decreased as compared to the first score when the second score is at least 10% less than the first score, e.g., at least 20% less than the first score, at least 25% less than the first score, at least 40% less than the first score, at least 50% less than the first score, at least 75% less than the first score, or at least 90% less than the first score. When the second score is not significantly decreased as compared to the first score, the subject is considered to be not responsive to the therapy.

[00124] The sequence information of the prostate cancer biomarkers and housekeeper genes is shown in Table 1.

[00125] Table 1. Prostate Cancer Biomarker/Housekeeper Sequence Information

Gene Name	RefSeq Accession	Sequence	SEQ ID NO:
<i>AAMP</i>	NM_001087.4	ctgctggggagtcgcctacgcctacttccctgcccgggaggaggggctcgagttccgcgtcgtc gcgcagagctgactctgggaggcggttggccagagaagtggatccgccgcttgcgcgcgc atggagtcggaatcggaaagcggggctgctgctgacacccccactggagaccctaagct tccatggtgatgaagagattatcgagtgtagaacttgatcccggtccgcccggaccagatg acctggcccaggagatggaagatgtgactttgaggagaagaggagggaagagggaac gaagagggtggttctagaacccagggaagggtggtcggcagcatggaggggcccgga cgatagcgaggtcactttgcatgctcagcatctgtgtttgtgtgagcctggacccaag accaataccttggcagtgaccgggggtgaagatgacaagccttcgtatggcggtcagcg atggggagctgctctttagtggtgcaggccataaagactctgtgacttgtgctggttcagccat gactccactctagtggccacaggggacatgagtggtccttgaagtggtggcaggtggacac taaggaggaggtctgtgctcttgaagcgggagacctggagtgatggagtggtcctcgg gcacctgtcctgttggcgggcacagctgacggcaacacctggatgtggaagtccgaatg gtgactgcaagacctccagggtcccaactgccagccacctgtggccgagtcctcctgat gggaagagagctgtgtaggtatgaagatgggaccatcaggattggacctgaagcagg gaagccctatccatgtactgaaggagctgagggtcaccaggggccactcacctgttgcct gccaaccaggatggcagctgatcctaactggctctgtgactgcccaggccaagctggtcag tgccaccaccggcaagtggtggtgttttagacctgagactgtggcctcccagccagcct gggagaaggaggagagagtgagtcacactcgggtggagtccttggcttctgcatgtgatg ccctggcagctgttggctacctggatgggaccttggccatctatgacctggctacgcagact cttaggcacatcagtgtagcaccagtcgggcatcgtgcagctgctgtggaggcaggcactgc cgtggtatatacctgcagcctggatggcatcgtgcctctgggacgcccgaccggccgc ctgcttactgactaccggggccacacggctgagatcctggacttgcctcagcaagatgcc tcctgtgtgtgaccacgtcaggagaccacaagcgaaagtatttgtgtccaaaggcctgac cgftaatggctgcagccctgctgtgtgtgtgtgtgaggggacgaagggaccctgcc	1

		ctgtctgccagcagaggcagtagggcacagagggaaggagggtggggccctggatga ctttccagcctctcaactgacttctccctctcctttctcttttagagaccagccagggc cctcccacccttgccagacctgggtggccctcagaggagggtggacctgtttctttca ctttcatttgctgtgtgagccatgggtgtgtattgtatgtgggagtaggtgttgagggtcc cgttcttccctccaagtctctgggggtgaaaggagggaagagatactagttaagatttaa aaatgtaataaaatatacttccagaaaaa	
ANO7	NM_00100189 1.3	aaagatagatcctgctccaggagccgggaagccttgcctggccagctgtgctggcacctc ccctgctgcttctggcccacttgcaggcaaggtgagggcagtcgaatggctgccactgcc tgggcgggggctccaaggccacccctcccaccctctgtcccgagtgaggacgggactct actgccgagaccaggtcacgctgagagggtggccatgacctccgagaccttctccggag ccactgtgccaggagcaggatgtctggcgacggggccagggaaggagacagcaccgtcc tgatcgatgtgagccccctgaggcagagaagggggtcttacgggagcacagccacg ctcggagccagggtgacagcaagcgccgctgcagagctgggagtcctgccaagccc cggatcgagacttctcctcgtttgggaggaggacctgaagctagacaggcagcaggaca gtgcggccgggacagaacagacatgcacaggacctggcgggagactttctggataatctt cgtgcggctggctgtgtgtagaccagcaggacgtccaggacgggaacaccacagtgcac tacgcccctcctcagcgccctcgtggctgtgtctgtactacggcgaagacctgcgctgaag ctgcccctgcaggagtaccacaaccaggcctccaactgtcggccggcctgtggcatggct gggcatcccaacgtcctgtgaggtgtgtccagacgtacccccgagtactactcctgcc ggttcagagtgaacaagctgccacgcttctcgggagtgacaaccaggacaccttctacaa gcaccaaggaggcaccaaattctgtttgagatcctggccaagaccctgatggccacgagaag aaaaacctgttgggatccaccagctgtggcagagggtgtcctcagtgccgcttcccctg catgacggcccttcaagacgccccagaggcccgaggtccacgcctcaaccagcgcc caagtccctttccagcactggcgcgctggggcaagtggacaagtaccagccctggacc acgtgcgcaggtacttcggggagaaggtggccctctacttcgctggctcgggtttacacag gtctgctcctgcagcggcagtggtgggcacactgggttctcgtgtggctgtctcgtgtgt tctcagacataccacgcaggaactgtgtggcagcaaggacagcttcgagatgtgccacttt gctcgtactgcctttctgtgctgtctcagcgctgtgcccctggccaggccggcgtgtgt tcgaccacggcgccacgctgttcttcagctgtgttcagtgccactgtggccgtgtgtgtga gtactgggaagcggaagagcgccacgctggcctaccgctgggactgtctgtactacaggac actgaggagaggcctcggccccagtttgcgcctcagccccatgacagccccgaaccca tcacgggtgaggacgagccctacttccctgagaggagccgcgcgcgcgcgcatgtggccg gctctgtgtgatcgtgtgtatgtggccgtgggtgcatgtgctcgtgtctatcatcctgtac cgtgccatcatggccatcgtgtgtcaggtcgggcaacaccttctcgcagcctgggctct cgcatcgcagccacgagggtgtgtgtgtgaacctgtcttcatcctcctcctccaaagtcta tgtatccctgcccacgtcctgacacggtgggaatgcaccgcaccagaccaagtctgagg acgcttccacctcaaggtgttcatcttccagtctgcaacttctactcctcaccgtctacattgc cttcttaagggcaggtttgtgggataccaggcaactaccacacctgtttggagtcgcgaat gaggagtgccgggtgaggctgcctgatcagctggcacaggagctcctgtgtcatcatgg tgggcaagcaggtcatcaacaacatgcaggaggtcctcatccgaagctaaggctgtgtg gcagaagttccggtctcgtccaagaaggaggcgggagcttctgcaggggctagcca ggggccctgggaggagcactatgagctgtgcccctgtgagggtctgtttgacgagtacctgg aaatggtgtgtcaggttcggtctgtaccatcttctgtggccgctgtccgctgcgcgcgtctt cgccctgtcaacaactgggtggagatccgcttgacgcgcgcgaagtctgtctgcaggtacc ggcgcccggtggcgagcgcccccaggacatcggtatgttccacatctgtggcgggcc tcacgcacctggcggtcatcagcaacgcttctcctgtggccttctgtccgacttctgcgcg cgctactaccgggtggaccccgcccacgacctgcgcggcttctcaacttccgctggcg gagccccgtctccttgcgcgcgcgcacacccgacgtgcaggatcgggttccgggaf gacgatggacattatccagacctactggaatcttcttccatccgctggccttctgtattgt ttgagcatgtgttttctcgttggccgctcctgtgacctcctgtgtcctgacatccagagtct	2

		gtggagatcaaaagtgaagcgggagtgactacctggcgttaagcagcactggctgagaaatgagg tctttttggaaacgaaacggaacaaaggatgagcagcccagaggctcagagctcagctccac tggacacccttcacggttcccaaggccagccagctgcagcagtgacgctggaaaggacatct gggtggtccttagggggagtggtccctctgagccctgcgagcagcgtcttttctcttccctca ggcagcggctgtgtgaaccgctggctgtgtgtgtcctcatctctgggcacattgacctgctcc ccccagcggcggttctctctcagagcgctgtcactccatccccggcagggaggggaccgt cagctcacaaggccctcttttcttctgctctccagacataagcccaaggggccccctgcaccca aggggaccctgtgctcctgggtgcccctccagccccctggacacgacaggttctcctcagggcag gtgggctttgtgggtcctcggccccctggccacatcgcctctcctcttacaacctgtgaccttc gaatgtttcagagcgagggccgttctcctcgtgtcctctgggaccacccgcccttctctgccc ctgttttgcgagggacatcaccacatgccccagctctcggacctgcagctctgtgtcccag ggccacagcaaaggctgtgtgaacccctcctctcattccagttatctgggtctcctggaattctct gtttcttfgaatcagggctgtgttccccctagccactacaggcgacctctgcaggtgcgcttita cttgcattctgcagcaattacatgtgtcctttgtatccttgcccaacttccctcctctccagctcc tggccccctggcccaggggcccccttctgtgttttacctctgttccctggggcctagtaccagca agcaccccaatgggggaggttttgggatgagaggaggaaaacgtgtatactgttaacatctgg tggctcttccccagaagttgtgttcatacataaattgtttccacgctggtatcataatgtgacgtg cagttctgcccctgtctgtgggagccacatgaagcttccccctggctaactgtctaccccgagc aatcccaagtgtggccgtctgtgtctaaaaaattggaictgtgtctcatctgtattgaltcttggga gttctacaagtggaaacttaagtgtcaaaaagaatatgtggtttttagctgagcgtgtgtgctcac acctgtaatccaggaacttttggaggctgaggcaggaggattacaaggtcaggaggttcggg actagcctgtccaacatggtgaaacctgtctttactaaaaaattgcaaaaatt	
AR	NM_000044.3	cgagatccccggggagccagcttgcctgggagagcgggacgggtccggagcaagcccagag gcagaggaggcgacagaggggaaaaaggccgagctagccgctccagtgctgtacaggag ccgaagggaacgaccacgcccagcccagccggctccagcgacagcccaacgtcttattgca gcgcggcggtcttcgaagccgcccggagctgccttctctcgggtgaagtttctttaga ctctaaagactcggagggaagcaaggaaagtgcctggtaggactgacggctgcttctgtcct cctcctctccaccccgctccccccacctgccttccccccccctcccgcttctctcccgag ctgectcagtggtgctactctcagccaacccccctaccacaccttctccccaccggccccccg ccccctgcggcccagcgctccagcccagtttgcagagaggtaactcccttggctgcgag cgggcgagctagctgcacattgcaaagaaggctcttaggagccaggcgactggggagcggg cttcagcactgcagccacgaccccgctggttaggctgcacgcggagagaaacctctgttttcc cccactctctctcacctctctctgcttccccaccccgagtgcgggagccagagatcaaaaaga tgaaggcagtcagggtcttcagtagccaaaaaacaacaaacaaaaaagccga aataaaagaaaagataataactcagttcttatttgcacctacttcagtgagacatgaatttggaa gggtggaggattttgttttttctttaagatctgggcacatctttgaatctaccctcaagtattaaag acagactgtgagcctagcagggcagatctgttccaccgtgtgtcttcttctgcacagacatttg agggtctcagagcgctttttgctgtgtgtcccgcaagtttcttctctgagcttcccgagg tggcgagctagctgcagcgactaccgcatcatcacagcctgttgaacctctctgagcaagaga aggggaggcgggggtaaagggaagtgtggaagattcagccaagctcaaggatggaagt cagttaggcgctgggaagggtctacccctggccggccgtccaagacctaccgaggagctttcca gaatctgttccagagcgtgcgcgaagtgtatccagaaccggggccccaggcaccagaggc cgcgagcgcagcacctccccggcgccagtttgcgtgctgcagcagcagcagcagcagca gcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc cccaggcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc cccacaggctacctgtgctggtgatggaacagcaaccttcacagccgcagtcggccctgg agtccacccccgagagaggttgcgtcccagagcctggagccgcccgtggccgcccagcaag gggctgcccagcagctgcagcacctccgggacgaggtatgactcagctgccccatccagct gttccctgtcggggccccacttccccggcttaagcagctgctccgctgaccttaaaagacatct gagcgaagcccaagcaccatgcaactccttcagcaacacagcagcaggaagcagatctacgaagg	3

	cagcagcagcgggagagcagggaggcctcgggggctccactctccaaggacaaffa cttagggggcactctgaccattctgacaaccccaaggagttgtgtgaaggcagtgctgggtgc catgggctgggtgtgagggcgttggagcatctgagtcagggggaacagctcggggggat tgcattgtacgccccacttttggagttccacccgctgtgctgccactcctgtgccccattggc cgaatgcaaagggttctctgctagacgacagcgaggcaagagcactgaagatactgtgagt attcccccttcaaggggaggttacaccaaaagggttagaaggcgagagcctaggctgctctggc agcgtctgcagcaggggagctcggggacacttgaactgcccgtctaccctgtctctacaagttc ggagcactggagcagagcagctgctgacagagtcgggactactacaactttccactggctct ggcgggagaccggccccctccggcggctccccacggctcgcacaaagctggagaa cccgtgagactacggcagcggcgtggcgggctggcgggcgagtgccgctatggggacct ggcgagcctgcatggcggggtgcagcgggacccgggttctgggtcacctcagccggcg ttctcatctctggcacactctctcacagccgaagaaggccagttgtatggaccgtgtgtgtgt gggtgggggtgtgtgtggcgggcgggcgggcgggcgggcgggcgggcgggcgggcg cggcgggcgaggcggggagctgtagccccctacggctacactggccccctcaaggggctggc gggcccaggaaagcgacttcaccgcacctgatgtgtgtacctggcgggcatggtgagcaga gtgccccatcccagttccactgtgtcaaaagcgaatggggccccctggatggatgactactcc ggacctacggggacatcggttggagactgccagggacctatgttttggccattgactattactt tcaccccagaagacctgcctgatctgtggagatgaagcttctgggtgtcactatggagctctc acatgttgaagctgcaaggtcttctcaaaagagccgctgaagggaacagaaagtacctgtg cgccagcagaaatgattgactattgataaattccgaaggaaaaattgtccatctgtctcttc ggaaatgttatgaagcagggatgactctgggagccccgaagctgaagaacttggtaatctg aaactacaggagggaaggagaggcttcagcaccaccagccccactgaggagacaacca gaagctgacagttgtcacacattgaaggctatgaatgtcagccatcttctgaatgtcctggaa gcattgagccagggtgtgtgtgtgtgtgacacgacaacaacagcccgactcctttgcagc cttgcctctagcctcaatgaactgggagagagacagctgttacagttgtgtcaagtggggc ggccttgcctgttcggcaacttacacgtggagcagcagatggctgtcattcagtaactcctgg atggggctcatggtgtttgccatgggctggcgatccttcaccaatgtcaactccaggatgctct acttcggccctgatctgtgtttcaatgagtaccgcatgcacaagtcccgatgtacagccagt tgtcgaatgaggcacctctctcaagagtgttggatggctccaaatcacccccagggaattcctg tgtcatgaaagcactgctactctcagcattattccagtgatgggtgctgaaaaatcaaaattctt gatgaactcgaatgaactacatcaaggaaactcgatcgtatcattgcatgcaaaagaaaaaattc ccacatctctctcaagacgcttctaccagctcaccaagctcctggactcggtcagcctattgc gagagagctgcatcagttcacttttgaactgctaataagtcacacatgggtgagcgtgactttc cggaaatgatggcagagatcatctctgtgcaagtgcceaaagatccttctgggaaagtcaagc ccatctatttccacaccagtgaaagcattggaaacctatttccccaccceagtcatgccccct ttcagatgtcttctgctgttataactctgcactactcctctgcagtgcccttggggaatttctctat tgtgttacagctctgtcatgaacatgttctgtaattctatttgcgggctcttttttctcttctctt cttttcttctcctccctatctaaacctcccatggcaccttcagacttgcctccattgtggctcc tatctgtgtttgaatgtgtgtgtatgctttaatctgtgatgctctatattggcccagtgcaag ttgtgtgttttacagcactactctgtgccagccacacaaaactgttacttatcttatgccaggga agtttagagagctaagattatctggggaatcaaaaacaaaaaagaacaaaaa gcaaaaacaaaaacaaaaataagccaaaaaaccttgcagtgttttctcaaaaataataaa taaataaaataaatacgtacatacatcacacatacatataaataaataaataaataaataa ccaatagttagcagagaaggtgaaaaattgcaggcccatggggagttaactgatttttcatctctcc ctccaggggagacttatttctgccaatggctattgccaattagagggcagagtgacccagag ctgagttgggcagggggggtggacagagaggagaggacaaggaggggcaatgggagcatca gtacctgccacagccttggctccctgggggctagactgtcactgtggagcaattcattatc tgaanaatgtgtgtgtgtaaaattgtctgtcatgttaatgctcaccceaaaaccttctctct cactctctgcctccaaactcagattgacttcaatgttttctaagaccgttgaactgaatgtctct tcaeccaaaacttgcgacttccacagaaaaagtctgaccactgagaaagagagagagag
--	---

	atftaaccccttgaaggccccatttgatccaggctctgttctcatgtgtgagtcaggaggga gctggagccagaggagaagaaaatgatacttgctgttctctgcttaggacactgactgaa tagftaaactctactgccactacctttccacctttaaagacctgaatgaagtttctgcca actccgtgaagccacaagcacttatgtctccctcagtgtttggggcctgaatttcacaca ctgcatctcagccatgctcatcaagcctgtttgcttctttggcagttcacagattctgttaag agccccaccaccaagaagggttagcaggccaacagctctgacatctatctgtatagccagt agtcacaaagatttctaccaactctcagatcgtgagcccttagacaactggaaagagg catcaaaaggatcaggcaagctggcgctctgcccctgtcccccagagatgataccctcca gcaagtgagaaagtctcacttctctttagagcagctaaaggggctaccagatcagggttg aagagaaaaactaattaccagggtgggaagatgaaggcactagaaccagaaacctgcaa atgctctctgtgacccagcataccacctgcagaagtcatgagaagagagaaggaacaaag aggagactctgactactgaattaaaatcttcagcggcaaagcctaaagccagatggacacat ctgggtgagtttactcatcactcctctctgctgctgattctgggctctgacattgccccatactc agattccccaccttggctgctcctcttagtcagaggaggccaaacctgagactttctacag aaccatggcttcttggaaaaggctggtgtgtgtgctcctaactttgccacccatgaactca gggtgtgcccctgggacactggtttatagcttctggcacacctgtgtgtgtgactcgttct caagcccaagtgcaagggaatgtccactactttctcatcttggcctctgctccttacttag ctctaatctcatctgtgaactcaagaaatcaagggccagtcacagctgccattttaattgat tactctgttgtgagaggatagtttctgagtgacatgatgatccacaagggttctcctcctg attctgcatgtatataatagccaaacgaacttcaaacagctttaataacaaggggagagg gaacctaaagatgagtaatatgccaatccaagactgctggagaaaactaaagctgacaggttcc cttttggggtgggafagacatgttctggtttcttattattacacaatctggctcatgtacaggat cacttttagctgttttaacagaaaaaatatccaccactctttcagttacactaggttcatfttaa taggtcctttacatctgttttggaatgattttcatcttttgatacacagattgaattatattttca tatctctcctgttaaatactagaagctctcctttacatttctatcaaattttcatctttatgggttcc caaattgtgactctgttctcatgaatatatgttttctattgcaaaagccaaaaactagtgaaaca gcagtgtaatfaaaagcaacaactggattactccaaatttccaaatgacaaaactagggaaaaa tagcctacacaagcccttaggcctactcttctgtgctgtgggttgagtgaacaaggagatttta gcttggctctgttctccatggatgaaggaggaggatttttttcttttggccattgatgttcta gccaatgtaatgacagaagctctatttgcagtcgctctgctctacaaacagagttggtatgtgt gggtactgtactacctgtgagggactggccactcagaccacttagctgggtgagctagaag atgaggatcactcactggaaaagtcacaaggacatctccaaacaagttggcagtgctcgatg tggacgaagagtgagggaagagaaaaagaggagcaccaggaggagaaggctccctgctgtgct gggcagcagacagctgccaggatcacgaactctgtagtcaaaagaaagagtgctgtggcag tttcagctctgctcattgggcagctgcccaggcccagccctctgagctgacatgggagttgtg gattctttgtcatagcttttctatgcccattaggcaatattgtgttcttggaaagtattatttttaa ctccctactctgagaaaggatatttgaaggactgtcatatatctttgaaaaagaaaatctgt aatacatatattttatgtatgttactggcactaaaaaataatagagagcttactctgtcctttgggt agttgctgaggttaattgtccagggtgaaaaataatgtgctgtagtgtagtccctctctgtccata ctctacttctaaatacatataggeatcatagcaagttttattgacttgaactttaagagaaaat gtccaccatccacatgatgcacaaatgagctaacattgagcttcaagtagcttcaagtgtttgtt tcattaggcacagcacagatgtggccttcccccttctcctctgatatctggcagggcataa aggcccaggccacttctctgccccttccagccctgcaccaaaagctgcatctcaggagactc tctccagacagccagtaactaccgagcatggcccctgcatagccctggaaaaataagagg ctgactgtctacgaattatctgtgccagttgcccagggtgagaggccactgggccaaggaggt ggttttcatgtttgacccactacaagggtcatgggaatcagggaatgccaagcaccagatca aatccaaaacttaagtaaaataagccattcagcatgttcatgtttctggaaaagggaagtctta ccccatgcttctgtaggcagatctgttctcaccattaatcttttgaatcttttaagcagttt taaaaagagagatgaaagcatcacattatataaccaaagattacattgtactgctaagatacc aaaatcataaggcaggggggagcagcatttagtcctcttggataagctgtccaaagac	
--	--	--

		agactaaaggactctgctgggactgactataagagcttgggggttttttccctaataatata catgtttagaagaattgaaaataatttcgggaaaatgggattatgggtccttactaagtgaattta taagcagaactggcttcttctctagtagtgcctgagcaaatgttgaagctccatcattgcat gggtggaaatggagctgttcttagccactgtgttctagtgcccatgttagcttatctgaagatg tgaacccctgctgataaggagcatttaaagtactagatttgcactagaggacagcaggc agaatccttatttctgcccacttggatggcacaaaagtatctgcagtgaaggcagaagaat tgaataacattgtaaatgaatattgtatccatgttcaaaattgaaatataatataatataata tatataatataatataatagtggtgtgtgtgttctgatagccttaacttctctgcatcttatttgggt ccagatcacacctgatccatgtactgtgagagagagatgcagtttgggttggaaagctctctca gaacaaacaagacacctggattgatcagttactaaaagtgttctccctattgggttgaccca caggtcctgtgaaggagcagaggataaaaagagtagaggacatgatacattgtactttacta gttcaagacagatgaatgtggaagcataaaaactcaatggaaactgactgagatttaccacag ggaaaggcccaacttggggccaaaagcctaccgaagtgttgaccagtggcccccttaattgg gacctgagctgttggaaagagaactgttcttgggtcttaccatccttggagagaaggggc agtttctgcattggaacctggagcaagcgtctatcttccacaaaattccctcactgagattg agggtcttgttactgggtgtgtgtgtgtgttaattctgggttggatattgtctgaagatttga caaatgaaaatgtgttcttctgttaaaactgtcagagtactagaagttgtatctctgtagggtc agggtccatttctgcccacaggtagggtgttcttctgttaagagattgacattctgttgcctag gacctccaaactcaaccatttctaggtgaaggcagaaaaatccacattagttactcctctcaga cattcagctgagatacaaatcttggaaatttttaccatagaagagtggtgagatattgaa tttagcagggtgagttcatagtaaaacagctttgactcagcttgaattatcctcatttgaattgg ccagaaagtaggttaatafctgatttggcttctgattccaattcagtatagaaggtgctagggt tttcttctccaccctgtctcttagcctggggaattaaatgagaagccttagaattgggtggccct tgtacctgaaacacttccacataagctacttaacaagattgtcatggagctgcagattccatt gcccacaaagactagaacacacacatatccatacaccaaaggaagacaattctgaaatgc tgtttctctgtgtgttccctctctgtgtgtgtgtcctcagatgtggaaacctgtactctgcagaggt gacaggccagatttgcattatctcacacacttagccctgtgtgtaacctgtactctgcagaggtg cctgggggggtgtctatccataagccacttggatgctgacagcagccaccatcagaatgac ccacgcaaaaaaaagaaaaaaatataaaagtccccacacccagtgacaccttctgc tttctctagactggaacattgattagggtggtcctcagacatgacattctgtgtgtcttggga attaatctggcagcagggaggagcagactatgtaaacagagataaaaatatttcaatattg aaggaaaaaagaaataagaagagagagagaagaaagcatcacaaaagatttcttaaaa gaaacaatttctgtgaaatctctttagatgggtctatttctacgggtggcacttggccctcact gggcagcaggaccagctccaagcgtagtgttctgttcttctttaaacttggaaatcttgttgg ctctaatacaattaaaaatggcagaaactgttgttggactacatgtgtgacttgggtctgtct ctgctctgttctcagaatgtcatccattgtgtaaaatattggcttactgtgtgcagctaaaaac ttggccacatccctgttattggctgcaggtatcgagttattgttaacaagagacccaagaaaaag ctgctaattgtcctcttattcattgttgaatttgttaaaacataaagaaatctaaaattcaaaaaa	
AR-V7		gacactgaatttggaggtggaggtatttgtttttctttaaagatctgggcattcttgaatctacc cttcaagtattaaagacagactgtgagcctagcagggcagatctgtccaccgtgtgtcttctt ctgcacgagactttagggctgtagagcgcttcttgcgtgtgtgtctccgcaagtttcttctctg gagcttcccgagggtggcagctagctgcagcgactaccgcatcatcacagcctgttgaact cttctgagcaagagaaggaggagcggtgtaagggaagtaggtggaagattcagccaagct caaggatggaagtgcagtttagggctgggaagggtctaccctcggccgctccaagacctta ccgaggagcttccagaatctgttccagagcgtgcgcgaagtgtccagaaccggggcccc aggcaccagaggccgagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc cagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc agcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagc ggatgttctcccaagccatctgtagagcccccacaggtacctgtctgtgagagggaac agcaaccttcacagccgagctggccctggagtgccaccccgagagaggttgcgtccaga	4

[illegible]

		cctgggctgctgctcctgctcttactgacagcactgccaccgctgtggtccctcactgcct gggctggacactgctgaaagtaaagccaccattgcagacctgacctgctcgtcgtggagag agccaccgtcttcttagaacagaggctgctgaaatcaacctggatggcatggtgggggtcc gagtgctggaagagcagctaaaaagtgtccgggagaagtggcccaggagccccctgctgc agccgctgagcctgcgctggggatgctgggggagaagctggaggctccatccagagat ccctccactacctcaagctgagtgatcccaagtacctaagagagtccagctgacctccagc ccgggttttggagctccacatgctggatccacatgacgctccttgggtgacccacgtt cggggcccaggactcattctcagaggagagaagtgcgctgtgctgctgctgctggga accgggacggacagcagcagccctgctggcctctcagacctctgcaggagcctcatgacc aagcccgctgctcaggctactgctgctccaccaactgctcttctcctggtggccagaatga gggggtgcacacagggaccactccaacagagccaggactatatcaacctcttctgcgcaa catgatggacttgaaccgcagagctgagggcatcgatagcctacccctacccgggacatct tcatggaaaacatcatgttctgtggaatggcggtcttctccgacttctacaagctccggtggt ggaggccattctcagctgctgcaaaacagcagggaaggtgcttggggagcctgagctgaa gatgaagaattatctaaagctattcaatatcagcagcatttttcgaggagtgaaaggcgag aaaaacaatttcagatggctgctcctccacaacacagccacagcagtgccagccctgggt ggcttctatacatctggcagaataccccagcaaacagagagccacacccatccacacc gccaccaccaagcagccgctgagacggacggttccatgccagctgctggaggaggaaca gacccctttagctcctcatccttagatcctggagggcacggatcacatcctgggaagaaggca tctggaggataagcaaaagcccccacccaatcttggaaagccctgagtaggcaggggcc agggtaggtggggccgggagggaccagggtgtgaacggatgaataaagtccaactgcaa ctgaaaaaaaaaaaaaaaaaaaaaaaaa	
CHTOP	NM_00120661 2.1	tttccgcccctctagctgctgctgacgctgacgtaattgcgtagacgcccatttagcc ggctcagacaagcactggacgtggcgccatttgttttggacaccgagcaggagctggcgg ccgctgcagacgaaaggcaggaaaggcaggccgggtgagcagaccgctggccgact agacagccaaccagcaacaacgaactgagctgcatactaccgcttacgcatctaaccaacc gcccctctagctaacccgagccctcaccgctcaactcagggttcggccgggtcccccggccgc ctgcgggagccgtgtgtggcagccccgggaggagcactggcgtctgttttcttctgattctgg gattcgaagatggctgcacagtcagcggcgaagtgtgtctaaaaagcaccaccaagatgtc tctaatgagcgttactaataatgctgaagaacaacagccgacgccagtgatattctggct tcgatgcagcaacaacagcagctagccagtgccagaacaagaagactggccagcagatg gagaatagacctctgtccaggcagcattaaaacttaagcagaagagcttaaaagcagcgct gggtaagagtaacatccaggcagcgttagccgaccataggggccctgcccaggggagc aatcggaggacgaggcctaccataatccagagaggcttggccagaggagcactacgtgg gggacgtgccaccagaacctacttagggggcggatgtcactccgaggtcaaacctgctc cgagggtgacgagccgtagctcccgaatgggcttaagaagaggtggtgttcgaggtcgtg gaggtcctgggagaggggcctaggcgctgagctatgggtcgtggcgaatcggtgtgta gaggtcgggtatgataggctggggaagaggggccttggaggccgaggccgagccgt ggacgaggagaggtgccctgtcgcctgtattgaccaaggagcagctggacaaccaat tggatgcataatgtcgaacaacaaaggacaacctggatgctgagttggatgctacatggcgc agacagatcccgaaccaatgattgaagcctgccatcctccatgagagactctgttagtca acacatctgtaataaaccttgagataacagatgagaagaaatctgattgatgctggatggacct atcacataggctgtggactacttgcaccagctgtgctatttagtgtgttccttttacttttgata ctgtgtgtatgaacccctttgtcttattgtttttgtttttttttttagggggaggggggg gtttccctccttggccagactctcttgaacacaaatgcattagcctgtgtgctagaacacct cttctacctctgtctccctcactgtcataatgctgacatgctaacattcttttttcatccctgt tgccccacagaacatccagaaaaaccggcagtggttctcctcctcctgaccttaggtttct gaaatagggttctgttacatcctcttcagatagcctgtttaaagtgttagaaggtctggagctcaa aatgcttctccacattgataatttagtaactgagaacattgacatcactacagggcagcat aagagggtcttcatgtgtgtagcagctctgtgttgaattcaagtgtctaccatgtacattgacagc	6

		acatataccataaccagcggttggtggaattgcactttctacctttgtatgagattacagacttt ccttctgggtttgtatcatgaccagagggttactatagggttggtttatactgcaatatagaggat cagaagccatttgatttgtaggtgtgtcagaaggagaatgatggcagacgaactgctgga agaggtcagaagatagccatgctaaaatgcattatctcctcatgtttatccaaactaatctgg actttccactcattagctttgtttgcccctgttccctgaagggttaagttcaaccatattctgtca actgttcagtttcagtggaatctgtattctgtgttcattatacaaaactgttcgcttaaatccaaaa aaaaaa	
COLIA 1	NM_000088.3	tcgtcggagcagacgggagtttctcctcgggggtcggagcaggaggcagcgaggagtgtgag gccacgcatgagcggaacgtaacccctccccagccacaagagctctacatgtctagggtct agacatgttcagctttgtgacctcgggtcctgtcctcttagcgccaccgcccctcgtacg cacggccaagagggaaggccaagtgcaggggccaagacgaagacatccaccaatcacctg cgtacagaacggcctcaggtaccatgaccgagacgtgtggaaccggagccctgcccgtatc tgcgtctgcgacaacggcaagggtgtgtgcgatgacgtgatctgtgacgagaccaagaactg ccccgcccgcaagtccccgaggcgagtgctgtccctgtgccccgacggctcagagtc acccaccgaccaagaaccacccggcgctcaggggaccgaaggagacactggcccccgag gcccaaggggaccgcaggccccctggccgagatggcatccctggacagcctggacttc ccggacccccggacccccggacctccggacccccctggcctcggaggaaacttctgtcc ccagctgtctatggctatgatgagaatcaaccggaggaatttccgtgctgccccatgggt cccctgtgctcgtgtgtcctcggccccctgggtcacctggtcctccaaaggcttcaagggt cccctgtgagcctgagcagcctgagcttcaggtccatgggtccccgagggtccccag gtccccctggaaagaatggagatgatggggaagctggaaccctgtgctcgtggtgagcg tgggctcctgggctcagggtgtcagaggattgccgggaacagctggcctcctggaaatga agggacacagagggttcagtggttggatggtgccaaggagatgctggctcgtggtgctca aggggtgagcctggcagccctggtgaaaatggagctcctggtcagatgggccccctgtgct gcctggtgagagaggtgcccctggagcccctggccctgctggtgctggaatgatggtg ctactggtgctgcggggccccctggtcccaccggccccctggtgctcctggtcctcctggtg ctgttgggtgctaagggtgaagctgtgcccccaaggggccccgaggctctgaagggtccccag tgtgctggtgagccctggccccctggtgctggtgctgctggtgctggaaccctg gtgctgatggacagcctggtgctaaagggtgccaatggtgctcctggtattgctgtgctcctg ctccctggtgccccgaggccccctggtgacccagggccccggcgccccctggtgctccaa ggtaacagcgggtgaacctggtgctcctggcagcaaggagacactggtgctaaggagag cctggccctgtgtgttcaaggacccccctggccctgctggagagggaaggaaagcgaggag ctgaggtgaaccggaccactggtcctgccccggacccccctggcgagcgtggtgacctg gtagccgtgtgttccctggcgagatggtgtgtgctggtccaagggtccccgtggtgaacgtg gtctcctggtgccccctggtgccccaaaggatctcctggtgaagctggtcgtccccgtggaagctg gtctgctggtgccaagggtctgactggaagccctggcagccctggtcctgafggcaaaact ggccccctggtccccgggtcaagatggtgccccggacccccagggcccacctggtgccc cgtggtcaggctggtgtgatgggattccctggacctaaagggtgctgctggagagcccgcaa ggctggagagcaggtgttcccgacccccctggcgctgctgctgctgcaaatgga gaggctggagctcagggaacccccctgccccctggtgctgctgctgcaaatgga ggccccctggtgctccccggattccagggtctcctggtcctgctgctcctcaggtgaagca ggcaaacctggtgaacagggtgttctgagacctggcgccccctggtgctgagca gagcgagagaggttccctggcgagcgtgtgtgcaagggtccccctggtcctgctggtccc cgaggggccaacgggtgctccccggcaacgatggtgctaagggtgatgctggtgccccctgga gctccccgttagccaggggccccctggcctcagggaatgctggtgaacgtggtgacgtg gtcttccagggtcctaagggtgacagaggtgatgctggtcccaagggtgctgatgctcctg gcaaatggtgctggtgctgactggccccattggtcctcctggtgccccctggtgctgccccctg gtgacaagggtgaaagtgtgtccagcgccccctgctggtccccactggagctggtggtgcccc cggagaccgtgtgagcctggtgtccccggccccctgctggttctggtgccccctggtgctg acggccaacctggtgctaaggcggaacctggtgatgctggtgctaaggcgatgctggtccc	7

	cctggccctgccggaccgcgtggacccctggcccatggtaatgttggtgctcctggagc caaagggtgctcgcggcagcgtggtccctgggtgctactgggttccctgggtgctgctgccc agtcgggtcctcctggccctctggaatgctggacccctggccctcctgggtcctgctggcaa agaaggcggcaagggtccctggtgagactggccctgctggacgtcctggtgaaagtgtgt ccccctgggtccctcctggccctgctggcgagaaggatccccctgggtgctggtgctgctggt gtcctggtactccccgggctcaagggtattgctggacagcgtggtggtgctggcctgctggt cagagaggagagagggttccctggtctcctggccctcctggtgaacctggcaacaag gtccctcctggagcaagtgtgaacgtggtccctggtcccatgggccccctgggtggt ggacccctgggtgaatcctggacgtgagggggctcctgggtccgaagggtccctggacgag acgtgtcctcctggcgcaagggtgaccgtggtgagaccggccccctggacccctgggtg tctggtgctcctggtgccccctggccccgttggccctgctggcaagagtgtggtatcgtgtga gactggtcctgctggtccccgggtcctgctggccctgttggcgccgtggccccggcgag cccaaggccccctggtgacaaagggtgagacaggcgacaggcgacagaggcataaag gggtaccgtggtctctggtcctcagggtccctcctggccctcctggtcctcctggtgaaca gggtccctcctggagcctcctggtcctgctggtccccgaggtccctcctggtcctggtgctcctg gcaaatggtgactcaacgggtcctcctggccccattgggccccctggtcctcctggtgctcct ggtgatgctggtcctggtggtccccggccctcctggacctcctggtccccctggtcctccca gcgtggtttcgtactcagcttctcctccccagccacctcaagagaagggtcacgatgtggcc gtactaccgggctggtgatggtcaatgtgtggtgacgtgacctgaggtggacaccacc ctcaagagcctgagccagcagatcgagaacatccggagccagaggcgagccgcaagaa cccccccgacactgcccgtgacctcaagatgtgccactctgactggaagagtggagatgact ggatgaccccaaccaagggtgcaacctgggtgcatcaaatgtctctgcaacatggagactg gtgagacctgctgtaccccaactcagccaggtgtggccagaagaactgtgacatcagcaag aaccccaaggacaagggtcatgtgtgttggcgagagcatgaccgatgttccagttcga gtatggcgccagggtcctcagacctcctggatgtggccatccagctgacctctcctgctgca tgtccaccgaggcctccagaacatcacctaccactgcaagaacagcgtggcctacatggac cagcagactggcaacctcaagaaggccctgctcctcagggtcctcaacgagatcgagatcc ggcgaggaggcaacagccgttcaactacagcgtcactgtgatggtgacaggtcacac cggagcctggggcaagacagtgtgtgatacaaaaaccaccaagacctcccgctgcccac atcgatgtggccccctggacgtgtgtgtccccagaccaggaattcggcttcgacgttggccct gtctgtcctgtaaactcctccatcccaacctggtcctcctccaccaccaacttcccccc aaccgggaacagacaagcaaccacaactgaacccctcaaaagccaaaaaatgggagac aattcacatggacttggaaaatatttttcttggcattcatcttcaaaacttattttatcttggac caaccgaacatgacaaaaaaccaaaagtgcattcaaccttaccaaaaaaaaaaaaaaaaaa gaataaataaataacttttaaaaaagggaagcttgggtccacttgcctgagacccatgccccggg taagtccctttctgcccgttgggtcttatgaaccccaatgctgccccttctgctcctttccacac cccccttggggcctccctccactccttcccaatctgtctcccaagaagacacaggaaacaa tgtattgtctgcccagcaatcaaaaggcaatgtcacaaccccaagtggtccccaccctcagcc cgctcctgcccgcagcaccgccagccctggggacctgggtgtctcagactgccaag aagccttggcatctggtgctccatgggtcttgcaacatctcccttctgttttggggggtcat ggcgggggagccaccagccctcactgggttcggaggagagtcagggaagggecagcaca aagcagaacatcggttgggaacgcgtgtcaatcccttgtccgagggtggtggcggg agagactgttctgtctgtgtaactgtgtgtgaaagactacctgttctgttctgtgtgtca ccggggcaactgcctggggcggggatggggcagggtggaagcggctccccattttata ccaaaggtgctacatctatgtgtgtgtgggtggggagggaatcactggtgctatagaatt gagatgccccccaggccagcaaatgttcttttttcaaaagtctatttttattcctgtatatttc ttttttttttttttgtgtgtgggtggtgtgaatttttcaaaaggtgctatttaacatgggaggag agcgtgtggtggtcagccagcccgctgctcactttccacctctctccacctgctctggt tctcaggcctctgctctcagacctctcctctgaaacctcctccacagctgcagccatctc ccgctcctcctagtctcctgctcctctgctccccgggttcagagacaacttccaaagc	
--	--	--

		acaaaagcagttttcccccagggtgggaggaagcaaaagacitctgtacctattttgtatgtgt ataataatttgagatgttttaatttttgaattgctggaataaagcatgtggaaatgaccaaacat aa	
EDC4	NM_014329.4	ttcttctccggccctggcaggttcgggagcctcggctcgtgggtgcccgaagtggaggcg gttgtgggtgtggcggggtcagcgacgtgctggcggtgggtttgcgaactgcgggtg gactgtgtagtaccggcgtccgctgtctcggccgtggcggtgagcgagggtgctgtgg tgcggcgcgcgcggaacgaacgcgggtgcgggcgggcgcccgccgagggcccat ggccctctgctgagcagcatcgacatcgaggacccacgcagcacctgctggacatccctaa gctggaccggcccgggcgcccccagtgagagagcccacggccatccagtgccctaca atggggacctcaatggacttctgtgtccagaccgctctgtcaggtgatagctacccagcaa acaagactgtcttcggaccatgccacccatgaacctgcaagagaagcaggtcatctgtctc aggagatgatagctccacctgcattgggattttggccaaggaggtggagattgtggtcagc tgaacttagcatttcaagcaagcccggggaagcaacaagtgaaaattcagcctgtcgtcca agtatgactgggaacagaagtactactatggcaacctgattgctgtgtactactccttggcc tatgccattcggcgtgccaacaatggctctgcccattgggtgggtgatcagctcagcacttcg gagcgaccctgtctcaagggttcacagcgaggtgtgctgtatctgcttcgacacccaac tctccacagctggcctgctggatgaggcaggaacctgttctgtgtgctgctgtgtgta atggcaaaattcaagaagagatctgtgtccatattcggcagccagagggcacgccactgaac cactttcgcaggatcatctgtgtccccttcacccctgagggagagcgaagactgtgtgaggag agcagcccaacagtgccctgtgtcatgaagaccgggctgaggtgtggacctggacatg ctccgctccagccacagtagctggcctgtgtgatgttagccagatcaagcagggcttcattgtg gtaaaagggtcatagcagctgcccagtgaaaggagccctctctcctgatgggactgtgtggt actgcgagccacgatggctatgtcaagttctggcagatctacattgaggggcaagatgagcc aagggtgtgtcacgagtggaacctcatgatggcgcccccctctcctgctcctgttctgtgac aaccataagaacaagacctgatgtccctttctggagggttccttattactgtgtctgaccagaa ccgagagttaaatgtgtgtgtacagtatcctggacctgctgcagactattcgttctccca gatatcttcagctcagtgaggtgtgccccctagcctcaagggttgcctggaacctctcagcagaata cctgattctcagcgatgtgtgcaacggaggtcctctatgtgtgaggtgtgtgcaaaaccaggga ggaggggccacgctgcttcagctccatctcggaggttcctgtcaccacccctgtgtgagctt ggtatccagggtgtgagtgctgctgcccgtacggcacactgaggtgtgtgctgtccggaagagg aaaatgacagcctgggtgtgtgtgtaccatggagccgggtccatggagctgtggtggtgg tgtctcatcaagctctttgtgtgcatactaaggcactgcaagatgtgcagatccgttcagc cacagctgaacctgatgtgtgtggccccactgcccaccacactgcccacgaggacttcaca ttggagagctctggtggccgaactgggctctgagggcctgggtcagccgctcacggctccca gcctgacctccgacgaatcgtggagctgctgtgacctgcccacttctcagctgtgagcagtg gaccaagcccaagtgtgtgacacctgacgcttcatgacacctagcgctccttgcagcagat cactgctctcccagcagcagcagcagcggtagcagcagcagcagcagcagtagcagcag ctcccttacagctgtgtgtccatgagcagcacctcagctgtggacccctccttgaccaggcc acctgaggagctgaccttgagcccaagctgcagctggatggcagcctgacaatgagcagc agtggcagccttcaggcaagcccggtggcctcctgctggtgctgtccagccccagctg acaaaactgactccaaggggcgggccagggtgctactgcccactctgcactgtccctggag ctgcagggaagtggagccccctgggctaccccaagcctccctagccgcaactgttccctga tgtatctctcagcttccactgcccctgtccaggacatccctgagattgcatctgagccctgt cccgtgtgtttgtgctcctgtgacccagaggcccttgagccagacagtatgcttcagcggcct cggcactgcacctgtgttcccacggccccggccagggcccgagctggccccccagctg ggtgtgatggaggccctggggtgtgagatcggcataataccccctcctcctgtgaggcagc ctgacccaggaggcctcgtactcgtgacagtcaggtttggcccacagcacctgacattactg tgagacctgagcaccctggcagaagccccagggaatggccttcaggaaaagcacaagag cctggccttccaccgaccaccatcacctgtgtgagcaacgtgacagccaggtgacagtg ctgagcaaaagtacatgatgatgaggtggccagcctgtcctgtcttcaggaggcctttggca	8

		ccaaagtctctgctccacggctgcttgcgaaggactggaagaccaagggaatccccctgaac ctcaccacaagctcaagaggaagcaagaagatgatgggagatgagccatgggatcccg gctcacagagcaccaggtggcagagccccctgaggactggccagcactaatgtgcaacag cagagagagctggcagagctgcccacagccaggaagagctgctgagcgtctgtgtacc caactcgaaggcctgagagcacagtcacagggccacgtagaacgtgcccctgagactggc acgagcaggaacagcggcggctggagcagcactggctgaggggcagcagcggggag ggcagctgagcagcagctgacacaacagtgttcccaagcactgtcgtcagctgtagctgg gctgctagagcgcagcagacgggatgagatcaagaagacagtcctccatgtgtctcaagg agtctggagcctatggcagcccaactgagcaactcagtggtaccaagctcacagctgtgga gggcagcatgaagagaacatctccaagtgtcctcaagaaactgactgatgccatcg cccagcagctgcagacacattacaaggccgatgcaggctgctaccgggaagccttcca gagtggtgtgctgcccgtttgagaagagctgccaggccatgttccagcaaatcaatgtag cttccggctggggacacaggaactgtgagcagctagaagccacatgaagagccgggaag gcacgggaacagcagggccaggagcctgtgctagcccagctgaggggcctgtgacac actgcagagtgccactgagcagatggcagccaccgtggccggcaggtttctgtgaggtg cagcaccagctgcatgtgtgtggcagcctgagcagtgatccatttagcacagctacagcg catcgttaagggtgaggtgaggtgtgctcgaaggagcagcagggccggtcacctccagc atcatgcagggccatgctcagctgtgacacctgtcccctgtcccaccttgactgcccag ggccagcaaggccatctcctgagctgtgagcagggccacccaatcaggcccttccagca ggcgctgacagctgctgacctgaacctgggtgtgtatgtgtgaaactgtggaccagccca gggttttggcagccacctgcccgtctccagcctgtgctccttccctacccagcagctg gcatctgacctggcactcgaactgacctcaagctcagctacctggaagaggccgtgtatga cctggaccacagtgaccccatcactcgggaccacatgggtcctgtatggccagggtgcgccc aaaagcttttcagttctgagggctgagccacacaactcactggcaagcagctcggcgctc cagcctcatgtgtgcatggcctgtgacccccagcctcccttagctgctaagcctgcttgccta gggtgtgggtgagtgactgaaggccagcagacaggcctagggctggggcaggggtgacggc gccccttaccctgctcagggccccatctctgggtgtttgggggtcagggagcagggagcactg ggcgtgtgtacagcgtgtgtgtagtcagaaagtttagctggcccagggcaggtattgcgcc tgtgtgggtgtgcatgctgagcagcatgacctgagatcgtgacaccactgtagtgaaatttc catgttcttttaccttaatttgatctttttgttttgaacaaatagaaatcaatgaatgcttt tggaataaaatggagtatgtgtgtg	
FGFR2	NM_000141.4	ggcgccggctggagagagcgggtggagagccgagcggcgccggcgccgggtgcggga gcccggcagggagcgcgcgcggccgcacaaagctggcgccggcgccgggtgcatgc ggcgctacctggcccggcgcgactgctctcgggctggcgccggcgccggcgagcc ccgggggccccgagggcgcagcttgcctgcgcctctgagccttcgaactcgcgagcaa agtttggaggagcaacgccaagcctgagtccttctctctctgttccccaaatccgaggcca gcccggcgccgctcatgcccgcctctccgcagcctggggtacgcgtgaagcccgggag gcttggcgccggcgaagaccgaagaccactcttctgctgttggagttgtccccgaaccc cgggctcgtcgtttctccatcccgaccacgcggggcgccggggacaacacaggtgcggg aggagcgttgcattcaagtactgcagcagcagcggcagcgcctcgttctgagcccac cgagggctgaaggcattgcgctagtcctatgccgtagaggaggtgtgcagatgggattaac gtccacatggagatatggaagaggaccggggattgtaccgttaacctgtcagctgggt cgtttcatctgctgtgtgtacacatggcaacctgtccttggccggccctccttcagttt agttgaggataccacattagagccagaagagccaccaaccaataacaaatctcacaacag aagtgtacgtggctgcgcaggggagtcgtagagggtgcgctgctgttgaagatgcggc cgtgatcagttggactaaggatgggtgctacttggggcccaacaataggacagtgcttattgg ggagtactgtcagataaaggggccacgcctagagactccggcctctatgtgtactgtcca gtaggactgtagacagtgaaactgtgtacttcatgtgaatgtcacagatgcatctatccgg agatgatgaggatgacaccgatgtgctgggaagatttgcagtgaagacagtaacacaga gagcaccactgtgaccaacacagaaaagatggaaaagcggctccatgtgtgtcgtcggc	9

	caacactgtcaagtttcgtgcccagccggggggaacccaatgccaacctgcgggtgctg aaaaacgggaaggagttfaagcaggagcatcgcattggaggctacaaggtaacgaaccagc actggagcctcattatggaagtgtggtccatctgacaagggaattatacctgtgtagtga gaatgaatacgggtccatcaatcacacgtaccacctggatgttggagcgatcgctcaccg gcccacctccaagccggactgcccgaatgcctccacagtggtcgaggagacgtagag ttgtctgcaaggtttacagtgtgcccagcccacatccagtggtatcaagcacgtggaaaag aacggcagtaatacgggcccgcgggctgcccctacccaaggttcfaagggccgggtg ttaacaccacggacaaaagagattgaggttctctatattcggaatgtaactttgaggacgtg ggaatatacgtgctggcggttaattctattgggatacctttcactctgcatgttgacagtctg ccagcgcctggaagagaaaaggagattacagcttcccagactacctggagatagccattta ctgcatagggtcttcttaatgcctgtatgtgttaacagtcattctgtccgaatgaagaac acgaccaagaagccagacttcagcagccagccggctgtgcacaagctgaccaaactgtatcc cctgtcggagacaggttaacagtttggctgagtcagctcctccatgaactccaacacccc ctggtgaggtataacaacacgcctctctcaacggcagacaccccctgctggcagggtctc cgagtatgaacttcagaggacccaaaatgggagtttcaagagataagctgacactggcga agcccctgggagaagggtgcttgggcaagtgtgcatggcggaaagcagtggaattgacaa agacaagcccaaggagggcgtcaccgtggccgtgaagatgttgaagatgatccacaga gaaagacccttctgtatctgtgtcagagatggagatgatgaagatgattgggaacacaga tatcataaatcttctggagcctgcacacaggtggcctctctatgtcatagttgagtatgcctc taaaggcaacctcagagaaatctccagccggaggccacccgggagtgagtgactcctat gacattaaccgtgtcctgaggagcagatgacctcaaggacttgggtcatgcactaccag ctggccagaggcatggaggtacttggcttccaaaaatgtattatcgagatttagcagccaga aatgtttgttaacagaaaacatgtgatgaaaatagcagacttggactcggcagagataca acaatatagactattacaaaagaccaccaatggcggtctccagtcgaagtggtgctccag aagccctgtttgatagagtatacactcatcagagtgtgtctgtccttgggtgttfaatgtg gagatcttccactttagggggctgcctaccagggttccgtgaggaacttttaagctgc tgaagggaaggacacagaatggataagccagccaactgcaccaacagctgtacatgatgat gagggactgttggcatgcagtgcctccagagaccaacgttcaagcagttgtagaagact tggatcgaattctcactctcacaaccaatgaggaaacttggacctcagccaacctctcgaaca gtattcacctagtaccctgacacaagaagtcttcttctcaggagatgattctgtttttctccag accccatgccttacgaacctgccttctcagtatccacacataaacggcagtgtaaaacatg aatgactgtgtctgcctgtcccaaacaggacagcactgggaacctagctacactgagcagg gagaccatgcctccagagcttgtgtctcactgtatataatggatcagaggagtaataatg gaaaagtaatcagcatatgtgttaaagattatacagttgaaaacttgaatctccccaggagg gaagaagggttctggagcagtgactgccacaagccaccatgtaacccctctcacctgcctg gcgtactggctgtggaccagtaggactcaaggtggagctgcgttctgcttctgttaatttgt aataattggagaagatttatgtcagcacacacttacagagcacaaatgcagtatataggtgtg gatgtatgtaaatatattcaattatgtataaatatattatatttacaaggagttattttgtatt gattttaaatggatgtccaatgcacctagaaaattgtctctcttttttaaatagctatttgc gctgttctacacataatttcttaatttccaggagcagagggtggaaaaacttttgccttcagg aaaatgggtataacgttaattttaataaattggtatatacaaaacaataatcatattatgttttt gtaatttaagtggcatttctatgcaggcagcacagcagactagttatctattgttgactaac tagttatcagatccttgaagagaaatatttacaatatatgactaatttggggaatgaagttt gatttattgtgttaaatgctgctgcagacgattgtcttagacctcctaagtccccatattaaa agaactcattcataggaagggtttcattttgtgtgcaacctgtcattacgtcaacgcaacgtc taactggacttcccaagataaatgggtaccagcgtcctctaaaagatgccttaatccattcctga ggacagaccttagtgaaatgatagcagaatgtgcttctctgtgagcgtggccttctgctctg agttgcacattaatcagattagcctgtattctctcagtgaaatttgataatggcttcagactctt ggcgttggagacgctgttagatcttcaagtcctcatagaaaattgaaacacagagttgtt ctgctgatagttttgggatacgtccatcttttaagggttgccttcatctaatctggcaggacct	
--	---	--

		cacccaaaagatcagccctafacctacatcagacaaaataatcgccgttctctgtactaaa gtattgtgtttgctttggaaacacccactcactttgcaatagccgtgcaagatgaatgcagatta cactgatcttatgtgttacaaaattggagaaagtatttaataaaacctgttaattttatactgacaa taaaaatgtttctacagatattaatgttaacaagacaaaataaatgtcacgcaacttatttttaata aaaaaaaaaaaaa	
<i>FXVD7</i>	NM_022006.1	ccccacatcggtcctgcttccagctgctgcagcgcgcccttcgccgcaaagcatccag cagccccctgctccggcccagcatggcgaccccgaccagacccccacaaaggctcctga ggaaacctgacccattttactatgactacaacacggctgcagactgtggcatgactctggaac catctgttctgctggttatcctcatcgctacagcaagaagggtgaagtgcagggaaggcgga ctccaggtctgagagcccaacctgcaaatcctgtaagtctgagcttccctctcagccctggt ggcgcgggcggtgaacaccttcccagggaactccgctgcggacccctgctgagcgcggg agcctgaggaccgggtggaggcggtggggacccagccgcgcgccgggagcgctccc gaatgagccgccccaccccaagggctggagccgctgcacccctgctgtccctctccag ccttgcaatgacgatccccaaagagcccgctgcacccagacccagggcctcagggcct ccagctcctgggatccgggagttccatcccgccccagcacccccagcatcccggtgatggc ccccctgcacctcctgtctcatcccgaaatccgctccctggccccctcagtgctcatgtctt gagcttaataaafgtgcatttgggttttctctg	10
<i>FYCOI</i>	NM_024513.3	accctcttgggtgctgcgctcatggccgctcagcaccgcgttccgctcttctcgttggcccc gaaagtcttgggtctgcccggcggtggaccacagagcgctgcccacatggagtctgacca ctgctgagcagacagccaccgaggcggaattctgagccttctctggaccagggcaggga gacatacagacaagaaggcaaaactacatggcctccacaaatgcagagagccagctcca gagaatcatccgagacttgcaagatgctgtgacagaactaagcaagaatttcagggaagcag gggaacccatcacgggatgacagcaccagctgcataaatttctataaacttgagtatcctctg caatttgatcagaaagagaaggccaccctcctgggcaacaagaaggactactgggattactc tgtcctgcttggccaaggtgaaaggagccaatgatgggatccgcttgcagtctatctca gagctccgaacatccttgggaaaggaaagagcatttattcgtactccttgggtgcaccagagg ttggcagacacettacagcagtgcttcatgaacaccaaagtgcaccagtgcactgtactatgca agaagcccccttctgcagccaaagctgagctcgacattgtgggccaactctatgagctgact gaggttcagttgacctggcgctcgaggggcttgaacttgatgctgcttggccaacatttgcca ggaggacgctgaccactggctcttctgcttacctgtggaacccctagccgagctccagc atgagcagcttggtgagcagctacctgcagactcaagagatgggtgcacatttgacctgaa agccccctaacaacagaggcattggaggccttgcagatgcgactagagctggaccagtt ggagggtcgaggagaagcagctacgggagcgcatgcagcagctggacagagagaaccag gagctgaggggcagctgtcagccagcaaggggagcaactgcagacagagaggagagg ggcgcactgcagcgaggacaacgttcgctcacttgccttggtagctgagctccagaagca gtgggaggtcaccagggccaccagaaactgtgaaggagctgcagacatgcctgcaggg cctggagctaggagcagcagagaaggaggaggactaccacagccctgcggcggtctg agtccatgctgcagcccttggcacaggagctgaggccacacgggactcactggacaagaa aaaccagcatttagccagcttcccaggctgctagccatggctcagcagaaggcagatagg catcagacacaaaggggccggcaagaacctattccagtgatgcggcccaggagatgcagg agctagggggagaagcttaagccctagaaggggagagaaccaaggtgcaggaggtcaac agacagcagagtgcccaactggaacagctggtcaaggagcttcagctgaagagagatgcc ggggccagcctggagcgctgtgaaggagatggccccactccaggaggagttgtctggga agggacaggaggcagaccagctctgacgacggctgcaggagttgctggccccacagagct cctggaggaggagctagcagagttgagcgggagaaaaaacagcaacaggaggagaa ggagctgctggagcaggaggtcaggtctgacccggcagctgcagttcctggagaccag ctggcacaggtgagccaacatgtgagtgacctggaggagcagaagaagcagctcattcagg acaaagaccacctcagccagcaggtgggtatgctcagcggttgcctggcgccctggccc agaactccagtgaggagtgagaagaatgaggccctgctcctgtgaactcagctgcaa	11

		gaggcctgggggaagccagaggaggagcagaggggcctgcaggaggcacagttagacg ataccaaggtgcaagaggcagccagggagggaagagctccggcaggccaacaggaggct ggagaaggagctacagaatgtgtcgggctgaaccagctcctggaggccaagctgcaagc cctgcaggccgattaccaggctttgcagcagcgggaatcagccatccagggtccttggcct ccctggaggccgagcaggccagcatccggcacttgggtgaccagatggaggcagcttgc tggctgtaagggaaggccaaggaggccatgaaagcccagatggcagagaaggaggccattc tacagagcaaggaggcgaggtgtagcagctgcgggaggagggtggagcagtgccagcaa ctggcagaagcccggcacagagagcttagggctctcgagagccagtgcagcagcagacc cagctgattgagggtctcacagcagagaaaggccaacaggaggttggcccaccactgaca atgaagcccgtgagctggctgcccagctagccctgtctcaggcgcagctggaagtccatcag ggggagggtccaacggctgcaggctcaggtgtggacctccaggccaagatgcgggcagc cctggatgaccaggacaagggtgcagagccagctaagcatggctgaggccgtcctgaggga gcacaaaacccctgtgcagcagctgaaggagcagaatgaagcccttaacagcccatgtc caggagctgctcaatgctcggagcgtgaaggggcactgcaggaggagaggccgctga ggccagcagaggaggaggagctgcggccctgcaggaggagctgtccaggccaat gcagctccagggaagcacagctggagcacgctgagctgcaaggagcagctgcaccgggccc aacacagacacagctgagctgggcatccaggtttgcgactgaccgtgaaaaggagcga gtggaggaggcactggcctgtgtgtccaggagctccaggacgccaaggaggcagcctca agggaggcagaggggcctggagcggcaagtagctgggtgcagcaagagaaggagagctt gcaggagaagctgaaggcggccaaggcagcagccggctcactgctgctgcaggccc agctcggccaggcagagcagcggggcccagagcctccaaggagctgcacaccaggagctc aacaccctcaagttcagctgagtgctgaatcatggactaccagagcagacttaagaatgct ggtgaagagtgaagagcctcaggggccagcttgaggagcaaggccggcagctgcaggc tgctgagggaagctgttgagaagctgaaggccaccaagcagacatgggagagaagctgag ctgcactagcaaccatcttgcagagtgccaggcggccatgctgagggaagacaaggagg ggctgcccgtgctgaagacctaagaaggaccagaaaggaactcgaaaaagccacaacaaa aatccaagagtattacaacaaactctgccaggaggtgacaaatctgagagggaatgaccaga agatgcttgcctgacctgtagctcaacagaaccaagaagtatctcaggagcggctgata gagctgctcagggacaaggtgctctcggcagaagtcagatgcccaggaaattccagcagaa gctcagtgctgaggagagatggctcgagacacagaggcaaacactgctcactgtaag cgggaggtcagctgagtggtgcggcggcaccactgcaggatagtggccgcatcttctgttac tactgctgcaacaactacgtcctgagcaagcacgggtggcaaaaaggagcgtctgctgcag cctgttccagaagctcagtgaaaggccctggctcccctgtagcagtggtcaggcactagcc agggagagcccagccctgcactgtcaccagctcactggggccccaggccacaggaggcc aaggagcaatacagactacaggccaccggacgacgctgtgttgatcatcacagatgag gaattgtgccagatacaggagtcggctcctcttggcctgaaacaccactgaaactgattctct cgacccaaatcggtctgaacaggatactacatcaacctcgctaacgctgaggacactgaag acatgcccgtggggcaggattcggaatctgctgctgaagtctgagaactgatgataaaa gtacccctcacagtgatgagatgcagcttcggggagggtagcaggagctgtttgtgag gtccagcacctacagcctgatcccatcactgtggccgaggcaggcctcaccatcagctggg tcttctctgaccccaagagcatctcctcagtggtgtcttccaggaggccgaggacacacc gctggatcagtgtaaggctctcattccacgaccgatgcaactcccacaaaggagaacatcc aggccagctcaaggctgcacacccggcatctacatgctcatcttcgacaataccttcaag gtttgtcttaaaaaggtattttatcacttgacggttgatcgccctgtgatctacgatggaagt ttcctgtagcttcagcacctcagtaactcacttcacacaggaaacactgctcttctcactg tcacataaagcatfttttaaaaagtcagctgtccaaaatcatcaactcagccccctggctgcc cctcagaggcgggtctgtggggaggactttgtgctcagcactctgcaccggccactcttagccc ccgaggcgtgaagggtcaggaatgtttccattagtagagactcagctgtgtgcacacc aaagggtgctctgcgaagggttaaacaccaggagaccatcagcctctcctgggagcaca gttggtacaggcctctgtgagaggtttacgggcagggtgattccactctgctgtgga	
--	--	---	--

	gagattttctgcccctgccccaccaggccctgcatgttgagactgagctgggtgactggcc atgccctgtgaatccicaggctgtgacgccctcaggctactcctgggaaaaggaggtacacag ccatcatgagtgctgggtccaggggaccocccggagatcctgaccagctcctccagctatgc tcttgcctcactgcccagtaagctggaggtgctccagaactcagcagtggtggaggggc ctctaagctgactctctttctggccctttgtctgggtgattctgctcctaaataaagcccttact cagccagacctctccacagctcaaaagcattgcccataagaatcagaagtaagataatcaag agcaaaaccactgtacttggggcctgcaatggctgtgtgactacatctaatgcccgaatg ccagccagtggtgatgtgtgaccacagagcaggatgtgtgattggctttagagctactcctca gctgatggcccactttgtttataataaagagcttctgccccactgacagatgtttactaatg atcatagcccaggtatgaaccactttcaaacattggggccttcttaacaaaagtctttgataact aagaaccaaagttaacagagtaaacagaggcatgatggatccctggggccctcctcctg acagggtcccaacagcccatttggccacttccactgctcagcccacacagacctccaggga gacatcccccttgaggcagagagatcctgttccctattccagacaagaatttatttacttcc ctgttctctgtgctcttttcttccccaaacagatagctcaccttggacagctcttctgctcctg ttcatggaaccagctgctgacgtcaggccccagggttcttccatgggtgaacagagcatctga caaaaggtccagtttggccagggtgagggagagagcaccagacaggctatccgagaat ctgagagctggggccggcagttctccagctaccccttggacctaagtcagctcacacatttc caaagtcttcttctgataacccctggtctggctgttttggaggcttgagaatgggtcaggggact ccaggccaagtcacacagagaccccaaacaccacacacagcagccacaacctcacca ccaacaaaggaggttttggggccacaagtaagaggtcatttctgggaatggactcagacct ftaaacagagaggttgagcacttccagtcagttttaaagcaaggcatggggaacagggaatag aaccttcaagaggttggccagagaaaagctgggccccttctgcttcttcttggagcag cctcttctggcagaagccatcagggtgctaatcatcttctcctggccaaggctctgacctgct tagtactggaatagaggtggccaggccccagcagctcttcttggcctgatgttctcctcaca ggcatgccagctggcctgagatgattcagaacaatcatgctaactttgaatccatccagccac ttgcaaatgataatcagaagtcagcttggcttcttcaaggatactgagagacttggccaagctg gagcaatctagaatcttggagtgcttggcttccaaaggatactgagagacttggccaagctg atgaccttctgaagtgtcactgacacatagcaacaagaaccaccattcactgagtagcta gggttggggccctgggacattccatctgaggtccttctgaacatgtcactccacagcagagg accggttgacagcttaccagaaccactcctccaggagagctggatgttttggctgcaacacct gagcactgactgctattgtcaaaaaagccttctgctgcttggaggactgcccgtgcccctg aggtagcttcttaactatgtgttcttagcgaatttatttttggctgggtgacattgtatttgg ttaggttctgtttaagctcaagtttctgtgctctctgagctacaaaacatcttggcataftaa gagtggctttataaataagcttattctgataattaatcagattcccaacttactgagaattaaggac tgggttactttaaagaatgcaaatagcaattgaagaaccactgctgagggtgtagccctgg ctagactgaattacactagaaatcagccagaaggaaagctccttgggacccagatcactctt tttttttttaaaagggcgaccccttggatggtcctcctctgaataacagttacgtctcctatc gataccagatgcttcttcatcatgcccactgaagccactcaccaccttcaagaacatgccaacc ctgtcagattcacttaccacaacaaggaggcacgttggcacaaaagtgttctcctcaggt ccaagtggactctacagagtgcttggactcaacacactggattccagggtggactggaccaag agcaggcaaaagacacgggaactgaaaaactccacagggttggagaatagaaatgaaaag ccacgctatafaactcaagaataaatggtgttttggaaatttfaaaatcatcgaagggtgtga aactatttcaggcccaaatgaaggaaatgccagttggggatgaaatcacagagcctgtgtt ttatgatatgggtgatgtcactgatgaaattttaaaggagtttcagttttaaagtgcgcatgatt ctacatatgagaattctttaggccaagaaactgtccttggctcagagggttgggaattaaagca gagagaagccattcgtgatgcttagaaccaaggatggtcatgtacacaagaccatcgagac ggccattctgtttacaaaacacttaccagaagacactttaggggaactttagtaagtcttct catttcattatgttcttccaaggaaacagagagactgaftaataattctcttcttctttaaagc acttttaaaataataaagtacatcttgaatttggggaggcatctctgatttaaaaaagaaaaag gctgcttgatgtatgtatgcagagacactctgcctctggtgctgcagagcaataaccaagcc	
--	--	--

		tcatttggaggctcaacatttggaaatgcactttaattgattaatcctcaattcatgtggccttacg ggatgtgtgggtctggaccaccaattcattcttctgccaagaattatctagaagcacatcaa ataccagcacccacctgtcaatgggggtggaactttgtatccctaaagcatattatttata gtgtctgccatgccatgtggaatactttatttttaacctcaggatttaataaagtaaacactatg acatttagaca	
HNRNP U	NM_004501.3	ctcgcgcaggcgcagctctcgcgtctccctcgcgaactcggtagaagggaattggcgcggttc gacaccaggcggatccgctctgcagcacgaacctatccagccgcagccgcagccgcg cccgggcccaggagcagccgcagcagccgccaccagtgccgagtgagcggagccgag tttgagcagcgcctagcgggtgaatcggggccctcaccatgagttcctgcctgttaagttaa aaagctgaaggtgtcggagctgaagaggagctcaagaagcgacgcctttctgacaagggt ctcaaggccgagctcatggagcgaactccaggctgcgtggacgacgaggagccggggg ccgccccgccatggagcccggaacggcagcctagacctggcggggattccgtgggc gctcgggagcagccctcgcagcaggagccgcggccggcgatgaagaggaggag aagaggaaaggaggagggaaggaatctccgtctggacggcgaccagatggagctaggga gaggagaacggggccgcccggggcgagccgactcggcccgatggaggaggaggcc gcctcggagacgagaacggcgacgacgaggtttccaggaagggaagatgagctcgg ggacgaagagggaagcgcggcgacgagaacgggcacggggagcagcagcctcaacc gccggcgacgcagcagcaacagcccaacagcagcgcggggccgccaaggaggccgc gggggaagagcagcggccccacctcgtgttcgcgtgacgggtggcggcccgggcgga ggcagggccagcagcagcgggaggggacggcaaacagaacagaagcggagata aaaagagggtgtttaaaagaccacgagaagatcatggccgtggatattttgagtacattgaag agaacaagtatagcagagccaaatctcctcagccacgtgtgaagaagaagatgaacactc gatgacacagtggtttgtcttgatacttataattgtatctacattttaaaatatcaagagatcgtct cagtgctcttcccttacaattggagagtttgccttcttggcgtggaggagaagcctcctatgtg gtgtcaaaaggcaaggtgtgtttgagatgaagggtacagagaagatcccagtaaggcatttat atacaaaagatattgacatacatgaagttcgtattggctgtcactaactacaagtggaattgta cttggtaagaagaattttcttatgggtattcttaaaaggataaaaacatgcaactgtgagact gaagattatggagaaaagtttgatgaaaatgatgtgattacatgttttgcctaaacttgaaggtgat gaagtagaactctcgtatgctaagaatggacaagatcttggcgttgccctcaaatcagtaagg aagttcttctgagcggcactgttcccgatgtctctgccacaactgtgcagttgaatttaattt tggtcagaaggaaaagccatattttcaatactgaagagtatactttcatccagaacgcccct tagaggatcaggttagaggaccaaaaggggcctgaagagaagaagattgtgaagtgtgat gatgattggctgcccaggagctggaaaactacctgggtactaaacatgcagcagaaaatcc agggaataataacattcttgccacaataactattatggataagatggtggcaggttttaaga agcaaatggcagatactggaaaactgaacacactgttcagagagccccccagtgcttggg aaatttatigagattgctgcccgaagaagcgaaattttattctggatcagacaaatgtgtctgct gctgcccagaggagaaaatgtgctgtttgcaggcttcagcgaaaagctgtttagtttgc ccaaaagatgaagactataagcaagaacacagaagaagaagcagaagtagaggggaaaga cctaccagaacatgcggtctcctcaaatgaaggaaactttacctccagaggtagctgagtg ctttgatgaataaacctatgttgaaactcagaagggaagagccaaaactcttggagcaatat aaggaaagaaagcaaaaaggctcttccaccagaaaagaacagaacactggctcaagaaa agcaataaaaataagagtggaagaaaccagtttaacagaggtgtggtccatagaggacgtg gaggattcaatatgcgtgtgtgaaatttcagaggaggagccccctgggaactgtggcgat aataggaggggcaacatgccacagagaggtgtgtggcggtggaggaggtgtggaatcgg ctatccataccctgtgcccgtgttttctggtggtgtgtactcaaacagagggaactaca acagagggtgaatgcccaacagagggaactacaaccagaacttcagaggacgaggaaaca atcgtggctacaaaaatcaatctcagggtacaaaccagtggcagcagggtcaattctggggtc agaagccatggagtcagcattatcacaaggatattattgaataccaataaaacgaactgat acataatttccaaaacttcacaagaagtcgactgttttctttagtaggctaacttttaaacattc cacaaggaggagtgctgcgggttccctttttagaagcttgggttgatttttttctttttt	12

	gtacattttaattgcagtttaaaagtgaatcgtaaagagaacctcagcattgtgcacgataagag aatgtgtcagtatctcaggggtctacattttatctgtaaaatgtgactttttttttttatcacacag aagtaaaatgtgtctgtacctgggtgtctttttaagaattactcccccaattctcacagagaa taacagtcgggagtcattgtcacataataagaatgttagcaaccagattcatgtaaggacta agtggctcctcatgaattgcattaagactctgtactgtcatattacactccatcctctgtagtgtg ctgggtagtggagggggtaagctaaatcatagttctgacaataactgggaagggtttttcttaa aataacaatgggaattgggtataatgggattgaaaactaaaacttgggaactaagatagagaagat ggagtgatgtagaagggtctgttaaaatgtaaaacttgggtgcattattgtgagggtcacaac ttgtgaaggtaataaccataattttccattgttctgtcattttgattctgaaaagaagctggcttg cccattcttataaaaaaactgtgttaaatccagttgtctaatgggatctatatgaagttagccat gtctgtatgcccttcccaaaaactgtataactagtgtgtctgtagttagtaactccaccatc ttgttaagctaatgaattgtgagtcaccatttatcttaatttttaactatgtcagttcttgaatgg gtatctccttagcctgtctgattcttttcttcttaagaagggtgggtggagaatttaatttagacgtt tgtttgcaataaaaagaattcattttactctgttttgggattctgcccataagggtcaaaatccctt tatataactccaagaggagaatttttaagtgtgtcttctggacagcttattctttactctgtca tagaacatttaggttttaaaaacttaattgtatactgacaattgatacataattatgaagtaagggtg aattcttccctccctcccccagacaacttttaacataattatgaaggggaaaagggtactgg ctgggagaagtaaacactgagtttatcatctttacagaatgctaatgtctcctcaactgattattt atatacatatataatgatacatgaaactctgggatcagatgcttttagaagccatcatgcaagcca gtcattgatgtcactgtacacaacactgctaacttgcactgtagctatgtaataacattagatccc ctaattgtaattatattgggtttgcacagaaactttaattcttccctcaccaatgtgaagttagga atcaggagtcacaaactgtagaactaaaattgacttcagctagcgtttctgtgttttttaggttg ctttgtaagttttaggtttctatattctgtattgtctagaattttgttttagccctttaaactcagatca taaatatgaattcatacttctaagggaattttctgtctataagctggagtttaggtgatgtataggttc agttgagacatttttgaacaggcacaatccttagttaacataagatatttaacagttgaagatagt gtcatggatttttatcttttttagcaagtaattgtctaaagaccactggcctgagctactactcttcagt atacatttaggtgtcatagactactagaggaaacagtttcagggtttgtatgctaatcagttgtg tgtctcaaaagtgtctttgtcccttaaaaagtgttgatatacttctagttaaaattgtcttataa ggaaattcattttataattgcagtgggaaagttaattgtcaagtaaacactaggttagactatcatgcc tgttttagccagagaatttgggggagagagaatagataaaaatggcaccagaaaaatgtt aaaatcttagtcaagactagaattatacaattgtctacactgtatggcagaataaaccttataa agtgttaaggaaattcagagaagggaatgtaccaataagcaacaggagaaaatttaggttaa gaagtaagatacgaacgagaacactgattattgtctatccttcccttgcctccctaattggcaag caaaactctgaacatctgaaaaggatgttagttctggacaaaatcctgactaccagaggaaact cactgtgagattgtctgtgattgaagggtgtcttctactaagggttatattttaagtgaataacac atgctgagtgtaaaactggcttggattgtgcagctgcagtagtacaaaaacagcatagaatttg agaaaactaaaactgtctatgagatagctatgagaaaactaaaactgtctatgagatagaattgat gtaaaattatgtgaaagttttccctcatatactcacatacagcctttgaagggtcttggctctga ccggttgatggccttgagcgagatgaatcatgaaattgagtcacaatcaattgacattgaaatg acaagaggaaaactcttaatacatataaaaacaagctctcatttgcctaggatagatactgtcttaa aaataaagactgaacctgatgttctgagcactagcaacaagggtattttaacaagtttaaggga attctctgaaaaagtataaaattattctaggaaacataaccataatagtgttttaagggaacttca cctggggtatttatattcatgaacagagtgtattctgtatttaaatgtctcatttgggaattgga tgacatgtttttgataaatttattcacaataataaattgacttttattctaggaccatgtgaataatgg gttcattgcacaaatacaaatattttaatagcttcttaggcagtggtgttagacatcttggatataa ataattgtagatctgtatatttgaatttttaaaaactagaataaacagagaggcataaacatactt agagtccaagtggtagtgttagcattggatataataaattggatgttttacaagggttttcataat tctcttctatacataaattgtctgttttcaaaagtggatggaacttggctgggtgtgtgtgtgtcac gcctgtaatcctgacatttggaggccaaggcgggagatcacttgagctcaggaggttga gaccatcctgggcaacatagttagacctgtgtcttgaataaaaaaaggatggaactgtt	
--	--	--

		agcagagaattttatctacttctcaacctgcttcagaatacccaatfgagatgttccccggaag atgaacacaatactgcatctgaagccatttctccacctaacatcttaaaatgattagagctaa actttgtcattcattcctaattctggagctctgagggtgaggtgttcagagtttggtgaataattgg gtttaagtttaacattttagtaataaaaaagcaaacacatacatgttaaggctgcacaataggtt gcaatacccatgcaatgggactcataccagcataaatggtgagggactgaacattagtgctt gagcaagaattgggttaactacctgagatctctaaaacagtaattgaattactaatacataacca caagtctcttgaattgtaattgctaaattaccctaaaacttagttaacgctgcagtgctcttat taaagcttttttgggggggggtgtgggcacagctactccataactttaattttaaagcatgaa ggtgactagctagtggttagtgcttggtgtagttacataggctgctctgaatcgtcctgtttc ttgcttagtattagcaccacaggtacatattgtaaaataagcattaaaagctattgtccagc	
HPN	NM_002151.2	tcgagcccgttccaggggacctaccctgagggcccacaggtgagggcagcctgectagca ggccccacgccaccgctctgctccaggccgcccgtgctgcccggccaccatgctcctg cccaggcctgagactgacccgaccccgccactacctcagggctccgccccactgctgg accccagggtcccaccctggcccaggaggtcagccagggaatcattaaacagaggcagtg acatggcgagaaaggagggtggccggactgtgccatgctgctccagacccaaggtggcag ctctactgcccgggacctgctactctgacagccatcgggcccgcctcctgggacctgtg ctgttctcctcaggagtgaccaggagccgctgtaccagtgagggtcagctctgcccgcgct cggctcatggtctttgacaagacgggaaggagctggcggctgctgtgctcctcgctccaa cgccagggttagccggactcagctgaggagatgggcttctcagggcactgacccactcc gagctgagctgagcaacggcgccgccaatggcacgtcgggcttctctgtgtgacgagg ggaggctgccccacaccagaggctgctggaggtcatctccgtgtgtgattgcccagagg ccgtttcttggcccacatcgtccaagactgtggccgaggaagctgcccgtggaccgcatcg tgggaggccgggacaccagcttgggcccgtggccgtggcaagtgcagccttcgctatgatgg agcacacctctgtggggatccctgctctccgggagctgggtgctgacagccgcccactgct tcccggagcggaaccgggtcctgctccgatggcgagtggttgcgggtgcccgtggcccaggc ctctccccacggctgacgtggtgggtgacaggctgtgtgtaccacggggctatcttccctt cgggaccccacagcgaggagaacagcaacgatattgcccgtgcccactctccagtcacct gcccctcacagaatacatcagccctgtgtgctccagctgcccggccaggccctgtgtggtg gcaagatctgtaccgtgacgggctggggcaacacgcagtactatggccaacaggccgggg tactccaggaggctcgtgagtcctccataatcagcaatgatgtctgcaatggcgctgacttctatgg aaaccagatcaagcccaagatgtctgtgtgctaccccgagggtggcattgatgctgcca gggcgacagcggtggtccctttgtgtgtgaggacagcatctctggacgcccagttggcgcc tgtgtggcattgtgagttggggcactggtgtgcccgtggccagaagccaggcgtctaccc aaagtcagtgacttccgggagtgatcttcaggccataaagactcactccgaagccagcgg catggtgaccagctctgaccgggtggtctctcgtgctgcagcctccaggggcccagggtgatc ccggtgtgtggatccacgctgggcttaggatgggacgtttttcttgggcccgggtccacag gtccaaggacacctccctccagggtcctctctccacagtgccgggcccactcagcccga gaaccaccaacctcaacctcctgacccccatgtaataattgtctgtctggtgactcctgtct agggtcccctgatgacgggatgctctttaataataaagatggttttgattaaaaaaaaaaaaa	13
KRT15	NM_002275.3	cactcaagggtgagcagcgtgtgtgtgaggaaggcagaaggagttggctttgctttagg ggaggagacgaggtcccacaacacctctgaagggtatataaggagccccagcgtgcagc ctggcctgtgtacctcctgcccagcatctctgggtttgctgagaactcacgggctccagctact ggccatgaccacacattctgcaaaccttctctccaccttgggggtggctcaaccgagggg gggtccctcctggtgggggagggtggcttgggtgggggagctctctggtgggaggtggaa ggcgaagtatctcagcttctctgtaggtttgtctctcagggtcaggaggaggatgggggt ggcatgagggtctgtgcttgggtggaggggctgtagtgttttcgggtggaggctttggagg ggcgtgtgggggttttgggtgggtgtgtgtggcgatggtgtctctctctcagcaatg agaaaattaccatgcagaacctcaatgaccgctggcctcctacctggacaaggctacgtgcc	14

		ctggaggaggccaatgctgacctggagggtgaagatccatgactgtaccagaagcagaccc caaccagcccagaatgcgactacagccaatactcaagaccattgaagagctccgggacaa gatcatggccaccaccatcgacaactccgggtcatcctggagatcgacaatccaggctgg ctgcggacgacttcaggctcaagtatgagaatgagctggccctgcgcaggggcgttgaggct gacatcaacggcttgcgcggagtctgagctgagctgacctggccaggactgacctggaga tgcagatcgaggggcctgaatgaggagctagcctacctgaagaagaccagaagaggaga tgaaggagttcagcagccagctggccggccagggtcaatgtggagatggacgcagcaccgg gtgtggacctgacctgtgtctggcagagatgaggggagcagtacgaggccatggcgagga agaaccggccgggatgtcgaggcctgtgtctcagcaagactgaggagctgaacaaagggt ggcctccaacacagaatgatccagaccagcaagacggagatcacagacctgagacgcac gatgcaggagctggagatcgagctgcagctccagctcagcatgaaagctggctgggaga ctcactggcggagacagagtgccgctatgccacgcagctgcagcagatccaggggctcatt gggtggctggaggccagctgagtgagctccgagatgagggctcagaaccaggag tacaagatgctgctgacataaagacacggctggagcaggagatgctactaccgcagcct gctcgaggggccaggatgccaagatggctggcattggcatcagggaagcctcttcaggagg gggtgtagcagcagcaatttcacatcaatgtagaagagtcagtgatggacagtggtttct cccacaagagagaaatctaagtgtctattgcaggagaaacgtcccttgcactcctcactctc atcaggccaagtggaggactggccaggaggcctgcacatgcaaacctcagctccctgcctca gagagctgaaaagggtccctcggcttttattcaggggcttgcagtcgctctattccccctctgc ctctccccactcttctggagcaaggagatgcagctgtattgtgtaacaagctattgtacagt gtctgtcatgtaataaagaattactttctctttgcaataaaaaaaaaaaaaaaaaaaaaa	
KRT23	NM_00128243 3.1	aactagcacgtggctcccgccccagactgcttcttattcactaacctttaccttggcagat gaaatataagattcatcaaccacattgacagcccattggcagggttctgtttctcctcctct gcagggtcacagacacacagagcccagccggtggcaggctcagccgggggtccggggctgct aacaacggctacattcctccccaggggccaagggaatcctgagcgcaggccagggtgtt gggtttgaggtgtgctggatgaaaggcaccctggaagtggaaagggttcggtcattcattaatta attacatctataattgagggttcttctaagagcagtcctttgaaagtacttcttcaaacagt actgcacaaaaggcatcagatattcaccactctcggctgcctcagcacagaagctttattct gggacctgagatcctgtctgagctggcttcccttccaggctcgtcaccctccctttagag atagtgatggttaagatgaccaatgctcagattattctctcattgacaatgccaggatggcagt ggatgacttcaacctcaagtatgaaatgaacactccttaagaaagacttggaaatgaagtc gagggtccctccgaaggaccttagacaacctgaccattgtcacaacagacctagaacaggagg tggaaaggatgaggaaagagctcattctcatgaaagcaccatgagcaggaaatggagaa gcatcatgtgccaaagtgaattcaatgtcaatgtgaagggtgatacagggtccagggaagatct gattaagggtcctggagatgatgagacaagaatgatgcttataataaagaagcagcagaga cttggacacttggatataaagaacagctctgcagccatgtccaggaggcagccagtcaggcca ctgtgcagagcagacaagggtgacatccacgaactgaagcgcacattccaggcccttgagatt gaacctgcagacacagtacagcacgaatctgttggaaaacatgttatccagaccagctct cggctactcctgcaagctccaggacatgcaagagatcatctccactatgaggaggaaactgac gcagctacgccatgaactggagcggcagaaacatgaataccaagtgtctgtggcatcaaa accacctggagaaggaaatcaccacgtaccgacggctcctggaggagagagtgaaagg gacacgggaaagaatcaagtcgagcatgaaagtgtctgcaactccaagatcaaggccata accagggagaccatcaacggaagattgtcttctgaagtgaatgaaatccaaaagcacgca tgagaccaatgaaagttccgctgtgtgtaaaatctatttcccccaaggaaagtcctgacag acaccagtgaagtgtctaaaagatacccttggaaattatcagactcagaaactttattttttt ctgtaacagtctcaccagactctcataatgtcttaatatattgacttttctaataaagtgcga gtttatgagggtaaagctctacttctactgcagccttcagattctcatctttgcatctatttgt agccaataaaactccgcactagctgcaaaaaaaaaaaaaaaaaaaaaa	15

MAN2B 2	NM_001292038.1	ggaagtggcctggcaccttcccggcctggccagggatggggcagctgtgctgctgcc gctgtggcaccgctcctgttctgctgacggccaggggtccagtcgccggccccatccgg gccttctgtgtgccccacagccacatggacgtgggctgggtctacactgtgcaggaaagcat gcgggcgtacgcggccaatgtctacacctagtggtggaagagctggcccgcggccagca gcggcgggtcatcgtgtggagcaggagttttccggctgtgtggatggcgtcgcctcggga ccagcagaataccaggtccgcagctcctggagggaaggacgctggaaattgtcatcgga ggccaggtcatgcatgacgaggtgtgacgcacctgtatgaccagatcctgcagctcacaga aggacacgggttctctatgaacatttgggatccggccacagttctcctggcaggtgacccg tttggcgcctctgcccacgacgcccaccctatttgcgtggcgggcttcaatgccacctoggc tcccggatcgactacgacctgaaggcagccatgcaggaggccgggggctgcagttcgtgt ggcgagggtcccatcctctcagagcggcaggaaatttcacgcacatcatggaccagtac agctactgcaccccgctccacatccttctccaacaggtcaggattttactggatggcgtg ctgtcttccccaaagcctccccaagatgggggtgaccccaacatgagtgagcctgtcaccccg ccaacatcaacctctatgccgagctcgggtgtctcgtgacagtatgccacgtggcgactact tccgtgccctgcacgctcctcaatgtcacctggcgtgtcgcgaccacacgacttctcctcta ttccacagaacctatccaggcctggacgggcttctacacgtcccgcagctcactgaaggggc tggcccggcgagccagcgcttgtgtatgccggggagtccatgttcacacgtacctgtgg ccggcccccggtggcatctggacccacctgggcccctgcagcagctccagcagcttgcct gggcccgtctccgaggtccagcaccatgatgccatcactgggactgagtcctcccaaggtag agacatgtatgcaacgcacctggcctcggggatgctgggcatgcgcaagctgagcctcc atcgtcctagatgagctccagccccaggcaccatggcgccagctccgatgcaggacctg caggacatttgcctcgtctacaacctggcctggacgggtcaccacctgcacctga ctgttggtttccctggagtcgcgtcacagatgaggcgggccaccagtgccctgcagatc cagaactcaacagagacccatctgcgtatgacctgttattctgaccacaatccaggcctca gttacccgcactacaacatcagaccactgcaggggcccaaggggcaccacaggagccgg ctgccactgtggcgagcaccttcaatttggccgaggctgaggagacgcaccagccatgc gggaggtacttgggtcctgtggcaaacgactgctacattgtctgctcgaccaggataccaa cctgatgcacagcatctgggagagacagagtaaccgaacgggtgcgctgacccaggaaftc ctggagtaccacgtcaacggggatgtgaacaggggcccaatttccgataactacctgttaca ccgggcaaggccgcgtgcctgcgtgggaagctgtggaatggagattgtggcgggacag cttgtgactgagatccggcagtaactctacaggaacatgacagcacagaattacacgtatgca atcgcgtcccgctcaccatgtgcgcaggggccatgacggggagctgctctgcccaggga tagagcaggagtagcaagccggccccctggagctgaaccgtgaggctgtcctgaggacca gcaccaacctaaacagccagcagggtcatctactcagacaacaacggctaccagatgcagcg gaggccctacgttctctatgtgaacaacagcatcgcgggaattactaccatggttcatctg gccttcatggaggtgcaaaagcaggctgtgtgtgtgtgctggagcgggcacatggcatctc cagccaagggaatggcagggtggaggtcatgctccaccggcggtgtggaacaacttga ctgggacctgggtctacaacctacgctgaacgacacctcagtcgtccaccagtgctctggct ctgctgggatcctgtgctccctcaccactgcctcgcgcagaggagcgcactggcgctgcagc acaggccccgtgtgtctgttcggagacctcgtgggactgcgcgaagctccaggacccca gcagcaagaggccgtgacgtgccccgaatttcaacctgcagatcctgagcatcctggct ggcgctacagctccaaccacagcagcactctcagaatcctggaaaggccatcgagggg aagcccaggctgacctccgcgtgtctgtcgtgcgtctaccacctgtatgaagtggcgag gaccagtcctgtctcagccagtgacagtgaatctggaggctgtgtgcaggcgctgggtc cgtgtgtggcagtgaggagcgctcgtcacaggacctgggatttgcagctgtgcaccgc tggagctggaggacggggcctggccgcacagagggtgacaccacctctccctcaggcca ccaggaggccccatcatcaccgtccaccaaggaaatccggacgttcttattcacttcaac agcagtgagccctgggcagatgccccggccccagggttccccagggaactccatgtaaca gaacagaccaggacagggaaggcagtgccggaggatgggactggggagtcagctgtct catctgcaggctaatggcaggaaatgtcatatttgggggttttccctaatttttaacaaaatt	16
------------	----------------	---	----

		acattacaagatccagggtttctccccccacactcaatcaagccagccctctctctctgtgcac gtaaaggatafttggcactcatgctgctcattcacaaaacacaaacccaggactttctgcc taaggcagagcacaagactcacagcagcaccgaagcgcatctgcccgtccgggcccctgcc ggcttggccaggctgccagtgtaactgtggacctactgctgcccagctgtttcatagactcat cccattgctgcaacagccctgcaaggggcttggctctccacagggcaggagagggaagt gtagcgcttagcgagagttccagccccagacgcccacctgtgctcagggcaccgctgccc gagcagagaaagccacagcagccgtcagagtcctagagagtgaaacacacagcaggga tgtccaatatcagaactaftaatacaataaagataaaccttcccaggtctatgcccaagagaat tgaaaacatccatccacacaataacctgtgtctccgcttatagcagcattactcaaaagtcaa acggttagcaacaacccaaatgtccatccacagatgaafaaagacatgaagtgtgttctgtccat acaatggaataattatttggccataaaaagggaaggaattctgacgcatgcccacagccgtgagt aatctacaaatattactgctaagtgaagaagccaatcacgagtttatgtgaattgtccagaata ggcnaactctgtgtatcagagacaaagcacattgtgtgttgcagggtactgtgaggaagagaga agaggcgtacagctaacaggggacgggcttcttgggaagatgatgaattgtggaaatgagg ttgcacaacttgtgaaatatactagaaaccaatgaafaaaaacttgggaagtgaaaaaaaaa aaaaaaaa	
MAX	NM_00132041 5.1	tgcgtgcccgtgtatccgggtgctgctgagggagtggttcttggcccgtgtgtgtgtgtgt gtgagtgagagagcgagtgagtgagtgagtgagtggtgtgtgtgtgtgtgtgtgtgtgtgt ttgtcggtagcttccccctccccttacccttcccctcccgcgcgcgtgctgagtgccgtc cctgggcccgtaggaatgagcgataacgatgacatcgaggtggagagcgcaggaagagcaa ccgaggtttcaatctgcccgtgacaaacgggctcatcataatgcactgggaacgaaacgtag ggaccacatcaaaagacagctttcacagtttgcgggactcagtcctcatcctcaaggagaga aggcatcccggggcccaatcttagacaaaagccacagaatataatcagtatatgcgaaggaaa aaccacacacaccgcaagatattgacgacctcaagcggcagaatgctctctgtagcagca aggggaaaagccgagagctgacaaagttcttcttctggtggaattcattctcttctccctcatg gaagatgcaagtaaaaggaaattccgtgcacttgagaagcgcaggtcaagtgcccactgc agaccaactacccctctcagacaacacgctctacaccaacgccaaagggcagcacatctct gccttcgatgggggctcgcgactccagctcggagctgagcctgaagagcccacaaagcaggga agaagctccggatggaggccagctaaagccactcggggcaggccagcaataaaaaactgtctg tctcatctgtctcatctcttctcagttcgttggtagagccctcagaaccatttaagagactttat ttttcttcttcccttttttttaattttttttttacgtagaagctcttggacaacagctctcgtctc cttccccatttccactgtatatttttaatttatttctcagggatttccctgtccccaacagggaatt ttaaaccaaaacaccccaacttggcagcttttctgtggaggacagacggccggccggacactc tgagcacatagtgctctcccaccctaccagctctccagccctgccgggacatgcccggg ggacgctgcccgtcccaggtggcctctcggcccgcctcacctctgatagactttgtgaatc tgaactgctctactttgagaagatgaccggtttggagtaatcagaatgaacctctccttttaa gggttttttttttcttttctaaaaagctatgtatcgtctctattgaagacagatccttagaga agtttctgtatataaaagggaagtggggacagattcgcagcacagctcgtgcatgtgtttac tctctctctctcagccagctgttttaagccttggcgccagcctcacggaggggcgtgtgaca ctctctgtgtatgtatggagatggcagcagtgaaagcagcagccaccaggagtgccattt gggggttgggacagggagggtgttttgggtggcatagagggtttgtataggggccagtgatga tgttttgataattatttctgctactttaaattgaatctgagtgaaattgtacctatttctgatgatcgg tcttgcnaagcgcagatcataaagtaagtgaatcttcttcttccgtgtgtatttctaaga aatagagccaactgattttgtatgaataccaagagcaatttacctgttactaaacccgcacc cagtgccggaccttccagccctcatcccacttcttctactgtcttggaaacctgtctccattg tgtgtacagccctgtgtctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt ctcatttcttgtcttcttctactcctgtctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt gttctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt caagttaaagcttcccccttactataagactataataaaaaacttattttatcttcttaaaaaaa aaaaaaaa	17

[illegible]

		taaacctgtatcatctgctgtggtccagttactcaggaggctgaggcaggaggatcacttga gccaggagggtgaggctggagtgagccatgactgtaccactgcatccaggcctgggtgacg gaggtagggccctatctgctgcccagtgagttctgtcatgcatcagacttggacctcagaattt cacctggacatgagaggtcagatgacataatgaatatgttctaacttctgaaacttttggagctt gttttgccccttgatagcacgtatccttagagaataagcttccaatttaaggcctgtctgtaatgg catctgaatgttccagcagcctaactgtgctctgctccagaaacatgtgtgtggcttccctacct ccacaccaaggagctgcttggctgggtgagtgaaagactgtcctgccagggtttccactaa aggtattataaagtcagtgaccacagaggggcccaatccctcttggccgctaaggctaagggt agggccagagagctgtagagacaggaccaccaggatgtctcatgtccataacacaagaga gcgctgcatgtttggggccaggcattactactatcatgaagaaaaatgaagagcaggatgc atgttagctttaattcactttaatagtataaacctcatttaggtagtagtattaaagccacaacaata atgccacattgaaacagcatttaataaaatgcataaagctaattcatgactgcaatactctatata acaaacacaacaatgcaaatcttctcaagactgaagacattgattagatataaaatfcagttta aaaagaacatgctatttttaaatgccatcacataaacaagtgatttcacagggagaagaaag ctgtataaagctgcagctttcaacagggttttaacctggcattaaaatgtaatggcaaaaccaat atttctatattgtgaagggtacagaaacgggtccaagaaaatcaacacccaaattt tcccttgatagatagatgctttaaagggtggtgaatgcagttacatttaacagagaagtcaca aactacaggtaaaaactacggctgtactgtgaaaaatgtgcagcttttcagttataaaactagtt gaacactggtttacaagataatccgtagaacagagagactgtagaaaaatatccagcacttga gttgtgtgtggcagcagcatttgagtgccatgaatgctatgtgcattaaaataattgattatacttc ctaaaagaaaagccatttttaatgcaaaagtctactacttccaaatgtattccaaacattaaattta acagctctatcaataataatgttgaaacttttttctaaaaaaa	
NDUFS 2	NM_00116615 9.1	aaaagccagccaggagctgtgggaggaaacgccctcagtaagatgaccgcggtcactgtt atctaacgcaagtgaagccgagtcacaggaccggatgtgtcagttcgacggtaaacgac cctgccagcttcaagagggtgggttctcactgtgcgaatagggtgagaagccaagaggaggc gcgctggaggttacttccgcccgttctcctccgcagctcgcagccggagtaagatggcggc gctgagggtgtgtgctggcttccggggcgctgcggcccagggtgctgcggcctggggctgga gtccgattgccgattcagcccagcagagggtgttcggcagtggtgcagccagatgtggaatggg cacagcagtttgggggagctgttatgtacccaagcaagaaacagcccactgggaagcctcca ccttggaaatgattggaccctccaagacacaattgtgaagaacattaccctgaacttgggc cccaacaccagcagcgcaggtgtcctgcgactagtgtgaattgagtgaggagatggtg cggaaagtgtatcctcacatcgggtcctgcaccaggcactgagaagctcattgaatacaa gacctatctcaggcccttcatactttgaccggctagactatgtgtccatgatgtgaacgaac aggcctattctcagctgtgtggagaagtgtgaacatccggcctcctcctgggcacagtggtg ccgagtgctgtttggagaatcacacgtttgtgaaccacatcatggctgtgaccacacatgcc ctggaccttggggccatgacccttcttctggtgtttgaagaaggagagaagatgtttgagtt ctacgagcagtgctgtggagcccgaaatgcatgctgttataatccggccaggaggagtgacc aggacctacccttgggttatggatgacatttatcagtttttaagaacttctctctgggtgat gaggttggaggaggtgtgaccacaataggatctggcgaaatcggacaattgacattgggtgt gtaacagcagaagaagcacttaactatggttttagtgaggatgcttcggggctcaggcatc cagtgggacctgcgggaagaccagccctatgatgtttacgaccagggttgagtttgatgttctc ttggttctcgaggggactgctatgataggtacctgtccgggtggaggagatgcgccagttcc ctgagaattatcgacagtgcttaacaagatgctcctctggggagatcaaggttgatgtgcc aaagtgtctccactaagcgagcagagatgaagacttccatggagtcactgattcatcacttta agttgtatctgagggtaccagttcctccaggagccacatatactgccattgaggctcccaa gggagaggtttgggtgtacctggtgtctgatggcagcagccgcttatcgtatgaagatcaa ggctcctggttttcccctgtggtgttggaagaatgtctaaaggacacatgttgccagat gtctgtccatcataggtacaggcctattgtgttagtagaggtatcctagacaaaggagttcgg gacgccacttgggacagaaggagaacacttctgttcaacataggccatggcattggactc ggtcctcaatcttttgagcacagtaatgggttctggtatcttgggaacaccactttttgtgttt	19

[illegible]

[illegible]

		attcattgtatgaaaattcctgtatgttttttaaatgtgcagtacacatcagccctactgagctaataaagggaacgaatgtttcaaatcta	
PPRC1	NM_00128872 7.1	gtagttccttccacaatcggctggcgagcgcgccagcgatcagagcagcgtgggt gttcagggggccaagatggcgcgccggggagagagagcgagtgccggccccc gagtggggggcccggtccggaccctggcgggggagcccggcgagtggtggggaagtc gaagccaagcgccgtatgggactttggcgctgtgagcgcgcgagcaggtgctgctgc atgaggagggcggtgattctggctttgtcagttctctcgctgggccatctctgagggaca aggacctggaaatggaggagctaattgctgaggtatgagacactgctgggaccatgcaga gctacatggatgctcccttatctccctcattgaggattttgggagccttggagagagcaggtta tctctggaggaccagaatgaagtgtcgtctcacggctctgacggagatcttgacaatgca gattctgagaacctttctcatttgacagcattcctgattcggagctgctgtgtcacccggga gggctctctctgcacaagctgcttactctctcggacaccccagaacgtgacctatcacc ccagttgacctactggggccagctacagcgagcagtagaggagtggtggtgaaatgtctct tcagatccctcttgggacttctcccacctcttcttagagaccttctccccaagcttccag ctggagacccccaagatcaagaccacgtggggccaatccacctccccagcagcgag tgaaggagaagaaggaggaggtggccagcttcagtgccagattcttggcgggagctt gacaactgtgtgagcagatcccgacttcccatgcatitggcctgcccaggagggaagat aaagcaacagcagcagagatggcagtgccagcagctgggtgatgagagcatctctccctga gtgagctgggtggggccatgcaccatactgctgcccacctcaccacctggcatcacttg aggatgagcttcaggagcagccagatgattgacactgctgagggtcgctagtgtgag attgtggggcagcgacccacagctggcgatgacctggagatccagttgtgtgctgcacagg tctctctggaccccgctgtgctcctggatgactcgctagagactagtctgcttgcagct gctatgectacactggagtcagagacagaggctgctgtgcccaggtaacctctgctctga gaaagagggggtgtcattgaactcagaggagaagctggactcagcctgtattgaagccca gggaggtcgtgagccgtgtgtgcccaggagcctcagaacccacctgccaatgcagcac caggttcccagagagctcgaaggcgaggagaagaagagcaaggagcagccagcagc ctgtgtggaaggctatgccaggaggctgaggtcatcttctcgcgggcagttcatgtaggtac agaagtgcaccttcaggtagaacaactgcagaaacagccctcaggaagaaactcaaaaaggt ctgggctctccagggtgaagggaagcccggttgggtcggcgctggcgagctgctt ggagaattctagccctaagaacttggagagaagtctggacaaagttagtctgtaagaag gccctctagaccttaccacaaagctggctgacactatccaaacaaatctataacacccatct ctctattgtgactctgcccagccagcccatgcccagttgactctgtgaagctgatccact gcagttggccctgttctagctggccctgtacgtgtgacctgggttgggtgacctgttcaac cagctcagaactgtgtgagcctctcccgctgagccagtgctgatcaaccagtcctgctga ctacgagcaggttgacctgcagtggttccatctcagataacttgcaccagttgatgctgtc ccgtctggcccagcaccagttgatctagcactgggtgacctgttctaatgacctgactccag ttgaccagtgctagttaagtccagaccaactgatccagacgtgtgtcagtgctatcagccct ggggggttcagaccccagctcctcgtggagtcagagtccttgaccaccaaagaccatca tccctgaagtcaagaggtgtgtgattctctgaaaattgaaagtgtaccagtgctacaacca tgaagccagacctcgccctctcagcttatctgagtaccggcgacgaaggcagcaacgcaa gcagaaacagaagagagaagtccacagcccccaactgggaagtggcctagccttccagag actcccacagggctggcagacatccctgtctgtcatcccaccagcccagccaagaagac agctctgcagagaagcctgaaacacccctgagattgcttgtgctgtggttccagccct gcttctctagtctgagccactgtaagcaaacctgtggcctcatctcccactgagcaggtgc catcccaggagatgccactgttggcagaccttcccctctgtgcagttctgtgtccctgtgt gcccacacctccctgatgtgtgtgcccctgcttccctgcaggtgggttggcatgcccccc agtctgccccacctcccttgcagcctcctagtcttccattgtctatggggccagttactatgat ccgtttactactatgcccccttgcacatcctggccttgtatctcatgtgtcccttctggtatcc ttgctgcccccccccaaacgggtgcccctagtgtctgtgactcctgtgcttgcctatgcgtgct cccactgagtggtgcttgggcacccccctctgcccagttcaccctacagttccacatgtac	21

		ctatggggcccttgggagtgggggccaggggccctcaacatgctccattctgtgtctactgttccccc cctcccttggcctccagcctccattgggagagctgttcccccaacataaaatggaggtctaggggca ctccagctggccctcctgaaaatgtacttccctgtcgatggctcctccccctcagctctgggcta cctggccatggagctcctcagacagagcctaccaaggtggaggtcaagccagtgctgcat ctccccatccgaaacacaaggtgtctgcccctgggtgcaaaagtcccagatgaaggctctagcat gtgtgtctgtctgaaggtgtgactgttgaggagccctgcatcagagaggctaaagccctgagacc caagagaccaggcccaggggagaagcccccttgcctgtaccaggctgtgtcccaacccaa ggcagagcactgtgtcccagctgcctgtgtgcccccagcccgtctagggaagctgtccttcc tgtcctaccccacgtactcagggttctgaagatgtggtacaggcttcatcagtgagattggaaft gaggcatcggacctgtccagctgtctggagcagtttgagaatcagaagccaaaaggaggt gtcctcctccggctcctgtgacagcttggctgttaggaaactcagggtccagctgtagtctc tggcagttctcgaagatgtcttctccttctcgtcatccttctccttctcctcctcctcctc atccagttctcgaagccgtcacgacccccctccccgggagaaagtgtacaaaaggagcgt cgggtacagctcttctcgttccatgaccattaccaaggcaaaagaggtgtacaaaaggagcgt gcaatagaagaagaagggtgtgttctcattggaaagatacctggccgcatgactcgtatcaga gctgaaacagagggttctccgttttggagagattgaggagtgaccatccacttccgtgtccaa ggggacaactacggcttctcactatcgtctgctgagggcatttgcagccattgagaggt ggccacaagctgcggcaggcagatgagcagcccttgcctgtcttgggggcccgaaggc agttctgcagaggagctatttctgacttgcacccgggaagacttgcaccagcactgt aaagagcaaatfttgattctcttgacttgcacattgtgaaacaggcccagaagaacctcagg aggtaaccttgggccccttccctgtctatccttttctccttggagggtgcccaacctctccacccc cttccctactctagggggagagagctgctagtgtgagatgactgtttataaagaatggaaaaa gtgaaataaaaaatattgttaatcagatttttaaaagggtatttgtttttataacaggtattgaa acaagttaacttgcattcctatgtaagataggaggggctgaggggatccccagtggttggaa ataagtcactatgcagactaataaacatcaactagagagaactccccaaaaaaaaaaaaaaaaa a	
RAD23 A	NM_00127036 2.1	gggtgtcagcgcgcgcattgctgtccccgggaagtgctcggcgcgccgcgccgct gggcgctaaatfgcggcgccgtgagttgcatgtgtgtgaggtcccgggcgccgct cgtcgcggccccccatggccgtcaccatcacgtcctcaaaacgctgcagcagcagacctca agatccgcatggagcctgacgagacgggtgaagggtgctaaaggagaagatagaagctgaga agggtcgtgattgcttccccgtggctgacagaaactcatctatgcggcgaagatcttgatg acgatgtccctatcagggactatcgcctgcatgagaagaactttgtgtgtcgtatgtgacca gaccaaaagccggccagggtacctcagcacccccagaggcctcaccacagctgccccaga gtcctctacatccttcccgctgcccccaactcaggcatgtccatccccacctgccgccag agaggacaagagcccatcagagggaatccgccccacgacgtcccccagagtctgtgtcagg ctctgttccctcttcaggtagcagcggcgagagggaagacgcggcctccagctagtgtgacg ggctctgagtagagacagatgctgacggagatcatgtccattggctatgagcagagcgggt cgtggcgccctgagagcagctacaaacccccaccggagcgttggagtagtctgtcgcagc ggaaftcttgggagccccgagccgggaacacgggtctgtcaggagagccagggtatcggag cagccggccacgggaagcaggagagaacccccctggagttcctgcgggaccagcccagttc cagaacatgcggcagggtattcagcagaacctgcgtgtgtgtccccctgtctccagcagct ggggccaggagaacctcagcttttacagcaaatcagccggcaccaggagcagttcatccag atgctgaacagagccccctggggagctggcgacatctcagatgtggagggggaggtgggc gccataggagagggggccccgcagatgaactacatccaggtgacgcggcaggagaaga agctatagagaggttgaaggccctgggtcttccagagagcctgggtcatccaggcctatttgc gtgtgaaaaaaatgagaacttggctgccaaacttctcctgagtcagaactttgatgacagtg tgcagggaagccaggccaccgaagccccacccttacccttattcatgaaagtgttataaaag aaaaatatatatattcatgtttatttaagaaatfgaaaaaaatcaaaaatcttaaaaaaca agcaaacagctccagcttctgtctcctaaagtggccccctgttcccatctccgggcccagaca ctctccccccctctctcctccccagccctgtctcagagaagctcgcagactggaggagg	22

		cgacagatgggcccctcttggcctctgtccagctctctgcagccagacggaaagcggtg cttgcctctccatccctcgaaaaacccctgaggacccccccatcctctctagatgagg gaagctggagccccaaatttgatcctcattggagtgcccaaatcttccatctagggaagt cctgaaaggccccagccccctccagctgtgcttggcctcagcctggagaagggtta acatcagctcattgtcaaggccacccccacccagaaacagaaccgtgtctctgataaaggttt gaagtgataaagtfttaaaactag	
REPINI	NM_013400.3	cccggcgggggagggtggggacgggctggcagttgtgaactcgaacctgcgctgtc ccgcgggcgggggaggcagagagtgggcgggaggccggccttcgggctccatgga cgggcgccgctccctgcacagcccccgagaggttaaggctggcctctctgcagtcaga ggtctgagctctgccatgggagatagggtgtctttattactgcagtttctctaacacctgggg ctaccggagtgtgggccaagcaggcgctgcagccgggaagtatcccaggaacatccc caaggaggagctggaanaagcctcaccagctctgcagctccaggggagctcagtgctg ttgtccagcttctcagagttgtgtgcagctcggatgtgcataggaaacagcagacacagg gagagggcagcataaaggcactgtaggaggcagtgccacattttctgcagagggaacc gatctgggaacgtctgtcaggggccccctggccatggcctggccagccccgactcctt ctgggcccctccagagtcacccagacctgggggaaggagtcggcgggctgaggcaa caaggcacgtcagtgcccagctctgtgccaagccccaggcaggggcccatcgtgtgcc actgtgaaggcacttccctggctgggtgtctgtgtgtcacacccgcccgtgccaggcc cggctgccccttgcctgcccagtggtgcccgtgtcttgcctatgccccctttagcactgc accgccaggtccatgtgtgtccacccagacctgggcttgcctgccacctgtgtggcag agcttccgaggctgggtggccctgtgtgtcatctgcgggcccattcagctgaaagcgcc catcgttgtcccaatgcgagagacgttctgtgcgacgaaagcagcttcgagctcatctgcg gggtgtccacctcccggcccggaggcccggcccctcatatgcggcaactgtggccggag cttggcccagtgaggaccagctagtgtccacaagcgggtgcacgtagctgaggccctggag gaggccgcagccaaggctctggggccccggcccaggggccggcccgggtgaccgccc cccggcccgggtggagatgcgtgcacccgccccctccagtgctgtgtgtggcaagcgcttc cggcacaagcccaattgatcgtcaccgcccgtgcacacgggcgagcggccccaccag tgccccgagtgcggggaagcgtttaccaataagccctatctgacttcgacccggcgactccac accggcgagaagccctaccgtgcaagagtgccggccgcttccggcacaaccccaac ctgtgtctcacagcaagatcaccaagcgatccgagggtgtgcccaggccgccccggcc cggggaggccccagctgcccagccggccccaggagtccggccgagcccaccccggc ggtaccttgaacccggcccaggagccgcccaggggccccggccagagcaccgcagg accgatcgaagccccccctccctctacagctgcgacgactgcggcaggagcttccggct ggagcgttctctgcgggcccaccagcggcagcacaccgggagcggccccttacctgcg ccgagtgcgggaagaacttcggcaagaagacgcacctgtgtggcactcgcgctgact ccggcgagcggcccctgcctgcgaggagtgcggccgccccttctccagggcagccatct ggcgccgcagcggcgaccacgccccgatcggccccttctgtgttccgactgcggcaa ggccttccggccacaacccctaccgtggcgccacccggcgatccacaccggcgagaagcc ctacgttgcctccgactgcggcaagccttcagccagaagtccaactgtgtcgcaccggc gcatccacacgggcgagcggccctacgcctgtcccagctgcgaccgcagcttcagccaga agtccaacctcatcaccaccgcaagagccacatccgggacggcgcccttctgtgtgcatc tgtgccagaccttcgacgacgaggagagactcctggcccaccagaagaagcagatgtct gagacgggtggcgggccgtgtgtgtgctgagagagggtgggtcttctgtgtgtggagt gcagtggtgtgggggtgctgcttagtctgtgagtaggggacaatgggaatcctagagg gatggaagacggggagtgagctgggtgggcccctgtagcgagagaggtcaacccgg tgccagggaacccacttcaagcgcaggggacccggcctccagctgggtgtgtctaaggc tccgtctgactgcccgtgtccctggaaaagcagcaatagcatccgccccttagagccctctg gttagaggagccaccagtggaaagggaagaccctcctctgtgttaacgccttaatgcc ctgtctttactgtaagttaacttaagatcattttgaagcaggcgtgtgtagagctctgtaaatgaa tgctctgggctagatacagcttggagaacctgtggcctgttagacagcacttggcccttgc	23

		cagcagcaagagggtgaagcgaagccactcttacctctccctccctccacctgccccctgc gtaggcacccagactggagagaccgtctgctgtaatacttccatctcttctcccaaaga gcagatcccaaggcatttactccttggtctgtctgctttatctgtcgcctccacgcgtgag agcctccctggtgtcagcagcactgtgtccaggctcttctgtgaacaccgcagccctctctt cgctcctccagagctcagcatgtcacggcaaggactgcgcattggtgatggaggccag ctgagggggaagttgctggtgagtttcttctccatttctagcatatggacacctggcctctgctt gagcacttaggtgacaggaacttcgcacactctgaggccctggatgattctaattgttagaaa ttctaattgttagaaatccttcttataatgaatgaattctgcttctctataatttctacattgggccc ttgtctgtctctggaaactaaacagaacaaccatttaccctctcttctcaactagagaataaag atttgggtttagaactggtaaaaaaaaaaaaaaaaaa	
SDR39 UI	NM_020195.2	actttacgcaggcgcttaggtctctagctctatgctgtgcttggggggcgaggacaggtt cattgggacagccctaaccagctgctgaatgcagaggccacgaagtgaacttgggtctccc gaaagcccgggcccgccggatcacgtgggatgagctcgtgcacggggctgcccagct gcgatcccgccgtcaacctggccggagagaaacatctcaacctctccgaagtggatga aaccttccaaaaaggaggtaatcggcagccgcttagagaccaccaattgctggctaaagcca tcaccaaaagcccacaaccccccaaggcctggctttagtcacaggtgtagcttactaccagc ccagtctgactcggagtatgatgaagacagcccaggaggggactttgacttttctcaacct cgtaaccaatgggaagctgcagccaggcttctggagattctacacgccaggtgtgtgtgc gctcagggggtgtgtgtggccgtgggggtgtgtccatgggccacatgctgtgccccttgc ctgggctgtggggggcccatcggtcagggccaccaattctccctggatacacatcgggga cctggcagggaatcctgacccatgcccctgaagcaaacacgtgcacggggtcctgaatgga gtggtccatctcctccactaatgctgagtttggccagacctgggtgtgtgcccctggccgc cgagccctcatccctctcccagcgtgtgtgcaagctgtcttggggcagacagctgtccatc atgctgtgtgaggggccagaaggtgatccacagcgaacactggccactggctaccagtattc cttccagagctaggggctgcttaaggaattgtagcctaagtaggtcgtggaaggccct gaggcctgttctcacaggcttcagggttaggcactgtgaataggctcagctcctctagagag ctgaagccatctggttcttagattctctccagctcttcttccattgttctgtgtctccacttatt gtctcaaggccgttaattctcatcagggttgggacattaatctttcaactcctgtgaagatttccagt ttgggttctctacatgtcctgcagctgccccacttctcttctacgtgtgtagagaatgctctgcag tttaggcaataaaaaataattgtctcactaaaaaaaaaaaaaaaaa	24
SETBP1	NM_00113011 0.1	aagcgcggggccggccggggcgcccgccgctcgcgcgcgcgcgcggggggg ccccggcgcccccgagctaggcgccgagctcgcgcgcgcgcgttggacagatgtctatc gccatggagttgcccagcagcaccttgggggctcggggcagcagcgggagcggggatc tgagcgagcgcggggccagcggagccggagccggggacatggttgagatctgatct cttctgaacacctatcgtgtctccatccctgggaatctgaccttagcaactggaccacttgtc ttggaatttgggtgtcctcttctcacttctcccttctcccttctcccttccctctcctgagaactc cggaaagactgtagagattgtcatggagtccagggaaccttaagcagctcccggcaagag ggggcgagtcagacttctcgcggtctcctcagccaagccccagctgctcctggtgtgca ggagaaccttctctccatccaggacctgggaaggggatcccggtggcgaggagcgc atggagccagaggaggaggaatgaactaggctcaggcggggatgtgattccaactcaac gcggacagtgaagaatgggtggcaggagatggttgaagagcagggaatttctatcaaggaa ggcaaatccacagagggaagtctgaagctaaagattcagaccacaaagcgggctaagaaa ccccaaagaatttggagaactatataatgtccacctgagatcaagatcacatcaagcagtctg gggaccagaaggtgtcccggtctggaaaaaatagcaaaagccacgaagggaaggaagaa agccactccaaaaagaagctcctcacagccagtaccttgcagccagtgacctcaaaaggattt cagccacagattaagactccagtaaggagggaagtctggaagagaagaggaggccaaggc atccattcaaaaaagcaattcctgtcccagggaacgtgcatgtgtcttctatgccccggaaacc cattccccgcaaaaccgggttctctcacttctcttctcacagtgaacctgcagctctgggcacaa gaagtataacttcgatgtgattctgcaagcccacacctgtgtgtcattccctgttcttctattca	25

		acaatggagacttggccaagattgtaaactagttagtgacagcatttgggcttatgatcttctt gctgctagctagacattctcttgggtctaaagataatccaaaaagatccagcttcacaatgc tgcctgaagagataatgcattagggcgccctgatgcagcattcactgtctccagggcagggc ttgatcccatgagtttcttctcagacgacacttaggaaacacatgccttactcttaggcctt tttctagcttgccttgatcagctatgccatggatcttctcttaccctatgctatacagagtat gggctccaagccacagctggcctgtcaagtgtgtgcgctgtccaccatgggatacatttag aaactttatagcaatttgacattttgtgatatccaagcatgtgattgtttctacgatttgtctta tagtattttaccaaagtctccacacaaaaagtatggattaaggacaaagtatctggtctcatca aagatcgtttgataagctctgttctagttaaccaacactgagcttctctagtttaataaaagagta ggatttggaaaaaaaaaaaaaaaaaaaa	
SLC14A 1	NM_00112858 8.3	acacagagcagagtggggtcttgagtatataactgttaggtgcctccctcagcaccatctct gagaagcactctccctgtcgtggaggtgggcaaatctttatcagccactgccttctgtgcc ggaagccagctagagtgtgtctttaaagaaaactgggcatctcctgctactttaaataaaaaact acctaaaataaagattataaaaaagtaaggatgaatggacggctttgattggcggcgctgtgtg acgcccgtcatgtgctgttttggaaggacccttttggaactaaagctgtgtgacgacagcgca gaggcatcgcccggttaagcttgccctggcagatgggtgcaggaaacagggagccagag gaagagatagccatggaggacagcccactatggttagagtggacagcccactatggttag gggtgaaaaccagggttgcctatgtcaaggggagaggtgttccccaaagcttggctatgt caccgggtgacatgaagaacttggcaaccagcttaagacaaacccgtgtgtctccagttcat tgaactggattctccgggcatatccaagtgggttctgtcaacaacccgtcagtggaatcctg attctgtaggacttcttgcagaacccctgtgtggctctcactggctgtgtggaacagttgg tctccactctgatggccctctgtcagccaggacaggtcattatagcatctgggctctatggc tacaatgccacctgtgtgggagtgactcatgtgtcttttcggacaaggagactatttctgtgtg gctgttactccctgtatgtgtatgtccatgacttgcctaattttcaagtgcattgaattccatgc tcagcaaatgggacctcccgtcttcacctccctttcaacatggcgtgtcaatgtaccttcag ccacaggacattacaatccattcttcagccaaactggctacacctataactacagctccaaat atctcctgtgtcgaacctcagtgccctggagtgtgtgaaatctataccagtgaggagtgtcagat ctatggctgtgataatccatggacagggggcatttctcgggagccactactctctcccca ctcatgtgcctgcattgtccataggatcattgtgtggcctagcagcggtactcagcttctcag ccccatttgaggacatctacttggactctgggttcaacagctctctggcctgcattgcaatg ggaggaaattgtcggcgctcacctggcacaacccacctcctgtgtgtgtgctgtgtcctgttca cggcctatcttggagtcggcatggcaaaactttatggctgaggttggattccagctgtacctg ggccttctgttggccacgctattgttctcatcatgaccacaaaaattccaacatctacaagat ggccctcagtaaaagtacttctctgaagaaaaccgcatcttacctgcaagccaagaaaaga atggttgaaaagcccttgtgagaacaagccccatttgcagccatgggtacagagtcatttctgcc tgactgtccagctaaactccagggtctcagcaaaactgctgttttcacgagtatcaacttcafa ctgacgcgtctgtatctgttctatgtctatttgtatttcttcaactccagggaatatccttgag catatgagagtcatccaggtgatgtgctctgtatggaaattgaaacccaatggggccttg gcactaagactggaaattgtatataaagtcaagtgtcacaacagaaggaggaagtgaatacaaa actattagttatttgaattcttgggttttagctgtgctcgtatgttaacagtattaaaaattaaa ccccataaaccactaagcccttatggaattcacagtcacaaaatcgaagttaactcagaattctg tgataagcagcttggccttttttaaatcaatgcaagttacacattatagccagaattctgtatcaca gagggtgcaagctgacagcagagctcagtcctccacttctgcaaaacaatggcctgcacctat ccctgtgtgtgtgacattctctcatgggacaatgttgggttttccagactgacaggactgcaa gaggggagaaaggaaatttgcatacaaaattattctgtattgcaacttttctcagagattgcaag gatttttaggtagagattatttcttatgaaaaatgatctgttttaaatgagataaaataggaga agttcctgtgcttaacctgttcttacaataaagaaaagtacttactgtatttatgaaatactcagc ttaggcatttttactttaacccctaaattgtttgtaaatgccacaaatcatagaattgttaccaa ccccaagggtctttaaatacatatttttattcatttgaggatgtctataaagactgaaggca aaggtcagattgtctacgggtgtttttataagttgtgaattcctaatttaaaaagctcattatt	26

		ttttgacacitcacaatatctctcagaaatcaatggcatttgaaccacaaaaagaaataaa gggctgagtgccgtggtcacgcctgtaatccagcacttggggagccaggcgggcaga ttgctgaaccaggagttcaagaccagcctgggcagcatggtgaaccctgtatctacaaaa aatacaaaaattagccaggcatggtggtggtgctgttagttccagctacttggaggctgag gtgggaaaatgacttgagccaggaggaggaggctgcagtgagctaagattgcaccactgc actccaacctgggcgacaagagtgaactgtgtctcaaaaaaaaaaaaaaaaaacaaaaa acaaaaacaaaacaaaacaaaacaaaacaaaacaggtgaaggattccctgttttctctcttta attttaagttatcagttccgtaagtcctgttaaccaacatactgaagacagcaacagaagtc acgttcaggaggactggctcacacctgtaatccagcacttgggagatggaggtaaaaggatct ctgagcccaggagttcaagaccagcttgggcaacatagcaagactccatctctaaaaata aaaaatagtaacattagccaggtgtagcagcacacatctgcagcagctactcaggaggctgag gtggaaagatcgcttgtgcacagaagtgcaggctgcagtgagctatgatcatgtcactgc actccagcctgtgtgaccgagcaagaccctatctcaaaaaaataaataaataaataaataa ttaaaaagggaagtcagttcatttacttccacttcagtggtatctgttagtatttggagggtgga aagtgaacgtaggaatcctgaagatttttccacttctagtttcagtgctcagtgacataata cattttgctgaatgaataacagaaatagggaagtaaacctacaaatattttagggagaagctc acttctctcttctcaggaaaccaagcaagcaacataatcgttccaattttaaaccaggtagcc aaagccttggaaactatgaatttgaactgtcataggtttatggatattgtctggagaagctcaa ttttcagtggttgaactgaaccttcttctttagggaaacgtgtgaagaagaatttggggaaaa aaaagcaagcataaccaaagatcatcagcagtgagaatctaggctgtggctgagagaaacc agaggcctctaaaatggaccggagtcgacttcagaaacaggatctaccatgcaggagcttct tgtgtcacacaaaatctgaatgggaacattgtacattgtcgaatttaaatgataaattttctca agctattttgttactatttctaaaattgaatatttgcaggagcacttatacttttctaatgtctg tatacaaaatttctatgcaagtcataaataaattatgctcacagctca	
SLC18A 2	NM_003054.4	agagccggacggggtaaactgagcggcgccggcgggcgctggggcggagactgcgac ccggagccgccgggactgacggagcccactgcgggtgcgggctgtggcgccgggcacggga ggaccggggcaggcatcgcaagcgaccccgaggcggagcccgaggccatggccctgag cgagctggcgctggctgcgtgctgaggaagcggcgctcgcggaagctcatctgttctc atcgtgttccgtgctgctgctggaacaatgctgctcactgtcgtgtggtccccatctccaa gttatctgtacagcattgaagcatgagaagaatgctacagaatccagacggccaggccagtg cacactgcctcatctcagacagcttcagagcatcttctctattatgataactgcactatggtc accgggaatgctaccagagacctgacacttcacagaccgccacacagcacatggtgacca acgctgcctgctgttcttccgactgtccagtgaaagacaagacctcctgaatgaaaacgtgc aagttgctctgttgttgcctcgaagccaccgtcagctcatccaacccttctataggacta ctgaccaacagaatttggctatccaattcccatatttgcgggaattctgcatcatgtttgtctcaaca attatgttgccttctccagcagctatgccttctgctgattgccaggtcgtcagggcatcgg ctgctcctgctcctgtgctgctggatgggcatgctgtccagtgctacacagatgatgaagag agaggcaacgtcatgggaatgccttgggaggcctggccatgggggtcttagtgggcccc ccttcgggagtgctctatagtttgggggaagacggctcgttctgtgtgctggccgctt ggtactcttgatggagctattcagctcttctgtctccagcgtccgggtgcagccagagagt cagaaggggacacccctaaccacgctgctgaaggaccgtaacatcctcattgtcaggtc catctgcttggcaacatgggcacgcatgctggagccagccctgcccactgtggatgatgga gaccatgtgtcccgaaagtggcagctggcggttgccttcttgcagctagtatcttctcat tggaaaccaatatttgggatactgcacacaaaatggggagggtggttgtctcttctgggaa tgataattgttggagtcagcattttatgtatctcatttgcacaaaacattttagactcatagctccg aactttggagttgtttgcaattgggaatgtggattcgtcaatgatgcttatcatgggctacctc gtagacctgcggcacgtgtcgtctatgggagtggtacgccaattgaggatgtggcattttgtat ggggtatgctataggtccttctgctgtgtgtgtattgcaaggcaattggatttccatggctcat gacaattattgggataattgatattcttttgcctctctgctttttcttgaagtcacactgcca agaagaaaaatggctattctcatggatcacaaactgccttataaaacaaaatgtacactcag	27

		aataatfaccagtcatafcccgaatggaagatgaagaatctgaaagtgaactgagatgagatcc tcaaaaatcatcaaagtggttaattgtataaaacagtggtccagtgacacaaatcatccagaact gtcttagtcataccatccatccctggtgaaagagtaaaaccaaaggtattatcttccatggt tatggtcgattgccaacagccttataaagaaaaagaagcctttctagggtttgtataaatagtgt tgaacctttatttattgtatttaattttataaatatcatacaatattttgatgaaataggtattgtga aatctataaatatttgaatccaaaccaataataaatttttaacttacattacaacatttgggcaaa aatcataftggtaafgagtggttaaaattaaagcacacattatctctgagactcttccaacaaga gaaactagaatgaagctgtaaaacagaatcaagtaagacagcatgttatatagtgacactga atgttttaactgtgtactatcaatataattatgctgtaaacagctagttctcgaagtgtagag gacaagaactgtgtcagttatctttgaatccataaatcttagctggcattagtttctatgtaatca ctacctagagagaggtgttaattatattgttaacatgttatctggtggcagcaaacactaaagc caataaaggaaaaacagtaaatgttccgaagcagagaaaaagcaaccaaacattgttatga actaaaagccttcccttaagatgcatactgtcttactggtatgaagaaaattgagggtacatgta ccttatactgtcaaggtgttttaaacatgataaggttaatcgcactctacttcaagtttagaaaag gaaacaagaagctgtaaaacagctgctgactttaatatctgactatattttgatctgttcgag gtcatccaaggtttctaggaataatatttttaggtgtctgaaactactatttttagactcctga aagttgtcacatcaatgtgaagacaaatttaaatgaaaatgaagaatgaattatgtctgaat catataftaagaagtaaaaataatagtgatcaggcagaaaaagaaaaatggaacatctaaaaat gtatgtgctaactatataatcagtggtgagtggtgtattttctaaagcatgacaacattgtatgtg cctttcagtgtaacagcaaatactgttaggaacattgtcaatttatgtcattttgtaagagatat gactggagtggtgagtggaatgtcttaataactactgtgaatcctgagttctataatcataa acaaaaattacttagtttctgtaagctaaagtgtgtttgtgtaacttcgacatcaaggagcaaa gaactttaagacagactcctcaatctgtgactttctattctctaggaagtaacactcgtttcat gaagcctttctgtgggcttcgattattcaagtcgtgtttctaaagtcagtggtttgaagcaaac gaactccaactcacttatttggcattgggcaacttggccaagtcgtccactttggaagatggct ctggaggaaactctcatatggctaaaaaggcaggtctggtttctacttctacaggtgtagagcc ttaaaaaagaaactgtctacaaattggttctctttgagggtttctgttctccctgcccccaatacc atatactttattgcaattttattttgctttacggctctgtgtctttctgcaagaggcctggcaag gtatgctgtgttggctccctgggataagataaaatataataaaaccttcagaactgttttggga gcaaaagatagctgtacttgggaaaaaaattcaagttctttatgactaatattctgtgttag caagactggaagagggtgttttttaaaatgtacataccagaacaagaacatacagctctctg aacatttttttgaacagagggtgtttttatgtttggacctgtaatacagatacaaaaactttaa tgaggtagcaatgaatttcaactgtttgactgtaagtgatctgtccatatttttagcaagtttact taataaatcttctgaacctgaaaaaaa	
SMC4	NM_00100280 0.2	gccctcttctgaagaggcgtttctggaccactgagcccccgcctccactgtgagcggaaacct accgtttttaaaaaatcttttcaaaacttgccaggtgtctttccaatattttaataatagtctg ctgctgtagaccacagagaaaagaatccctcgtctcttcttctacttagtagaaacttctaccg cgtaggtcccgccagggagtcgcgcagtcgcgagcagacaataagatggcgggtgataatc gccgcacttttttcaaaatagtgatccagaaatcattgcgcgactttgtaacgaatttccgttc gagtttgatttttagggcgcattttcagtggaaggaccggagccgaaacaccggtaggagc ggggaggtgggtactacacaaccgtctccagccttggctgagtggtgactgtcctgcagcgac catgcccgtaaaaggcaaccagccctccactgcccggcgagagagggaagggccgcccgc cgccgtccctgacggcgccagcagcgacggagcctgagccgctcgccgcccgcagc gagagcccagccaccgcccagagactgcaagtgaggaaactgataataagatttagaag agattttgaacagcattctctctccccgcctccagcaatgaccaatgaagctggagctcctcg gcttatgataactcataattgtaaacagaaactcaaatcctatgctggggagaaaaattctgggac ctttccataaagcgttttctgtattatcgggccaaatggcagtgggcaaatccaatgttattgattc tatgctttttgtgttggctatcgagcacaataaataagatctaaaaactctcagttataatcat aattctgatgaacacaaggacattcagagttgtacagtagaagttcattttcaaaagataattgat aagggaagggtgattatgaagtcattcctaacagtaatttctatgtatccagaacggcctgca	28

	gagataatacttctgtctatcacataagtggaaagaaaaagacatttaaggatgttggaatctt cttcgaagccatggaattgacttggaccataatagatttttaattttacaggggtgaagtgaacaa attgctatgatgaaccaaaggccagactgaacacgatgagggtatgctgaatatattagaa gatataattggttggacggctaaatgaacctattaaagcttgtgtcggagagttgaaatatta aatgaacacagaggagagaagttaacagggtaaagatgggtgaaaaggaaaaggatgcc ttagaaggagagaaaaacatagctatcgaatttctaccttggaaaatgaaatatttagaaaaa gaatcatgtttgtcaatattatattatgagttgcagaaacgaattgctgaaatggaaactcaaaa ggaaaaaattcatgaagataccaaagaaattatgagaagagcaatatactatcaaatgaaat gaaagctaagaataaagatgtaaaagatacagaaaagaaactgaataaaattcaaaaattatt gaggagaataaagaaaaatttacacagctagatttgaagatgttcaagttagagaaaagttaa aacatgccacgagtaagccaaaaactggagaaacaacttcaaaaagataaagaaaagggtt gaagaatttaaaagtatactgccagagtaacaatafcattaafgaacaacaaccagaaac aatgccctcaggaaggaagaaagaaagaaagaaaaaattaaagggaagttagtgataaggcc ttaaacaggaacacaaagggttcagaaagaaaaagaaagtcagagagaaagaaacttatggg tttcagcaaatcggtaaatgaagcacgttcaagatggatgtagccagtcagaaacttgatac tatctcagtcgtcataatactcagtcgtctcaattaactaaggctaaaggaaactctaatgtagct tctgagactctcaagaaaggaaagctgcaatcagagatatagaaggaaaactccctcaaaact gaacaagaattaaaggagaagaaaaagaacttcaaaaacttacacaagaagaacaaactt taaaagtttggttcagatctcttcaaaaagttgaagaagcaagagctcattagcaatgaatc gaagtagggggaagtccttgatgcaataattcaagaaaaaaatctggcaggaattccagga atatatggagattggggacttagggagccattgatgaaaaatacgacgtgctatatcatcct gttgcactgcactggactacattgtttgattctattgatagcccaagaatgtgtaaaacttctt aaaagacaaaatattggagttgcaacctttatagggttagataagatggctgtatggcgaaaa agatgaccgaaaactcaaaactcctgaaaatactcctcgtttatttgatttagtaaaagttaaagatg agaaaattcgccaagctttttttgttcttacgagataccttagtagctgacaaacttgatcaagc cacaagagtagcatatcaaaaagatagaagatggagagtggttaactttacagggacaaatcat agaacagtcagggtacaatgactgggtgtggaagcaagtaataagaaagaaatgggttccct cactgttattgaaatctctgaagaagaggtaaacaaaatggaaatcacagttgcaaaacgactc taaaaaagcaatgcaaatccaagaacagaaagtacaactgaagaagagtagttaagttagc gcatagtgaacgagaatgaggaacacactagaaaaatttactgcaagcatccagcgtttaat agagcaagaagaattattgaatgtccaagttaaggaaactgaagctaattgactgtctacagcc cctgacaaaaaaaagcagaaattgctagaagaaaacgttagtgcttcaaacagaaatgat gctgtgctgagaaagctgtgtaagtagaagctgagggttaaacgttcaacataaccatcgtg gaaatcaataatcataaactcaaggcccaacagacaaacttgataaaataaataagcaattag atgaatgtgcttctgtattactaaagcccaagtagcaatcaagactgctgacagaaaccttcaa aaggcacaaagactctgttctgtacagagaaagaaataaaagatactgagaaagaggtgga tgacctaacagcagagctgaaaagtcttgaggacaaagcagcagaggtcgtaaagaataca aatgctgcagagggaatccttaccagagatccagaaagacatcgcaatctgcttcaagaatta aaagtattcaagaaaatgaacatgctcttcaaaaagatgcacttagtattaaagtgaacttgaa caaatagatgtgtcacattgtgaacataattctaaaataaaatattggcacaagagatttcaaa aatatcactgcatcctatagaagataatcctattgaagagatttcggttcaagccagaggatct tgaagcgatcaagaatccagattctataacaaatcaaatgcacttttggaaagcccggtgtcatg aatgaaccaaacctcgggtccatcgagagtataaaagaaggaaagaaattgtattgcaac gggtagcagaattggacaaaattacttatgaagagacagtttagacaggcatatgaagatct tcggaaacaaaggcttaattgaatttatggcaggttttatataataacaaataaattaaaggaaaa ttaccaaatgcttactttggagggggacgcgaactcgagctttagacagcttgatccttct ctgaaggaaatcatgttcagttgtcgaccacctaagaaaagttggaaaaagatcttcaaccttctg ggagggagagaaaacacttagttcattggctttagtattgtctctcaccactacaagcccactcc ccttacttcatggatgagattgatgcagcccttgattttaaaatgtgtcattgttgcatttatat atatgaacaacaaaaaatgcacagttcataataatttctctcgaataatatgtttgagatttcg	
--	--	--

		gataagcttattggaatttacaagacatacaacatacaaaaaaagtgtgtcgttaaatccaaaaga aattgcatctaaggagcttctgtgaaccttctgctgaagatcttcaagtgtgtaacagtgtaattcgt attttttctattgttaaaggattatgagttgtataaaatacatactccctaactagatcatgaaact ggttctgttttaicagttgtcattgttaaagtcataaaaaatactctataaattgcttctagattaca aaaatatgacaactctgttaagtagcagactatggagaaaaatgagttacctggagggcaggt aacttgcctaaactaaaaagtatgttagtggcgaagtcctaagcaaggtgtgtctatcaagg ctcagcatacctctgtgggcttctgattacacactggaaatgcctgccaaactaatcttggata gatctttaaggcattccacttagcttgcaggttgagacaatcaccacagttattaccctaaact atgaacataattttgtaaaccagtcattctgaattatagtgaagaaattaaatatatgctttctag aattgatgttgaccatttatgacttaattaccagagagccagtaaattaggacagtgttcaaca agcctaggctatctcgtaagttgaaaaataccactatagtgtctcatgagtatgaagtaagat ggcctctgatttacctgggtcaatttacaactttcaactttatgataggtttatccgggtactaaat gcatctcaactgtatagtttcaacttatgataggtttacaggatgtagtcceactgttgaggagc atctatttaggggttaattacttttagtaataagtggaagtaagataccttgagtaagtgttgctat aaaatgtcagcgtattttacactattggctcaagaatgtataatgctaaggacataagttgg caaccacttggttttggaaggacttctgggtattgtattagaagctgccttagctgttaaattctg gggtatttacctgaaggaaftaataaagaggttaattgtcttctcagtgggccattgttttagata tttaaaaaatccaacagtttctatcataatgtaactgtaaaaatgtaaacacattattagcatggac ttttaataaagatttaagaagaagcaagatcgggaaaaaaaaaaaaaaaaaaaa	
SPARC	NM_00130944 3.1	gggagaaggagggggccgggggaaggagagacaggagggaggggaccacgggggt ggagggggagatagaccagccagagctctgagtggttctgttgcctgtctctaaaccct ccacattcccggggtccttcagactgcccgagagcgcgctctgcctgccctgcctgcct gccactgaggggtcccagcaccatgaggggcctgcatcttcttctcttgcctggccgggag ggccttggcagcccctcaagaagccctgcctgatgagacagaggtggtggaagaaactgtg gcagaggtgcagtgatctgtgggagctaatcctgtccaggtggaagttaggagaatttgat gatgggtgcagaggaacgaaggagggtgtggcggaataatccctgcagaaacacca ctgcacacacggcaagggtgcgagctggatgagaacaacaccccctatgtcgtgtgcag gacccaccagctgccagccccattggcgagtttgagaagggtgtgcagcaatgacaaca agacctgcactcttctgccacttcttgcacaaagtgcacccctggagggcaccagaagg gccacaagctccacctggactacatcgggcttgcacaaatcatcccccttgcctgactctg agctgaccgaattccctgcgcatgcgggactggctcaagaacgtctcgtgtcacccctgatg agagggtgaggacaacaacctctgactgagaagcagaagctgcgggtggaagagatcc atgagaatgagaagcgctgaggcaggagaccaccccgtggagctgtctgccccgggact tcgagaagaactataacatgtacatcttccctgtacactggcagttcggccagctggaccagc acccattgcaggggtacctctccacaccagctggctccactgcgtgtcccccctatccca tggagcattgcaccaccgcttttgcagacctgtgacctggacaatgacaagtacatgcctct ggatgagtgggcggtgtcttgcgcatcaagcagaaggtatcgacaaggtactgtgtact aaatccactccttcacagtagaccggattctctttaaaccctcccttgcgtgttccccaattgta aaatgttggatggtgtgtgtcttgcctggagacaagggtctaacaatagatttaagtgaatacatt aacggtgtcaaaaatgaaaattctaacccaagacatgacattcttagctgtaacttaactttaag gcttttccacacgcattaatagtcacattttcttcttgcattttagcttggccattgtcttaattgg cacatgggtggacacggatctgtcgggctctgccttaaacacacattgcagcttcaactttctc tttagtgttctgttgaactaataacttaccgagtcagacttctgttcatcttcttgcagggcttgg ctgcctgtgggttccccagggtggcctggagggtggcaagggaagtaacagacacacgat gtgtcaaggatggttttgggactagaggctcagtggttgggagagatccctgcagaacccac caaccagaacgtgttgcctgaggctgtaactgagagaagaattctgggctgtgttatgaa aatatagacattctacataagccagttcatcacatttctccttcaactttcagtgagtttctt tcacataggctgttgggttcaacttttgggagcacggactgtcagttctctgggaagtgtgcag cgcatctgcagggtcttctcctcctctgttcttggagaaccagggtcttcttcaggggctctag ggactgcagggtcttgcagccaggaaggccaaaatcaagagtgagatgtagaagaattgttaa	29

		aatagaaaaagtgagttggtgaatcggtgttcttctcacatttggatgattgtcataaggttt ttagcatgttccctcttcttcacccctccctttttctctattaatcaagagaacttcaagttaat gggatgtgctggatctcacaggctgagaactcgttcacctccaagcatttcatgaaaaagctgc ttcttattaatcataaaactctcaccatgatgtgaagagtttcacaatccttcaaaataaaagt aatgacttagaaaactgccttctgggtgatttgcattgtcttagtcttagtcaccttattatcctga cacaaaaacacatgagcatacatgtctacacatgactacacaaatgcaaacctttgcaaacac attatgcttttgacacacacacctgtacacacacacggcatgtttatacagggagtgatg gttctgttaagcactaagtttagctgtttcatftaatgacctgtgtttaaccttttgatcactacca ccattatcagcaccagactgagcagctatctcttttattaatcatgttcattcattcattcatt cacaaaatatttatgtatgtattactctgcaccaggctccatgccagcactggggacacagtta tggcaaagtagacaaagcatttctcatttggagcttagagtcaggagggaatacattagataat gacacaatcaaatataaattgcaagatgtcacagggtgtgatgaaggaggagtagggagagacc atgagtatgtgttaacaggaggacacagcattatcttagtctgtactgttccgtacggcagcca ctaccacatgttaacttttaagatttaatttaattagtttaacattcaaaacgcagctccccaatc acactagcaacattcaagtgtgagagccatgcatgattagtggttaccctattgaataggtc agaagtagaatctttcatcatcacagaaagtctattggacagtgtcttctatagatcataag actacagagcacttttcaagctcatgcatgttcattgttagtctgtattttgagctggggttt gagactcccttagagatagagaacagaccacagaaatgtgtcaattgcaatgggccaca tacctagatctccagatgtcatttccctctcttatttaagtattgttaagattactaaacaataaa agctcctaaaaaatcaactgtattctgtgttctctctacacagtgaggaggcgagcagtag gagagattggccatttggctgtgcccatttgggaatgcaagcccagcactagctcataatc tctaggaatctgtagagaggaatgaagtaatttcagcattggctcattcagtcattcggcg acattcatcaggtacctgcaatgtgttagggatctttagtagtgagcagctgtgtgtatcctgtc tccctggagcttctaacattctagcagggcagaccacataaatttgcaactgttctgata aaaacgtgtgttaaggaaataaagcagagaactatcatggaaaaaaataaaaaaa	
SOLE	NM_003129.3	gtctgggcccagcccagctggctgagacgcgtggagcctggcgccgagtgggggc gtgcgacgggttactctgttactggggccgcgcgcgtggcgagagccgcgcgcgcga gggatgtctgtgaggaagccgtcgggagccgcgcgcgcctgagggaggtacctgga aaccaccttttatcggtgggaagtgcagtcgcgtgggctgtggggccagcgaaac gggaggcccttaaatctttaggttgggctgcatgtccctggagccgcactctgtagtcgag gccatcttttggagaaggcgtcggcgttggcgttttccgaggttggctgtacagtgtctc cgtccgcggaaaaagaagcctctgaaccgcgcgcgcgcgcagcccccgtgccttcggc cgtctcgcgcgcgcgcagaggttagccacgttccccagtgccgaggtgttctgtgacc ctccctcactcccattccctctgaaggggcacctgtcttgggtgagaaaagaattatagcac gaagagccagttacagaagagttatccatcccgagcaaccgtcagggaacacatcaa aaaagaaaaaagggaatctggaattcctgggagagggagcagctgtctcgggagc tgttcagcagggcgaatttttaataactgttctacgccctafacaacttggcttcacatactttac actaaccttatatgatttttaaaactggtctgacgttctcgtcctgggacactgttactgga gtctggccggctctccgtctccttgggtacctcatttggggagaaccttaaacccactgag cagataatctccgcttgaccgggtgccaccaagaagccttgaaccatgttgactttctgg gcattgccactttcacctattttataagaagttcggggacttcacttctggccaacaggag gtcctgtgtgtcgtgtgtgttctctcgtcgtggcctgtgtctcctaccgtgtctgcaccg aaacgggggtctcctcggcgccagcagagcggtccagttcgcctctctcgtgattct ctcaggcctgcttcttcttcttctgggccaatccccctgaatcagaaaataaggag cagctcagggccaggaggcgcagaaaaggaaacaaatattcagaaacaagcttaataggaa cagctcgtgtacatcaacatctctcagaatgaccagaagttatcatctgtggagctggcgt gcttggctctgttggcagctgtgttccagagatggaagaaagggtgacagtcattgagaga gacttaaaagagcctgacagaatagttggagaattcctgcagccgggtgtgtatcatgttctca aagaccttggctgttgagatacagtggaaggtctgtatgccaggtgttaattgttatcatgatt catgacaggaagcaaatcagagggttcagattccttaccctctgtcagaaaacaatcaagtgc	30

		agagtggagagcttccatcacggaagatcatcatgagctccggaagcagctatggcagagcccaatgcaaagtatttgaagggtgtgtgtacagttattagaggaaagatgattgtgatggagttcagtagaagataaagagactggagatatcaaggaaactccatgctccactgactgtgttgagatgggcttttctcaagttcagggaaaagcctggctccataaagtctctgtatctcattttgtggctttctatgaagaatgcaccacagtttaagcaaatcatgctgaactattttagctaaccggagtcagttctatctaccagattcatccagtgaaaactcagtgactgttgacattagaggagaaatgccaaggaaatgaagagaatacatggttgaaaaatftaccacaaatfaccctgacacctgaagaacattcttagaagccactgacaattctcatctgaggtccatgcccagaagcttcttctctctcatcagtgaaagaaacgaggtgttcttcttgggagacgcataataatgaggaatccacttactgttgaggagatgactgtgtctttaaagatataaaactatggagaaaactgctaagggtatccctgacctttatgatgatgcagctattttcagggccaaaaaactattttactgggcaagaaaaacatctcattcttctgtcgtgaatatcctgtcaggctctttatgaattattttctgccacagatgattccctgcatcaactaagaaaagcctgtttcttatttcaaaccttggtggcgaaatgtgttgctgggtctgttggtgtcttctgtattgtctcctaaccctctagttttaattggacacttcttggctgtgcaatctatgcccgtgtattttgtcttaagtcagaaccttgattacaaaacctcagccctctcagtagtggtgtgtattgtacaaaagcgtgtctgtataatttctcctaatttactcagaatgaagtatatgttgcattaaaggggaaccatttgaatgaatatttgaacttaccagtcctaaagagacttttggagaggatataatagcatagtaccataccacttataaagtggaaactcttggaccaagatttggattaaattgttttgaagttttgtatataaatatgfaaatacatgctttaaattgcaatttaaatgaagggttaataaagttagacatttaaaagaaatgattgttaccataaattagtgctaattgctgaggagaactacagttttcttgaatttagtatttagatgagttgttgacatgcaataaaatgaagaatgaa	
STRIP1	NM_00127076 8.1	attttaccagccctgttcaagatggagttgctgtgttcacacatctctgacaaaaatacagggtatttcggagtcaccagacctggagtttgatgtctgacacagacaagtggtgctgcagagctctcggagctttacagctacacgggaaggccagaattcctgatgaatgaaaatgctttgaggaggacttccggatccatgtgacagacaagaagtgactgagctggataccaaccagcaccggacctatgccatgaggtcctcgtgatggcttggaagtcactgcccaggagagaagagactcaagggtgctcagcgaattctctatgttgcacaggcaggtttggggaggtgcagctcggaggcgagaggtgcagtcctggatgcgctacaacatcttctcctcctggaggtgggcagcttcaatgctttgttgagcttctgaacatggaatagacaacagtgccgcctgcagcagtgctgtgagggaagcctgccatctcctgctgacagcacagacctcagggtcctgctcaacatcatgtacctgatagtggagaccttcatcaggagtgtaggggtgacaaggctgagtgaggaccatgcggcagaccttcagagccgagctgggtcctcccgctgtacaacaatgagccatttgcctcatgctgtttgggatggtgaccaaaatttgcagtggtgcacgccccctcacttcccatgaagaaagtctcttctgctctcgaagacagatttgcacgctaggcggctttgaggagctgcagagcatgaaggctgagaagcgcagcctcctggccctcccccgcttctgaggacagcatcaaaagtatttcgcaacatgagagcagcctctccaccagcatctgctcagacttgattgagcagcagcagaacggggcgccggagacacaaggctctgataaagcaggacaacctagatgcttcaacgagcgggatcccta caaggctgatgactctcgagaagagggaaggagaatgatgatgacaacagctctggaggggggagacgtttccctggaaacgggatgaagtgtgcctccccgctacagcaccacagactgacaggctgacttgcctccaaagggtcctccgtgggtcccaaggctcagagagaaaagacattgagatgttcttgatgcagccgcagcaaaattataggttacacttaggcagtgacacgaacacagtggtggggctgcccaggccaatccacgaaagcatcaagactctgaaacagcacaagtacacgtcattgcagaggtccaggcacagatggaggagggaataacctccgctccccctctcagggggagaagaagaagttagcaagtcctgcagaacctctaccaaggcttgcctcccgacctgcctcagtatatgattgccctcctgaagatcctgttggctgcagcaccacctcaaaagccaaaacagactcaatcaacatcctagcggacgtcttgcctgaggagatgcccaccacagttgtgcagagcatgaagctgggggtgatgtaaacggccacaaagggtcattgttaaggccatttctgtgtcctgctgctgctcaagcatttgaattgaaccatgtctaccagtttgaatacatggccca gcacctgggtgttccaactgcattcctttgatcctaaagtcttcaatcaaaacatcatgtcctac	31

[illegible]

		gtgtaatgatgaatgtgctgtcgaagggtgtgccccctaccctataagggtgtgctgggcattgaa ggcagggaagatttttaagatagattgaggtgtgtttaaataaatttcctgtaaaccaacaataaag caaagaagagggttcattttgtataataacactgtgttcaaatagtgatgttagacttaacctaatft ataaacaagagattaataatctccatgcatagtttagacaaaaaagatgtttcaataaaactact gtcttgtataataaattgttccacttccctttccacaggccctagaacagttaagggaacataa tttgttaggtctccacataaattggaatctggccaacaacttgggtcatcctttagtgaaftaga ggatttggctaccctgagtataattatattcatttctctgttctcctctgttattataactaacttcta aactaaactaatgtgaacagtaggggaagcaagggtcccaatgcataaagttcttgcactgttg cacttacttaatacaataaattgtttttaaagctttgtagtatttttagtgattaacatcctaagt ggtaggtattaggtaattgtgctgtcatgagaaaaattgagactccaagaaaactggacacca gggtgaggggtgtgttgagacgggaatagggttagctgcccccttggaaaaacagtgtgtagag atggctgagtgcaattggctcacacttgtaatcccaacacttggaaaggctgaggcgggaggat cagtatactggtagctgtgagcccaaggagtcaagatcagcctgggcagtatagcaagacc catctccatttttttaattgatttttaattaaaaaagaacaacaggatagagctgttgggtg gcacagtggcccaaggagcagcttcagagataaattcctgtgtctatgatccctgtttaaactcca aattacagctcggacttggatatacatcattgttaacattgtagggaaggaaaaagctgtgtgtg aaaacgatttgcatttgggtaaaataaagtgaccatgtctttgttctgtaatactgtgtgactgtg gtgtgttaattgtgtgacatggagagcaaatatgaacttggcctggattttaaagggcctagaaft tgggtagttgccaagagggttctcctaggtgtgttataaanaacctattcacagaattctcctfaa aaaaaaaaaaaaaaaaaaaa	
TMPRS S2_1	DQ204772.1	taggcgcgagctaagcaggagggcggaggcggaggcggaggcggaggcggaggcggaggc gccgcctggagcgcggcagggaagccttatcagttgtgagtgaggaccagtcgtgttgagt gtgcctacggaaagccacacctggctaaagacagagatgaccgcgtctctccagcgactat ggacagacttccaagatgagcccacgcgtccctcagcaggatttgcgtgtctcaacccccagc cagggtcaccatcaaaatggaatgtaacctagccagggtgaatggctcaag	33
TMPRS S2_2	OM_TMPRS 2- ERG_T2E4_C OSF28.0	gggaacaaaagctggagctccaccgcggtggcggccgctctagccctcaaggaaactctct gatgaatgcagtggtggcgaaggcgggaagatggtgggcagcccagacaccgttgggatg aactacggcagctacatggaggagaagcacatgccacccccaaacatgaccacgaacgag cgcagagttaactgtgcccagcagatcctacgctatggagtacagaccatgtgcggcagtgct ggagtggcgggtgaaagaatatggccttcagacgtcaacatctgttattccagaacatcgtat gggaagggaactgtgcaagatgaccaaggacgacttcagagggtcacccccagctacaac gccgacatccttctcacatctccactacctcagagagactcctctccacatttgacttcagat gatgttgataaaagccttacaanaactctccacggttaatgcatgtagaanaacaggggggtgca gcttttattttccaaatacttcagtatactcgaagctacgcaagaataftacaactatggccagatt taccataatgagccccccaggagatcagcctggaccgggtcacggccacccccacgccccagtc gaaagctgctcaacctctccttcacagtgccccaaaactgaagaccagcgtctcagttaga accttatcagatttctggaccaacaagtagccgccttgcaaatccaggcagtgccagatcca gctttggcagttctcctgagctcctgtcggacagctccaactccagctgcatcacctggga aggcaccacgggggagttcaagatgacggatccggacgaggtggcccgcgctgggggag agcgggaagagcaaaccaacatgaactacgataagctcagccggcgccctcctgtactactat gacaagaacatcatgaccaaggtccatgggaagcgtacgctacaaggttcgacttcacagg gatgcccaggccccccagccccccccggagtcatctgtacaagtaccctcagacc tcccgtacatgggtctctatcacgcccacccacagaagatgaacttgtggcgccccaccctc cagccctccccgtgacattctccagttttttgtgtgccccaaacccatactggaattccaactg gggggtatatacccccaactaggctccccaccagccatagcttctcatctgggcacttacta ctaaagacctggcgggaggtcttccatcagcgtgcatcaccagcccacatgccacaactct atcggagaacatgaatcaaaagtccctcaagggaatgaaaaaagcttacttggtggcgtggg aagggaagcgggggaagatgccaagactcttgggagggaggttagtgtaagtcttactgaagt cttactacaaaatgaggagatgctaaaaatctcacgaatatgacatactctctgtgactg cttactacaaaatgaggagatgctaaaaatctcacgaatatgacatactctctgtgactg	34

		accctgtaaaagacagctgtatgtagaagcatgaagctcttaaggacaaaagtgccaaagaaagtg gtcttaagaataatgtataaacttttagtagagttgtaatcccactaatgcaaactgggatgaac taaagcaatagaacaacacagttttgacctaacataccgtttataatgccattttaaggaaaact acctgtatttaaaaaatagaacatatcaaaaacaagagaaaagacacgagagagactgtggc ccatcaacagacgttgatatgcaactgcatggcatgtgctgttttgggtgaaatcaatacatctc gtttgatggacagctgtcagctttctcaactgtgaagatgacccaaaagtccaactccctttaca gtattaccgggactatgaactaaaaggtgggactgaggatgtgtatagagtgcgtgtgatt gtagacagagggggtgaagaaaggaggagggaagaggcagagaaggaggagaccaggggct gggaaagaaacttctcaagcaatgaagactggactcaggacattggggactgtgtacaatg agttatggagactcaggggttcacagtcagtggtttataccaaccagtggttaggagaaggg acacagcgttaatggagaaaagggaagttagtaattcagaacaaaaatgcgcctctcttct ttgtgttcaaatgaaaaatttaactggaaftgtctgatafttaaggagaaaacattcaggaaactc attatgtgggggctttgttctccacagggtcaggtgaagagatggccttctgtgctgccacaatca gaaatcacgcaggcattttgggttaggcggcctccagtttcttctgtgctgcgaacgctgtgctg ttgtcagaatgaagtatacaagtcattgttttcccccttttatataataattatataacttatgcatt tatactacagaggtgatctcggccagccaaagacacacgacaaaaagagacaatcgatataat gtggccttgaattttaactctgtatgcttaattgtttacaatatgaagtatttagtcttagaatgcaga atgtatgttaataaaaataagcttggcctagcatggcaaatcagattatcacaggagctcgtcatttgc acttttttagtgaactaaagtgtctaatgaaaacatgtgctgaatgttgggtgattttgtgtataatt acttgtccaggaaactgtgcaaggggagagccaaaggaaataggatgtttggcaccccaatgg cgtcagcctctccaggctccttctgctccctcctgtcttttatttctagccccttttggaaacagaa ggaccgccgggttcacattggagcctccatatttatgcttggaaatggaaaggagcctatgaag ctgggggtgtcatfagagaattctagtctcagccctgttcacaaatcccaatttaactctgtatg attaaaaatcaatttgttgaaacagtgaacaagctaccactgtaaggcgcaactgtatttactgtgc gggcggtatccccgggctgcaggaaatgcgatatcaagcttatcgataaccgtcga	
TRIM29	NM_012101.3	ctcctcacagggtgtgtctctagtctcctgtgtgtgctgccccactccctgcccagagacgcctgcc agaaaagtcacctatctgaacccagcaagccctgaaacagctcagccaagcacctgcga tggaaagctgcagatgctccaggagcaacgggtgcgagccagaagccagggatgcccg agcccgtcgggccccagtggcagctcggagaatggcaccaggctgacggcaaggatgc caagaccaccaacgggcacgcgggaggcagctgaggggcaagagcctgggcagcgcc ctgaagccagggggaaggtagggagcgccctgttcgcgggcaatgagtgcgcgacccatc atccagttgtcaggtccggggacgacaagaactccaactacttcagcatggactctatggaa ggcaagaggtcggctacgcagggtccagctgggggctgccaagaagccaccggttacc tttgcgaaaaggggcgagctgcgcaagtcattttctcggagtcggggaagccacgggtgc catcatggagccccggggagaccggcggaacagctacccccgggcccagacgggctttt ttcacgggtccaagtcgggtccggaggaggtgctgtgctgactcctgtcatcgcaacaagcaga aggcggtcgaagtcagctcgtgtgtgctcaggcctcttctgcgagctgcactccaagccccacc tggaggggcgcgcccttcgagaccaccagctgctcgcagccatccgggacttttagggccc caagtgctccgtgcatggcaagacgatggagctcttctgcagaccgaccagacctgcact gctacctttgcatgttcaggagcacaagaatcatagcaccgtgacagtggaggaggccaag gccgagaaggagacggagctgtcattgcaaaaggagcagctgcagctcaagatcattgaga ttgaggatgaagctgagaagtggcagaaggagaaggaccgcatcaagagcttcaccaccaa tgagaaggccatctcggagcagaactccgggacctgtgtcgggacttggagaaagcaaaa ggagggaagtggggctgctgctggagcagcgggagcagggatgctgtggaccaagtgaagg tgatcatggatgctctgcatgagagagccaagggtgctgcatgaggacaagcagaccgggga gcagctgcatagcatacgcgactctgtgtgttctgcaggaaatttgggtgcatgtatgacaatt actctctcccccccccctgcccacctatcatgtcctgtgaggggggaggggctgggacag tactagcgcaacttcaaggagacgacctgtcaatgtatgcatgcgccaactgtgagaagatgtgc aaggcgagacctgagccgtgaacttcatgtgagaggcaaccacgtgggaacgggtgtgtgaccatc gctatgtgaacaactacacgaacagcttcgggggtgagtgagtgacccggacacacatgaa	35

		gagatactccatgtacctgacaccceaaaggtgggggtccggacatataccaggccctcgtctcc tggccgcttcaccacagagaccaccagaaagaafttcaacaatctctatggcaccacaaagttaa ctaacctctccgggtctctggagtagtactctccagcattcagaactctgacaaftgacctgcccgtc gtccaaaggcagctctctctctctctgaaaggctatccctccctcatgctgggagccaaagcccc aaggcccagcccagacttggaaatctggcaagcagactatgctgtctactaccggccattc tacgtcaacaaaggcaacgggattgggtccaacgaagccccatgagctctctggcgggaaggga acgaggcggccacaccctgctctctctctgaccctgctgctcttgccttctaaagtactgtgctt gtcttgggtggggaggggagccctgctgctgacactggccctctgacgcccctctgcccagcctctgg ggggcagttgcggccctctccgacttcccactggccacactccattcagactccttctgcttgg tgacctcagatgggtacacatctctgtgctcagaggccaacccatcacaggggtgagatag gttggggcctgcccctaaccggccagcctctctctctggggtggatctgggggctagcagtg agtaccggcatgggtatcagctgctctctccgcccacgcccctgctgtctcaggccctatagac gtttctctcaaggccctatcccccaatgtgttcagcagatgacctggacagcacagccaccat ctccacttcaatggcccactctgcttccagaggactggccctacgtgtctctctctctctct acctatcaatgcccagcatggcagaacctgacgcccctggccactgcagatggaacctctc agtgtcttgacatcacctaccaggcgggtgggtctcaccacagccacttggagtctgtggtc cctggagggtgggtctctctgactggcaggatgaccttagccaagatactctgttccctctg ctgagataaagaattcccttaacatgataataccaccatgcaaatagctactggcccagcta ccatttaccatttgcctacagaatttcattcagctacacttggcattctctctggcagtgagggt ggctgggctgaccgcaaaagggtgcttaccactgccccacccctcagccgttggcccacatca gaggctgctctctctctgattacccccatgttgcataatcagggtgctcaaggattggagag gagacaaaaccaggagcagcacagtggggacatctccgtctcaacagcccaggccctatg ggggctctggaaggatgggcccagcttgcaggggttggggaggggagacatccagcttgggc ttcccccttgggaataaacattgggtctgtcaaaaaaaaaaaaaaaaaaaaa	
UNC45 A	NM_00103967 5.1	acttaacaaccgaaagtaaccgcgaatgcggaaaggcgcaggggattgagatcacccgagttt ccgcgcggcttggagtacggcctagaagaagagagatgttgggggttccaggccaccaggaca gaggtggtgtagtgaaactctcatgggcacacagagaaggtcaggccccccttgcctgacaggccat ctgtggggctactgctgctctctcagctgggtgaccttggccagccaacctctctcagctctg gtccaccaccctcacttgtgtccagacaccggggtatgccatggccgtactaccctgtgttct tttgcctctgctgtgtgattctccagaggaagccctactgctgcccactgcaggctgcaggggg gctctctgctgacccgggctgaatttgaggccctgtaccaagtcaatctgtccgctcttccgcc ccgcccacctcctcaggggcccaggcccgcctcctagtgtctggcctctacaacctactgtgtgt gacctctgatgaccgttagacctctgctgacctctgctgggtcggggccggagttctgggctgga gccaccgcagggtctccctctgggtccctccgcgcgagctccctgcagggtctctgcggggac agcttaggtgctgcccggagcttgcctgacactgcgattccagagccaagcgccccgcccctg cccggggcgcgtccctccttagccctgcccctctctgaccccacctccgcagcgaagagtggg gcgggggcagctgcgggtgggtcccgaaaccagactgcgcccgcccagagactgcgct gcgcggggcagagacaaactctccgcgagtgcagctccagctcagttgagcagctgcgcgaag gagggcgaatgagctgttcaaatgtggagactacggggggcgccttggcgggctctacactcagg ccctgggtctgagcgcgacgcccaggaccaggccgttctgcacccggaaccgggcccgt gccacctcaagctgggaagattacgacaaagcagaacacagaggcatccaaagccattgaaaa ggatggtggggtatgcaagcactctacgggcggagccaagccctagagaagctggggccg cctggaccaggctgtcttgcctgacagatgtgtgagcttggaggcccaagacaagaattt ccaggaggcccttgcgggaacatcggggggccagattcaggagaaggtgcgatactgtctctg acggatgcctaaagtggaaacagatgtttcagatactgttggaccagagaagaggcactga gaaaaagcaaaaggttctcagaacctgggtggtgctggccaggggaggtgctggagcggga gaagatcttccggagttaattgggggttcagctcttgcacagtttactggacattgggagagactga cctcatgctggcgctctgctgacgctgggttggcatttgcctgagcatcagtcacggacagtg gcaaccctgagcatactgggaactcggcgagtagtctccatcctggggcgtgggaagccagg ctgtctccctgctgctctcccaactctcagcttctgttcttcttccctcaagggaaggtctcaa	36

		aaaaggcttcgaggcaagaagggtgccatcattgtggatccgcccgggagctgaagggtc ctcatcagtaacctcttagatctgctgacagagggtgggggtctctggccaaggccgagacaat gccctgacctcctgattaaagcgggtgcccgggaagtctctcaaggacccaacaacagcct caccctctgggtcctgaccaagggtctgaaaaagattttggaagtggggggtctctacaggga ccctcctggggagctcgagtgaccgcaaacagccgcatgagcgcctctattctcctcagca agctctttgatgacctcaagtgtgagtcggagaggaggagaatttcacagactttgtgaaaacta catcaagagctggtttgagggccaagggtggtggccgggaagctacgggccatccagacggt gtcctgcccctgagggcccatgtgacgtggcaaccgggcccctggagctgagcgggtgtca tgagagtggtgattgctctgtgctcctctgagcaggaggaggagcagctggtggccgtggag gctctgatccatgcagcggcaagggttaagcgggcccctcattcatcactgccaatggtgtctcg ctgctgaaggacctatataagtgcagcgagaaggacagcatccgcatccgggctgtagtg gactctgtaagctcgggtcggctggaggagctgacttcagcatgaagcagttgtgaaggct ccactctcaaacctggctaagcagtgctgaaagtggctgtgcaatgaccagatcgacgcagggc actcggcgctgggcagtgaggggccctggttacctgacctttgatgccagctgtaagggaag agttgtggaggatgcggctgctctgaaagctctgttccagctcagcaggtggaggagagggt cagtgctctttgctgggtccctcagcgtggtgaactgcaccaacagctatgactacgaggag cccgaacccaagatggtggagctggccaagtatccaagcagcatgtgcccagcagcac ccaaggaacccaagcttcgtgcgggctcgggtgaagaagctgctggcagcgggtgtg gtgtcggccatggtgtgcatggtgaagacggagagccctgtgtgaccagttctgcagaga gtgtctcctcagggtcttctgtgctttagtgaagaggtagaggaccgagggcactgtgtgtgc ccaggaggcggcagggcgctgacccgctggcccctggaaggcacggacgtggggcag acaaaggcagcccaggcccctggccaagctcaccatcacctccaacccggagatgacctccc tgccgagcggatctatgaggtgtccggcccctcgtctccctgtgtgacctcaactgctcagg cctgcagaacttcgagggcgctcatggcccatacaaacctggctgggatcagcgagaggctc cggcagaagatcctgaaggagaaggtgtgcccattgatagaaggctacatgtttgaggagc atgagatgctccggcggcagccacggagtgatgtgtaacttgccatgagcaaggaggt gcaggacctcttcgaagccaggccaatgaccgactgaagctgctggtgtgtgtacagtga gaggatgagctgtacagcgggcagctgcccggggcttgccatgcttacctccatgc ggcccacgctctgcagccgcatcccaagtaccacacactggctggagatcctgcaggc cctgcttctgagctccaaccaggagctgcagcaccgggggtgctgtgtgtgtgtgaacatgg tgagggcctcaggaggagattgccagcaccctgatggagagtgagatgagagatctgtca gtgctagctaagggtgaccacagccctgtcacaagggtgctgctgcagcctgctggacaag cagtggaatatgggtcttaccacaaccaacccaagatggagagtgagggggtgtgctccctggcc caaggctcatgcacagctacctattgtggcacggagagtaaggacgggaagcagctttggct gggtgtgtgtgctgcatcccaatactctgtgcccacctcgtgtgctgcccctaggatgtcctgtt ctgagtcagcggccagctcagtcacacagccctgcttgccagcactgctgcagcctcact cagaggggccctttttctgtactactgtatgcagctgggaatgggggaaggtgcacccaacac agcctgtgatcctgggcatctggaagggtgcacacatcagcagcctcaccagctgtgag cctgctatcaggcctgcccctccaataaaagtgtgtagaactcaaaaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaaaa	
XPC	NM_004628.4	cgaaggggcgtggccaagcgaccgcctcggggcgggggccggcgttctagcgcacgcg gccgggtgcgtcactgcgaagtggaaatttgcagacaagcaacatggctcggaaacgcg cggccggcggggagccgcggggacgcgaactgcgcagccagaaatccaaggccaagag caaggcccggcgtgaggaggaggaggaggtgctttgaagatgagaacccccaaaga agagccttctcctcaagtttcacaaggaaaggagaaaagggtgcagtcacctcgggggt tcagcagatggtcagcaaaaaagaaagtggccaagggtgactgttaaatctgaaaacctcaa gggtataaagatgaagccctcagcgatggggatgacctcagggaactttccaagtgaacctca agaaggcacaccatctgaagagagggtctacatgaatgaagacagcaatgaagaaggag aagaagtgaaaatgattgggaagggttgaaagactagtgcctgtgctgggtgacgtg agagaaagtacagccttctcgtatcttctgctgtgaaagccagtgagatagagattgaaa	37

	cgccagagcagggcgaagacaagagaagaagtgaagataaaaactggagttgagacat atctcggaggcgatgaaacgtttcaataaagggtccatgaggacacacacaaggtcac ctctctgctgctagcaaatggcttctatcgaataacatctgcagccagccagatctcatgc tattggcctgtccatcatccagcccgtttaccagagtgctgctcagatgtggacacctac tacctctcaaacctggtaagtggttcattggaacattacagttaatgcagaactttcagccagt gaacaagataacctgcagactacattggaaggagatttgctatttactctctcagatgatg agggaattggccatatttcttactgattctcgggctctgcagctctgacccggctgtattgt ctctacagccaatttctctgaagtcagcaacagcaagggaagaaaccttccaggaaaga ttgactgcggatccaggaggtcctcagaacttccagccaagttctagaaaaccacacaaa ccaaagaccagcaaggaaccaacaagaggaaacctttgctaagggcacctgcaggcca agtgccaaagggaagaggaaacaggaggcagaagaaacggagcaagccctctccag cgagggaagatgaggggccaggagacaagcaggagaaggcaaccagcgacgtccgcat ggccgggagcggcgggtggcctccagggtgtcttataaaggagagagtggtgatgag gctggcagcggctctgattttgagctctccagtggagaagcctctgatccctctgagagatt ccgaacctggccctcaaaagcagaggaaagccccgctctcagaggacaaagctgggt ccaagagtgcctccaggaccatcgtgggagccatcgaaggaccaagctgcccagcggc atctcaagctctcaagcagtaaaaggcgaagaaatgtgcagcgatggtgagaaggca gaaaaaagaagcatagctggtatagaccagtggctagaggtgttctgtgagcaggagaaa agtgggtatgtgtagactgtgtgcacgggtgtgtggggccagcctctgacctgttacaagtacg ccaccaagcccatgacctatgtgtgggcatgacagtgacggctgggtccgagatgtaca cagaggtacgaccagtctggtgacagtgaccccaagtgccgggttgatgctgagtgt gggcccagaccttgagaccataccagagcccatttatggacaggagaagaagaagactt ggagtttcaggcaaaacatggaccagcctttgccactgcccattgcttatataagaaccac cctctgtatgcccgaagcggcatctctgaatatgaggccatctatcccgagacagctgcc atccttgggtattgtctgtgagaagcgggtctactccagggtgtgtgacactctgattccag ggacacgtgctgaagaaagcaagagtggtgaggttgagaagtaccctacaagatggtg aaaggcttttctaaccgtgctggaaagcccgaactgtgagccccagctgcccgaagaaaa tgacctggcctgtttgtctactggcagacagaggagtatcagccccagtgccgtggacg ggaagggtgcccgggaacgagtttgggaatgtgtaccttctctcccagcatgatgctattg gctgtgtccagctgaacctgcccatactaccgcgtggcccgaagctggacatcgactgt gtccaggccatcactggtttgatttcacatggcgtactccatcccgtgactgatgatacat cgtctgcgagggaattcaagacgtgctcctgactcctgggaaaatgagcaggcagtcattg aaagggaaggagaaggagaaaaaggagaagcgggctctagggaactggaagtgtctggcc aaaggctctctcatcaggagaggctgaagcgtctacgggcccgaagagtgaaggagca gtccccacacagatgcaggaggtggactctctctgatgaaggagggggaccagctctca agcagaagcggccaggatactggctgctcctggcctcaaaaccgagaagatgaagaaaa gcagaagctgaagggtgggcccgaagagacccaaagggaagaaagcagcagcttccc acctgttcccatttgagcagctgtgagctgagcggccactagaggggcaccaccagttgct gctgcccactacaggccccacacctgcccggcatgcccagcccctggtgtgtggggct tctctgtgagaaggcaactgaggcagcatgcacggaggcgggtcaggggagacgag gccaagctgaggaggtgtgaggtcccgtctgctcagccctgtcagattcaccaggg tgaagcctcaagcttttctaccaaaagccactcaccctttgagctacagaacatttgccta ggagatactcttctcctcagacctgttcttccatcttgaacatcagttttgtatgaagc caccgggagatttctggatgtgtgtcatccgtgaatcgctgacgtttctccagttagatc ttcatctgtccgacaagttaactgcctcgggtgaggacacatttctcagggccact taccttcccctgagtcaggcttactaatgtgcccctactgcccctttgagtaggggagagag cagagaagtacaggctatctgctgggatctagtttccaagtaacattttgtggtgacagaagc ctaaaaaagctaaaatcaggaaagaaaaggaaaaatacgaattgaaaattgaagaaatgta gtaaaatagatgagtgtaaactagattgtatttacttagataaaatgtataaagctctgtac taaggagaaatgactttataacattttgagaaaataaagcatttatctaaaaa	
--	---	--

ALG9	NM_00107769 0.1	gtctttgtccctcggcgacaccgtttccagccaaagctatgtctcgcgctcaccgacttc atagggtgcccgaatctttttccagggcttccatggctagtcgaggggctcggcagcgcc gaaggcgagcggggccagcagtggggatacggccccggctcgggacaagctgcgggag ctgctggcgagccgagagcgggcgcgcgagcaccggaccgagttatctgggaacaa agcaggacaagctgggcacctgaaggatctactgcttcaagtgtctgcttcagcaaggtta tgtgtgtctctcctgagcaacatctctgactgtgatgaacaatcaactactgggagccaacac actacctcatctatggggaagggttcagacttgggaatattcccagcatatgcccattcgctcc tatgcttacctgtgtctcatgctgcccagctgcatttcatgcaagaattctacaaactaataag attctgtgttttacttttgcgatgtctctggtttgtgagctgtattgtgaactttactttacaag gctgtgtgcaagaagtgtgggtgcacgtgagtcgaatgatgctagccttctgtgttcagcac tggcatgtttgtctcatcatcagcattccttctagtagcttctgtatgtacactacgttgatagcca tgactggatgtatgtgacaagacttccattgctgtcgggagtagcagctggggctatctt aggctggccattcagtgacgtcttgggttaccattgcttggatttgcgtgctgaacaacag gtggaagagtttcttcatgtgtcgtgatggccctcatactatttctggtcgtgtgtgtgtcatt gacagctactattatgggaagtgtgtgtgtgacacacacattgtttgtataatgtctttactcc tcatggacctgattttatgtacagaacctgtgtatttctatttaataatggatttctgaattcaa tgtagccttgtcttggctcctagctcctaccactgacttcttattgaataacgtctgcagaga tttcatgttcagaatttaggccaccctgttggcttacccttggctccaatgtatatttggttataattt tcttcatccagccctacaaagaggagagatttcttccctgtgtatccacttataatgtctgtgg cgctgtggctctctctgacattcagaatgttaccatttgtgttcaacgataatgcccgtggagca ctatactgtgacatcgaaattggctggcattagggaactgtcttctgttgggcttgtcattttctc gctctgtggcactgttcagaggataatcacgggcccctgtattgtatccagaattttaccgaattg ctacagaccaacatccacactgtcccagaaggcagaccgtgaatgtctgtgtgtggaaaa gagtggtatcgaatttccagcagcttcttctcctgacaattggcagcttcagttcattccatca gagttcagaggctcagttacaaaaccttttcagagaaggacctgtggccaccctgattgttcccta ctgacatgaatgaccagaatctagaaggagccatccagatatattgatatcagtaaatgccattat ttagtggatttggacaccatgagagaaaacaccccgaggagccaaaatattcattccaaataagaa gaatggatcagcttggccatagaccattctgtgtgtcttagatcttcaagctgtcgtgggc attctatgtccccttccgtcagatcagtafacagtgtagtaaaactacacatctcacaaccccg gaaagcaaaagcaaatcagggaagaaaagtggaggttagcaacacacctgtggccccaagg acaaccatcttgaactattgattccagtgacctgactcctgcaagtcacgcctgttaacatttg taataaaggcttctgacatgaatactgggaatctgggtgctcctgtagtcaaaagtctatttcaa agtctaatcaaaagtcacatttgcctcctgtgtgtgtctgttctgtcatgtaacttttgcagctag gcagagaaggccctaaagcacagatagatatattgtctccacatctcattgttttctctgttca attatttactagaccggagaagagcagaaccaacttacaggagaattgaaaatcctgtgtact ggatggctgtgataagctgttctccacactctggcctggcatctgagaactgaagccctctt aggccatatgggcttctccacaaaagctgttggcagctcctagcagaccttctattgaaatcc tcatgctgaaaatgaacacagcctagttgccaacccacatgtcctttcacctccagcaagact aagcttctttaaagcattcacaggactaggacctgtcctggagctatctcaggaaaaagggtg accatttggaggaactgtgacctaatfttattataatgatgctctaatfttcatttcttacaaccaa ctgtaactataagggtgtattgtcttttgttcagtttttagcatgtattttgaattctagactctcc atgtgaagataatcaacagacaaaactacaactgtataggacatatgttgagaaaattctatcaat tgatacatttggatgacatcacatttttaagtaatgtaatctgaggccattgtcaggaaattag aattttctttttttaaaccacccagtgaaaaggatcagtgatatttatagcacctatttttagt tctgtctgtgtgaggcacatcctgcatggggcacttctagtcaaataggcaatgataaggacc taattaaaatgtgataagtgatactatttctttaaagcctttacagtcagtacttcagtttacaag gcactttcacagcatctgttgaatccacagtcacaacatgtggtagacaaggcagggtgattt ttatccccattttacagataaggaaacaggctcgggtgtgggagtgaggggaggtaagata gfttagtgccaaagtcacacagccagtaagtaatagagctgggactggaaccagggttccctt actctcatctattgtcctccatattcctcactcaaccatgaaaacattactgaaaggactgatga	38
------	--------------------	--	----

		gggtaaccagagacctaactgafattgtaactttctattttaaggagaattgtgctgtatttgagt tctttggagcctccagctgctgtgtgtagaccagcacagcagtgctgtgtgagcagcctg acctgtggcaggaaagtagtgcttctgttgaagtcattgttctttgagccacacaggatcca aatatcagtactattctgttagtcaatctgggtcacattatagtgcttatttccctaaagggtaa ctgatctgaatatctgcaaataggatgaatctattttcagaagtccatcttctatttttttttt gagacagagtgctcattctgtgcccagctggagtgagtgccgcatctcggctcgtgcaa cctctgcccctcagggtgaagcaattctcatgctcagccaccgagtagctgggattacagg catgcgccatcatgcccagctaattatgtatttttagtagagttggagttccacatgttggccag gtggtcttggactcctgacctcaggtcatccaccgctcagcctccaaagtgctgttatta caggcgtgagccaccgacccagccccatcttctatttcaagagaagggtcattcattatagg aactgtgtccaagagagaagaaaagaagtgataacagaagaaatggctagtacaataatfaa aaagctcctcttggagatctcctctgcaggaatatcagagacggagttgaagcgtggagagg taataggcttagacagatcagaacaataactggggagtggtgaggaatagactgggctcccc ctgtctgaaagatctgtgcatttaattctcaattctgattactatttccagtgtaaaactagcac atafagctgactacagagacagagaattttaagtgaaacatttgccttactgtagtaataatgtg ctgttcttcacagtagctaaggccctctatgtttccagaggtaaataagaatccaggaaatgga ggccatctgtgatgaatggcttttttctaataaagtagtataatgctgtttatctgtttgtcatctt gttttttttttttaaaaaaacaaaaccttaattataatataagcgcaagaaaggccaggactgat gcagggaattccttggaaatatcagttctatcacttttaaaacctgatttggatctctctgtctat gtatgtcttttagtgagagcacaatacatggcagaaacgctgtgccaatgttataggtaaggat atagaaatgaatgtttttgtgtgaaggtgtttcatgtgatattttataaacacattttaaaaaatct ccatcacttttttagtataggaaagtagctttgcctgggaaaaacagttcaacacacctgctca gagtagcagttctccctcaaaaagcagtggtcagcctgactgactgttctgttgcctcaaaag gagggaagcatgcaagatacttatttctcatagattgtggagtagagggatgtgggactaca gattattattttttccccgagacagagtgctgtctgtgcccagggtggaaacaaatggcagc acctcagctcactgcaacctgtctcctccgggttcaagcaattctcctgttccagcctcctgagt agctgggattacaggcacacaccaccgactcagctaattttttagtatttttagtagaggtgg ggttttacatgttggccaggctgggtcttaaaactcctgacctgttaatcatcccgcctcggcctcc taaaagtctaggattacaggcatgagccaccgacccggccagataattttaatagccttgg atcatggggtgagtgaggagtaggtatacttggcaaatgcatggtctctgatttctagctcta aagcagccttatctgaatcccaaatcttgtatgctgagtagtaccattactgaaccagtctgcacg gtaggcatctgctacaaaattacctcctacctgtaggtgtcatctgataaagaagaagaca gggtatttttaatttttagataatcacagaaaattgcagcccatactctttattaccgaattcaagt tggaatagacccttgttttaaatcatgatgggtctttatcccaatcatttatctgggtcattttcc aactttggagttctaggaaagaaacctgaaaacctgafatgattctgcagcatgaggtctacgg gacctttgggcaagctccagtggaatcatttattgtgtttgcatctcctgggatttattgaaat aagaattcactgtgattatgtagtcttctggctagatcaggcagctcgtctttaatttggtaattt tatttctctgaagaggagagagggtacaatttaacttggcctccacaagcatattaaagctc acgtgttaatcagtgcatcttatgtcctacattaaatgcttgggttaaatggataaatggacat gtgccagctttaatttttttgaacagaagatcagacttccgtatggcatcgttggatttcaga ggctttctgtgtatctgtaaatctgaatgttgccttctgccagctgtataaccagggtattcatg ctgcaaatgaatcagggaagcagtaaatgtttaaagcaagagtattgtcgaattcactgtcttc ctgatcctgtactttattcaggtgtcgggtttacattacatacttatatttctgtgaaagaaaga gttaataaattgtagcagtttga	
SEPN	NM_031475.2	agcggagcgcagggcagcgcggagcggagggccagggccacagccgctccgctccgg cccgcagatccccagcggcgcagcgggctcctctgcccgaagaacacgtgcatgg cgtcctgggggaaggcgtgagtgcgagtcggcgccgacgcggcaccatggccctg gagcagggcgtgcaggcggcgcgagggcgagctggacgtgctgaggtcgtgcacgc cgaggcctcctggggccctcgtcgcgacccgctggacgcgctgcccgtgacccacgc ggcccgcgctgggaagctgcactgtctgcgtctcctgtggaggagcggccctcccgcc	39

[illegible]

		actgcccgggtggagtgaaatagaggatgagggggccctgaccctgtgtctccaaatgctgcac cccccccgaccctgtctcgcgcacctcgagccccaftaaagcgctctcatctgggtcccg ttactca	
YWHAQ	NM_006826.3	ttggcggtggaccgcccctcggccccggggtaggctgacaggaggggtcctcagctaa agccaaaagcagatcaaaagtgggtggactcgcgtcgcggccgggagacgtgaagctctc gaggctcctcccgctgggtcggcgtcgcctcgtctcctcgcctccgccccggcccc ggccccgcgccccgcatggagaagactgagctgafccagaaggccaagctggccgagca ggccgagcgtctacgacgacatggccacctgcatgaaggcagtgaccgagcagggcgccg agctgtccaaacgaggagcgcacacctgctctcgtggcctacaagaacgtggtcggggggccg caggtccgcctggagggtcatctctagcatcgagcagaagaccgacacctccgacaagaag ttgcagctgattaaaggactatcgggagaagtgaggctccgagctgagatcaatctgcaccac gggtcctggaattgttggataaataattaaatagccaatgcaactaatccagagagtaaggtctct atctgaaaaatgaagggtgattacttccgggtaccttgcgtgaagtggcgtggtgatgacgaaa caaacgatagataattccaaggagcttaccaaaggagcatttgatataagcaagaagagatg caaccacacacccaatcgcctggggcttgccttaactttctgtattttactatgagatttta ataaccagagcttgcctgcagcgtggctaaaacggcttttgatgaggccattgctgaactga tacctgaatgaagactatataaaagacagcaccctcatcatgagctgcttagagacaacctata acactttggacatcagacagtgaggagagaagatgtatgcggcagagaaggcgctgaaaaact aaatccatacagggtgtcatctcttcttcaagaaccttttatacatctccaltcttattcca cttgatttctatagcaaagaaaccattcatgtgtatggaatcaactgtttatagctttttcacac tgcagctttgggaaaacttattccttgatttgtttgttctggccctcctggtgtgcagtactgct gtagaaaagtattaatagcttattcatataaaacataagtaactccaaacacttatgtagaggga ctaaaatgtatctggatttaagtaactgaaccagttctgcaagtactgtgtttgtattactgt gaaaataagaaaatgtagttaattacaattaaagagtattccacataacttctaatttctacattc cctcccttactctcgggggtttcctttcagtaagcaacttttccatgctcttaattgtattcttttag taggaatccgggaagtattagattgaatggaaaagcacttgcacatctgtctaggggtcacaaa ttgaaatgctcctgtatcacatcggagggtcttgtgtatctgtgcaacagggagtttcttatt cactctttatttgcgtgtttaaagttgccaacctcccctcccaataaaaattcattacacctcctg cctttgtagtcttggatttactttactatgtatagaagtagcatgttgcgtccagaatacaagca ttgcttttggcaaataaagtgcagtgcttcttaatacactagaaaggggaaataaattaaagta cacaagtccaagtctaaaactttagtagctttccatgcagatttgtgcacatgtgagaggggtgctc agttgtctagtgtgattgttatttagagagttggaccactattgtgtgtgcttaactatcagctgagtc ccaaaaaaggccttgtgaaaattgtatgccctatgtaacagcagagtaaacataaataaaagtac attttataaaccatttactatggcttftaacaattgcataccatattttaagggacaggtgaattt actactttctaaagtttattgatacttccctttatgtaaaaatgtagtgtataccatatatttccacatt gtgcattgtgacacacttgtctagggatgcttggaaagtgtataaaattggactgcatttcttaga gtgttttactatagatcagttctcatgggccatctctcctcagatgtaaatgatatctggttaagtgt tatatggataaanaagtgacattttaaaactagcaaaagttaaaaaaaaaaaaaaaaaaaaa	40
VPS37A	NM_00114515 2.1	gcagaggggggcgagagcgccccggggggcggggcacgcaagtgcggcgggcggg gtggtggagcgctggggcgccaggctccctggcgtggccggttggggcgtctgggcccgtgaa gggtgggacctcctgttccggggccgcaagtttccctctccagccgcccgcggttctgtagcatgt ccccagaaactcgggggagcgcagggcaggacagggcttagagaagacgcggtccccagcgc ttgggcacagcgacgtccaccccgctcctgtgtcgttggagaaccgcggcgccgagccact gggagaagcaggccagagccttcaggggcctccggcccggtggaccggaggaggtatgagc tggcttttccccctgaccaagagcgccctcctcctccggcgtgggtccccgggtggcctcacc agcctccagcagcagaagcagcgctgatcgagtcctcctcggaactcacactccagattgct tctctcacagtttctcaggaaaaaacagtgatcagtgtttatccaccaatagacatcacttaat ggataaacaaggagtgatgtattcctctccttaagtaaacattttacaaatgactcagatcttgg aaaaaattatccagactctcttggatgaatttttgaagaactctccaatttttagcctccttcaaca	41

	gcatttcttatctafacagtaaccaagtgaggatgtctctctfatgcttctcagggtttccatttctt cctccatactctccacaagaagcaaacaggagatcacttcttatctgttctgacacigtittctt cttcaacaacaagtcataccacagccaagcctgcctcctcatttgggtgctcttcaaatctgc cattaccattccacagtggatgcttcaataccgacaagccaaaatgttttgggtacaagat gccagatgtccctgatgcatttcagaactctcagaactaagtgtgtcacaactcacagatatg aatgaacaagaggaggtattactagaacagtttctgactttgcctcaactaaaacaaattattac cgacaagatgacttagtaaaaagtattgaggaaactagcaagaaaaatctcctttggagccc agcttggaaagccaaaagacaaactgttttagataagatgaattacttacacagatgaagtc cttctgaaaagagatgcaaggcagcatgaacttagtgagagctgtatgtcaagtgccttc aggcaagattgaaagtgtgacatgaagctgaggagaatctgataatattgcagaagact tcttggagggaagatggaatagatgatttctcagtagcttcatggaaaagagaacaattg ccactgtagaagagccaaggagaagaacttcagcaggcgatagcaatgcacagccaattg catgtctccatagatatttctggaaacatgaactgccaaagagaggaatgggacacaaaaacc aaacactgttttatatttattgtttgcaactggcatttcatcagtggtctaaattcacagatactta tatagattgtatacagaactgagactgatttgtaccgattagaatgattgctatgactttgagaa attttctgcactatttgcactgaaattttatttattgttgataaattgtatcatatttaagtccactg ctgttctcttacttgaattaaatgcctatgcatgtacttttagctagttttaataatttataaaacttc atttaatttatttttaactgaagtccatttcttataagatggtatttagatttttctcttaa cctttttcaaaaacttttcaactgtgaggaaacccttatttcttcttgggataaaaactttcaa aagcaatttaagatattcatagtgttaggaaacaccaaaccctgcctatgtgccaatctcacaaaag aaacttttaatactacaataaatcaaaagaataaaccagctgttcttataattgttctattttaa actaaagatgcatttaagaagcaatacaagtaaatatttaccataataggaaaaaaaagtgtc ctttcatttaaccattccaacagaaattcttatgctaatttaaacatatatctggtagggttg tgggtggataggtttctaaattcctaattgtaaaaacaatcttatgttaataatacactaaatctata cacaaaaaagtcagtgaaactttctgaccttactgtgagttacctttcctaagaggaagacta tagtaataagtaaaaatttaatttttaggcaatcctgatttttaagaaatttaattgagtgttctgtat tacctgagcagttgtcttataccgtgtcacaaaattcatgtatttcttgagaagccctaaagc tcataaaggaaaatgcctgaactatgtagctcaggcttggtaaggtgccatcaaatfaca acaaactaatgcataatttgcctaaattcatccagtagattgttctccaacaccagcatata gtatagattgtctgttttttatatttttagttctctgtacatgttttggcaataaagttaggaa gaacaaaattattttagaattaaacatgcttaataatttagtctgtttgtggagggcaggtattc acgtggactgagatacaatgttggatacagaaaataacttcatgttctctgacactgtgctaa ggacatgctgttaagcttcaagtgaccagatgaggaaaggaataaattattactcctgattt gtagataactgaggtaagagtgttcaaatfataatgtagtcttttgggtattcagaaaccttctta tactgcactggccaccagagcttaattttccagcagttacagcaatggagatagaacagctc caatctttgccaaccatcaggttctagaaaccaggtagggtgtatccataacaaggaggga gcataccacagccctcatttgattaattcatttgatctatctatgtttaaagtacactaggaat aaggcattgtggaatactatacaaaagataaacattgtttagatgcttatctactttcctttcaca gaaaaacagaaaaaagaacattttctacagagtaaaaatgttctacataatcacatgagta gttcatctcagtggttttattctttaaagtgaactatccagtttcatctataccattcattggataa cctgttacaacccagtcagaaacagagcagtgatcagttatctgcatttaacaataagaca aatcagttacataaaggttatgtatgcaccacgatgaaaagaatctgcattgaatagcccg tatgaatgtgggtctgttttgaacagagattaaagtaccatttttctaattttatggctatatatt tcttcataaaaattgtcacatcggagaagcagtgccacaggaaaaatgaaatgcattgtgaaa gtttgtattctgatttacaagatgagatagaatacagaataaagggaatacttaggagtact aggctaafcagtgacgaattgtcataggtagagatttaaggttaataatcttaaaatagaagaa aattctaaatcaatcaatcagtgagataaaactaaacagaccacttcaaggtgaaagaaatt tctaggcataaattgagactaggaaatttatatcagaafagagggtgcttgacacatataatgct taaatgaaggacagctcagatttattttaggagaagaaagtaaaatgtgctcttaagaa taaaaatttattctatggttctctgatcatcaccttcattctataaaaagctcagttactgatt	
--	--	--

		tgctgggtcatggtcaaaattctfacctatftatftcataatcaactttaaaaaataaattacttgcatt ctatatattactaatgggaagtaatatgcctcaaatcagtttatactggattatccctatgcttta aaccactgctctcaataaaacacttctgattaatgtttgattatagatatttagcttggggga tatttagcttgggttagccatgctctgaagaatctgtgaagtacagtaagtttaataag caataaafgtaacctttatataaatctcagtgctaggtaacttctaataagcagacgaacatgtt acataaafataatgtctgttgtaaaaagttgaggggactaaaagttatgactctgatatgg aagttgtcataftaaaaactacattttaaacatcaafatttatactatttgcctttcaataaaag catagtgctgttggcata	
PRRC2 B	NM_013318.3	gcagatcgggagcgggtgccgagaaaafttccttagatgacatttcacgcaatgtccgat cgttggggcgaattaccaaggcaaggatgggaaaagcaagtactcgaactcagccgtttt gataagtataaaggaaaatcagtagacgcgattagatcctcagttattcctagacatgcttaca gagcttgggaaagtgtgctgagcccgccatgccaccgctgcaaacctgccaagcttga agtctgaaaacaaaggaaacgaccccaacatcgtgatagtacccaaggacgggacgggat gggcaaacagcaggtatcagcaagacccaagagttccagtcgacggcctctcagccgc cggagtcgctgcccgcagccgggttgcagaaatctgtctcaatttgcagaaaccgacacagt caatcagtcaggagaaatacaaatcagtgccaggtggaccaaagtcattgggcacagctgaat ggaaagccagtaggacacgaagggtgttaaggggctcaagccgactgttatctctctccc gaggaafttcgacgctgaagcagctggaggcagggacaaggctggcaagaaaagggg cgtcttagatctgtctatggccaggaccaagcctccgcccagaaatgtgacaagctgga gggaggcggtggcgacacataattctgccacgtctctgagcacctccccactgagctg ggcagcaggaaactcagtagcgggagatggagcccctcctcgcatgtaccagcgattcta aggacccctctctccgcccgcagcctgtccgaaaaggggcttcacagttcatgggaat gtataccaccaccctacataacatgacatgtctctgtttatgtgttcggcgaagtcacagaa aaccagggtacagtggaaacgaggtcttttcccttctcagctccgcttgaaacctgagttc cttttagacagttccagatgaatgaccaagacggaaaagaaaacaggtcggattgtctgcc cactccgcccactaaggcagctgtggagcgggcaccacggcccaccattatcaatgcgga aaacctgaaggcccttgacgatctggacgcgagtcgcatgatggctggcagggcctccat gaagaagtggactattctgagaactgaagtgcagtgatgatgaagaggaggaaggaagtgt gaaggacggcagggccaaagtggaaacagttgggaccctaggaggcagcggcagttgtcaat gagctctgcagacagtgccgacgctaagcggactcagaggaagggaaggactgggctg aagcagtggtgtgctccgtgtgtgcgaaggcggccagaccctcagccaccgcccaggga agcttcagtggtggcaccaggccctgactaccagaagtcataatgggcagcatgttcgg caacagtcacagaggacaaggaggacaagccccaccaggcagaagttcattcagtcag agatgtccgaggcgggtgagcagcccgaagcggcgggaagaggagcggcggagc ccgggaggagaggctgcccgtgtgtgccaactcaagcagctggaccagaagtgtaa gcaggcacgaaaaggcaggtgagggccgggaagcaggcagagaagggaagtgcctgtgtc caagtgtgagaaggcatctcccaggaaaacggccctgtgtccacaaggctcccaga attccctgcccagagacccccaccattccagaaggagcaccacagtgctcccagca gtggcacagagcaacagcagtgaggagaggccagagaggctgggtccctgcacaggga gttcaagtatcagaagtcccttctccccgattccagcggcagcagcagaacaacagcagg agcagctgtacaagatgcagcactggcagccgggtgtacccccggcgtccacccccagcg cacctttacccacacacccccagatgttgggttcgatccaggtggtatgtatgtccttct acatggacccacgtatcacgcccactcggaccccggtggacttctacccctccgcctgcac cctcaggactgatgaagccatgatccccaggagtccctcaatgggacaggctgtgtctct gaggatcagaactgtgtccccactccaagaaagaaaagtgacccccatcagactacccc ctgtgtggagcccagagggtacatggcactgcagagcaagggtaccgctcccgcaccc gaagtcagtgacaccttggtatggacatgctgtcagggaatgaagctctttctctgctca ctcggaaaggcagggggcgtaagtgtcagcgcgatctttagggagagaggggagggag tacttgagtgctttgacaagaaggccaagcagactttgacagctgtatcttctcaagaat aggccaggagctttgtttccaccccaagaaatgttcaggatgcaggtgctctcgggggtca	42

[illegible]

	ggaaaaactccccagtttgcggagcagagcttccaggcgcgctggctcaggcatccag ctccatcctctgttggtgctccagcggggtcaactacagctccttcggtgagtgatccatgc caccatgctgttgctctgttagcaccttctgtcttatccaggcagccacctcccgcct gtacctgagtgccatgtgtttgaagtcagcccggctggttctcaaacgatacctcagca gcagagttaccaacaggccgctgctccagcagatccgatcctctcacacatctctgca ggcacaagctcagcttgactgagggtgggtctctgtgtccagtcccaggagatcttca gtccttgagccctcagatctcaggtgtfacatgcacccagcctgtcaccgcccagcacca tgatcctctctgggggcacagcctgaagcctccatactcggcgttccaggcatgagccct tggagatgtgaagccgagctctggtcaccctaccagccatgagcgggaaccaagccct ggtctacaggggccagctcagccaggctgctgctgggtgctccagatgttgactccc agctcccacagctgaccatgccactgctcgtacggctccgggcagcagccactgacctg cccagctctatcagctgcccactgggcagagcctctcgttggggcccccgaggattcct ccgcccgggtccagccgccagctctgaacaccagcagagccctctcagatggagatg aaaggcttccactttgcggacagtaaacagaatgtccctcaggaggccccgtgccatgccca cagacctacaggcctagctctgtagccccagtggaagccctctggatcagcagttaacat gggctctgtgcagggaactacgtgcaacaggcaaaacaacagtggtgagaaaccag cctgggagccgtgaagctgcaggaggccccctggctgctccagatgaagcgaaccgg agcgatcaagcctcgggtgtcaagtgaggagagtaaggcctgacagtgctgctgctgccc acctgctctcctactgaggacgggtgcccagctcggcctcgacacagccgacactggg gagcctcaccagatccaccgtccaaatgctggcccagactgagagacctccctcttcca ctccgaaagctcgtgtcaaccagcttgacccgtgatatatggcattgacccgttctt gatacgaacaaaaaagcagacgactcctcatccatctgctctaccgtgactgtgagtg acgctcctgtgcagtgcatgttgcctcctgctcctcctctgctcggcgagccagg gcgcttctcagcagtgcttccggcccagccgcccacccataggcacagtgatttggcagca gggtcatcttacttgaggcttttggtttaaatgtagccaagggttttacaagggggaaaggaaa agaaaaacaaaacgcaagctccatgtgtatagctgaacttttatgtttcttgcagccccctc gtccttccatctctagcctctgctcgttttagtttgatacgtcactgcagtaccttaagggtga ctcttaagaaatcatccctcctgattcctcagctggttacccttgagggtatttgcaaaaagaa aaggagggttcttggggcacogattgcgagcattctggtgctgctccccgcctgggaagc gatggggtgctcagagcagcaggcaggttgggggagggggggggtcatagttgggtcca gtcctggttgatgagcccaggggcgttacaggcagccatgaagtgtatgacagttttagc atgagaatcacacagggtcctgtcctgggtcctctaaagccagtggtgagctgggcacc agagacaatcatggagatggctgctggtgctccaggttggcccagatggggtgagctg acataccacaggccatccaggccccgtgggctctgcttctggggctccataacctgcccctg cagggggtgctgtgttttccacatttcttccctgaagccttctgtaacctgtcatttcttctc ctctcgggagcctgctgcttctctgacctgtctccacctccacacagctcagctgaacac cattggtgatggaggagtgaccgtgtgtgtgtcccaagtgaggccactgggagttgt cctttcctccttcttctcactcccagcagcagaccaggtgtcaggacaggaggcctgag ctaagcagtaggcacagctctggttctcagacggcgggggcaggtccagggtgaggt gggtggagggtgaccaaagggtccaaaggcctgcgcagccctcgggaggggcagcttctcc agccagaggctgtgtgagccatcgtgtgctggcgttgggttaagtaagaaacaaggaaatca ctccagattctgtatccaaggaaagggaaggggacagttcaggttctcagctgtcttagg ggtcactgagcgtctacctctcctccagaggaggtggtcagaacacatgaggaggggg gcccgggatgcacccccaccagaggctgctcagcgtctcacgggtgcaggacagcgc tcaggcttgggtctaagctctgtgttagttagaacatggggaaggagcatcttaggaactg ctgaagtaacttctactgctctcaaatctaaggaaaggcgggagaacggcctcctaccaacag cgcccacccagagctgctgggaaaggcagtttactgaaagggtgcttactgttcacctg catcttcagcagctccctcctgcccctacctggtcttttccctcttataccaagccttactgt gagtccttcccaggggctgcccaccgacaggtccaggtccctacctgagcttctgtc tcttttcttctccactgcaagcggctgtgtggggtgggatgagccctctctgtcccca	
--	--	--

		ccggccctccttgccaagccattcctgggtgagttcaggccctgcggggagccacacatcatct ccacctggacacttgagccgcatggccagaccctccacctgatgctgggtgctgctgctg ttgtcaaaagaagccttctggatgctgttaagatgtacccttcagggtgaacctggtatcagacc cacagtactgtctgttggagaaaaataaaaaaaggtcactgttctccagcccttttctct tacctggatttcttcttcttctctccccaccccaaataaaaaaacaaaaaactagaaattat ttatatgtattgatgtttaggtctaggtgaaaaaaaagaagtaaatgttctactgtctatttata tataatgtctgaataaattctgtgcaggaaaggccagggaattgcatgtgaagtctgggtgcagtc accacctgtgtgtgacctgagctgcagtcctctcgtcgtgagatgcagggtttaaagtgcagctggg gggctgagggcaggccctcaggccctccagcggcccaacccctccttggctctaatgaaatgca gttcttagtgagagatgtttaaggtgcaatatactcttcttccctgggttttagagccaagct caaggtagtaggacgtagggtcttatttttttcaaaccctcactcagagcgcagatacatg cagaggcttctgcaggataccacggggccttagtgggaacaggtggagaccagcacttcc ctttctgtcgtcgtgaggtagggattgggggtcagaaccactcacttttgcctgttaaaagtgc cctcctgacgtcggcagctcgtccttggctactggggatgcggctcgtgtcagccaccagt ggccttgcggtattgtccaccatccactagagtgggatgaagtccagagtgtgggtatatact cagatgccatctaccactggggacttcaatgccagctgcatttgggttgggttcttaactgttg gcttctccccacagcgtttttgttttttaaacattcatattgttttcaaacttggaaatcatagaca ctctggcctcaggttctttaaagggggaaaaaagaagatgactttatttcaactcaagaaaatca gttcagttccaagctgtgtgcttccagccactctagggacacttggggaaacctgtttaaactgt tgacatcagtgcttccagccgtgtgtcaccctcctatcttctggtatctgcttccgcatgtgca gtgacagcttctggaaagctgagcacacacaggtgcacagccatgctgtgtgcttggcctgcta cggcagcatggcagctcgtgtggagccttctcccttgcatttgggttccctgtgccaagtgc tgcaggctgcccctcaaatcttcatgttccctttcacttctgcagaacaagcctgggttagag ggctgtcgtgaaatggccttgaagaccaaggtatccaggatgtgtgctcacttctgtctgttctg tgaatgtgggaaagcttaggtcttcagaaaagcagctccttctgaaatgtgacgggacttaag cagggaagtcacccagggacaggagtgtgctcaggtgtggggatggagcgtgtgcccagccat gctccaccaggggccaccaatgtgtagtgtgctgtgtgtgttccgggcatgtgagacgtgtctt actgtttccaccccactgtgtgtgtgtcctcagggtgtgtgtgtgcacccctcagagcccactt catgttctgaagcctcagagtggaaatctctgctaaggctctgtgtgagcgttcttccctgtga tctaaaggggacactgtactcaagcttttgacctcatgcttctgtgtagtaaaaaaggattgggg gtttgtttgttctgtgagagggtgtgtttgtttgttttcttcttgtttatgttttggccttctctt tcttccatgttagaccagatattgaaagggcagacagatggctagaggtgttaatgtgcagctgt ttatacgggtattttgggaaacttaccttggatgggaaatcgaatcgttgattaccaggccggtg ctggcacactcaccctgccttccctcgggttcagttacattgttctcttcaaatatgtgtat tgtactagctcttctcatatgaagaattctctcttatttaataaaaaaagtftaaaaa	
DOPEY 2	NM_005128.3	tccacagtgcttggccagaagccttgcataaatatttgaacaggattgcccaatacttttctgct gtgagaatgtgaagtatgattccagaagagcaggagctcttaaatgattacagatacagaagcta ctcttcagttgattgaaaaggctttgagaaaattttagtctcagtgtaaatgggcggatctcatatc ttcacttggcaaaactcaacaaggctctcagagtaacctgaggtaactcttgttgcagaagcgg ctcctcatcagcaaaaagattagctcagttgttgcacccctgcctgtcccagtggtgtccacttaa agctcttggaaaactacgagattatctttaaactcgtggggaccaaaatggctggccaaggactt gtttctgtacagctgcgggttatttctctcctggcacacgcggcggtgtcgggtgaggccgggtg ctgctcaccctgtacgagaagtacttctcccactgcagaagctgtcctctgccagctgtcag gccttcatcgtgggcctgtcgcgggccttgaagagggtcctcagatctccgacagaaacgg atgctctgtctcgtgagactgtcgtggtgtgttggcaagaggtgttttacaccgcccttgggg gagcgtctcggccagccgttcacccgctcctcgtcctcagctcttctgtgtgggcacatcaa cagggtatcccccgccggcgaggacagaagtacatgctggggaccaatcaccactcaggt gaagtctttgcgttccctcctgttggactcaaatgttctgtgcaaaagaataatctggaaatcgt tctgttttttccatttatacctgtctgattccaatgagagagccatccccctcctcagatctg acatcgtgcacacttctcagccgcacccagaccctactgagaaggacatgttccctgaac	43

	agaagactgtatgcatggttactaggtcagacataaaaggaaataccgttgtgccagaatct gaaatctcaaaattctatgaagaccagtcgtcttatttttggaaaaatactccaagatcttttagt gagggtttggtgagatattgcatcagaagttcatagatgtgacgtggaggaaacgccatcat gcataacctgaagccttttcgcgtctcatcagtcgttgacaagccagaaataggcctcaag tggttgggaatttctcgaagtcacagggcctttatttactcagagatgccccgtgctc tgatcttaaaacttagctacaccagagtggaattcgtgataagtgcaatcaaggaaaacaga aatgcctctgagattgtcaaacggtaatttctgataacttcttaagcacagactttcttgg gattatagacaagggtgtttgaggatgcttttagaccagtgaaagcagcggttacagcgtgagga acagcgtcagccccccccacggctcggagctcgcgcctctggtcttctgctgagatg tcattctttggaacttactctgaggtgcaaacccagtatctccctcaggtgctcggctgctg gtgcagcctcttctgaggtgacatggaggccttaagttaactgaactcacgcatgcttgaaga cgtgttcaagggtcagcaaatgcccagatgctccttctacctcgcacagggagtcaccaca gcggaaacctcaggtccagtaaaagggtgaaaacggcaaaataatttggaaacaaaggcagtg attcccggtgacgaagatgcttctgttccccctctgaagtctgaggacagtggtatcggtcctc agtgctctgcacggagctctctgagcacttgagggttctcctgagtttctggaaggac gacgtttggaagaaggcgggagcatgcagaggacgtttcttgcacccaagagctaatacgc caactttgccagcaagaacatttttgagtacagctgacagcgtcaggagaagaaagcaagt ccgaggagcctgcagggagaggacagggatgggacgcagagcctgagcagcaatgat tcagcaggaagaactcttgggagcccaagccatcactgtgctcagttcaagcagatgct gtcagactgttccagcacgagggtctcattcaagacaaaagttcagagtcaccatcgct tcgcccagcagccctgccagaaaaacggggagaaatggatgttgagaagggtgctattg acctgggggttcagggaggaacgcagggaggcctttgccgcgcctgccacctgtgct ggattgtgccactttccctgtctactgtccgaggaagagaccgagcagctctgtgcaacgt cttccagctgccaggagccggtgattccagtttccatcttggctgaagtccctcatgactattg ctgctgtgtgactgactgtactcctccagaacgtggccatttccactctgtggaagtataaac cattccagctccctggcgtgtgtcattgaagacaagatgaacgcctataagagctctggacac aaccttttttggcaagctgcagatggtgacgttctcctcattgtctcaggatattggaagt cattgcagagaaaacagatttctatcagagggtgctcgtgtgcttggaaatcagctgaacaaa gagaccggggagcatcacgtcacctgcgtagaattgttctaccggctgcactgctggcccct acggccaacatctgcgaggacatcatctgcatgcccctcctggaccctgacaagggaacaa ggctggaagctctgttagatttccgtgatctggcatctgacaagagagatccaaggcagtcg agtaacatctcacaatcgtctctttagataggtccttgttctgctgctgacagcctggcctgca cggatgtgtgcatcgtgctgagccaggggtgctgctgctgctgctcctcctcgggga cgtggctcgcacatcctgaacccgtgctcctgctgctgctgagccaaaacccagagaacct ccatccactgctcaagcaggagaactcggccgatgactgcaccgttgggttaacagggaag aaaacctctttcagagaggcatgcgcagtgcccgagcctcaggagagcggctctgaagagc acctgctctgagccagttcaccacagtgaccgtgaagccatttgggcccgaagtggagaag gagcccagagaagtaccgctgcgaggcagctgagcgaaggagagctgcctactacgtg gagcttccagacaggacggccacggcggcccgacagcagcagcagcacaccgagctgc agatacaagctcctgccacacggacagcgagaacacgtctcttctctcctcctccacga cctgcaggagctgagcaacgaagagaactgctgtgcacccatcccatggggggcagggc gtaccccaagcgtcggccctgctggcggccttccagtcagaaagcttcaaggctggggcc aagttaagcctgtgctgggtgactcggacaagacgcaggcttctgagtgcttctcagcga cgaggaggcggacttgagctcaggccctcaccacatcaggctgctaaagcagcagcg ggaaaggcaggaggcctgagggccttgttaagcacatcctgctctacctgcagccctacg actctcggcgggtcctctatgcttctcgtgctgagggctgtgctcaaaccaacctaaagg aattcatcgaggctgtgtcaggactagcatggataccagctccaccgcgcacctcaacctca tctcaacctctcgtcgcacacaggaggccctcattggccagagtttctacggaagctcc agaccaggttccccacgtgtgccccactctgctcctggagctgctcactacctctgctcct gagcttctgctcctactaccctgtatttgaaggctcgcaccgagacattctcggcaacc	
--	--	--

	gggacgtgcaggtcaaaagtgtcagggtttgatcaggataatgatgcagctggctcagttgg ccaagtcttcggaaaggaaagaaacgtggagttcatccacagcttgcagaggtgcaaagt caggagttgtcctgtctccctgtcggcgtccatgtacacagccagaagcgtacgggctg gccaccgcccaccacggcagggccctgcccagaggacagcctcttgaggagagttcatta acttgggtcaggaccagatctggagtgagcaccgctgcagattgagctgctgaagctgctg cagggtgctgattgtcttggaaacaccacctgggtcgggccatgaggaggcggaaaaccagc ccgacctgtcccgggagtggcagagagccctgaactccagcagggccatcagcgccctgca gtacgtgcagccccaccctcaccctccagggtcttctggtctctgctgctgaggggtct gcagcccgcctacgttacggcatgcatccggcctgggtgagcttggtcagcattcctgccc ctacttcggaaagtccctgggtgacgtgacacccttgggttcagattgcaaaaactg gatgacttggtaagcagtatgaaagcgaatctgtgaagctctgtcagcacacctcgaag agggaaaacatttctccagattatccactaccctctagaagggtctaacgaccttgaatttt gtcttttggaaacaagccaaacaaaacaaaagaccatggctgcaggtgctcctgccaacttga ggaatggcagaaatgccatttggaaagagctgcctcgaactgttaacaccatgccccttctg gaatgttctcagaaaggagagactcaaaagagacctgtcgtatctctagggccacgaag ggatctcttccgttactttaaaccacaaaaccataagacaaaaaatttagacttcttaaac cccttgacggcccactctgggttcagttgacagcggctgttgcggcagttgtgagcagaaa gaaagcccagcgtcacagtaagatgaagattatcccaacggcaagtgcatccagctaacc ttgtcagacttgggtgtgctcactcagcaccctgcagactgacacgctgctgcacctggtaagg agggtgtgaagaggccaccccaagtcaagggggtgatgagaaatcgcccctagtgacat tctgtgttgagtttctatgtcttttccaaaggctccagctaccagccttgcaagagaactt tctcactgttgggagttatgaagagctgtacagttgaatctagccccacctgggtatttctg cttctcagcatgctgaatgacttgaacaagaactcccaacctggaaaacaagaaggaccaa aaagacctgcaggaaatcactcagaaaatcctagaagctgtggggaacattgcccgtcttcc ttggagcaaacacagctggcctaagcagaacactggaagtgaaggcccaacctcagccctct agaagaatctgctgctgaggagcctgtatgtgctgctgcagcttcagcaatggtgtcttca tccgcccgctgggtgtacagcgtgcaagccctctctctcctggcagaggtactgcttccctc ctggacatgggttatcgaagtgtgagaaaggagaaagctgtgccgttaatctccgctgtctta ctatgttttccatacttacgaaccacagtgcttacaatgctccagcttccgggctggcgctc agctgtgagctccctgagtggtatgctacacaaagcagcctggaggagggagctct ggagctgttctgaccccgttcttctcagatggatacttctgtgttcattggaagtcattattg accatctttgactcatgagaaaacaatgttaaggatttaataacatgcagagcagttcttga aactattctcaagtttgaacagaaagccatgctgttaaagcgccaggctttgtctgttctcagtg gagaacttgataacacaccttacccttccactgatacaagaacgcctgacagacaatctcag agttggacagacatccatagttgctgctcagatgttctttttcagagtttgcgtctaagaatat ctcctcaacattgacttcatgtggccaataatggtctctgaattgattcagacattcacacagct tgaagaagatctaaaagatgaagatgagtcattgagaagcaccacaaagtaaacagaacga aagtttcagtcgggatgcaaatggacctcagtgggggagatacccagagtgaaactcatct tgtatttatcagcttgcgaattcttggacacagcgttcttcttccacctgacaagatgccattatt caaatttataggtgggcatttattccagaagtggacacagaggccctgcccctctgctggatg tagaggagaatcaccaagaatgcaaacccacactgtcaggattctagaacttctaaaattaaa gttggggaaatcagtagctgtgatgagatcacatgaagagtgaaatccgcttctgccc cattctgttccagcatcaggcagttgatgcatcttctcagcttcaaatggtgcatttaagacc agagacagctgctgctgtagccaggaactccattcttggacttctgctcacagatagccc aaggatcttaaaacaactggaagaatgcatcgaatatgatttctggaacatccagaatgttaac catgtgagagagaatfatgttaatccatgtattggacttactgaaaaccagggtatattctaaag aagaagaaggcaggatagtgctttgaacaagcctatttccatttgaagtagattcaggct agggtcgggtgctcacacctgtaatctcagcacttggggaggccaaggcagagcagatcatt gaggtcaggagttgagaccagcctgaccaacatgggtgagacctgtctctactaaaaataca aaaattagctgggtgtggtggcgccctgtaatccagctacttgggaggtgaaggcatga	
--	---	--

		gaattgctgaacccaggagggtggaggctgcagtgagccgagatcacgacactgcactcca gctgtgtgacagaatgagaccatctccaaaaaaagtagatttcagataattactgtt cagcaacaggacacacctccctaatgctgttaatatattgaaatctgattctgcatttctctc aatttatgtaataaaaataaataatataatcatctaacagtagcacaaattgtaatatgaagta aagtatgaagataatgaagaagtgttttcttggtaagcagttatagggctttctcagtatatt ctctttctctaaaagtftaaacttattaaaagaatgtatttttaacctttcaaaaaaaa	
<i>NDUFB 11</i>	NM_019056.6	gctctggccggcccggtgattgtcaccgcccgtaggggacagccctggcctctctga ttggcaagcgtggtccacctccacacccccttgcaacgctccctagtgagaaaaaggga gtagctattagccaattcggcaggggccgcttttagaagcttgatttctttgaagatgaaga ctagcgggaagctctgecttttcccagtgggcgagggaactcggggcgattggctgggaa ctgtatccacccaatgtcaccgatttctctatgcaggaaatgagcagacccatcaataaga aatttcacgctggtccgaaaatggttggcccccacgaagccacgacaactggaggcaaga gggtgtctaacgccccgctcattggaaaacaaatcagatctgggacatataatagcgtggc ggaggcggggcgatgattgtcgcgtcgcacccactgcagctgcgcacagtcgcatttcttc ccccccctgagaccctgcagcaccatctgtcatggcggtggctgtgttgggttgagcgtc ggcgtcttttggcgagcggcgacgcgagggctccggccgcccgtccgctgggaat ctagcttctcaggactgtgtgctccccgtccgtgtggcgggaaaggcgccccagaaacc gaccacaccgtggcaagaggaccagaaaccgaggacgaaaactgtatgagaagaacc agactccatggttatgacaaggaccgcgttttggacgtctggaacatgcgactgtcttctt tggcgtctccatcctgctccttggcagcaccttggcctatctgctgactacagggtca cagggtgtcgaagagcgtgggatgggatgaaagagtgtcccgccggaagctgagaggc ttgtgaaataccgagaggccaatggccttccatcatggaatccaactgcttcgacccagca agatccagctgcagaggatgagtgaccagtgtctaagtggtgctcaagaagaccgcctc ccccccctgctcgcattctgaccttctcagagcacctaattaaaggggctgaaagtctg aaaaaaaaaaaaa	44
<i>ND4</i>	NC_012920.1	atgctaaaactaatgtcccaacaattatattactaccactgacatgactttccaaaaacata attgaaatcaacacaaccacccacagcctaattattagcatcatccctactatttttaacaaa tcaacaacaacctatttagctgttcccaaccttttctcgcacccctcaacaacccccctctaa tactaactactctgactcctacccctcacaatcatggcaagccaacgccaactatccagtgaaac actatcacgaaaaaaactctacctctctatactaatctccacaaatctcttaattataacattca cagccacagaactaatcatattttatcttcttgaaaccacattatccccaccttggctatcat caaccgatgaggcaaccagccagaacgcctgaacgcaggcacatacttctattctacaccc tagtaggctcccttcccactcatcgcactaatttacactcacaacacccctaggctcactaaac attctactactactctcactgcccagaactatcaaaactctgagccaacaacttaatatgacta gcttacacaatagctttatagtaagatacctctttacggactccacttatgactccctaaagcc catgtcgaagccccatcgctgggtcaatagtacttgcgcagctactcttaaaactaggcggct atggatataatagcctcacactcattctcaacccctgacaaaacacatagcctaccccttctt gtactatccctatgaggcataattataacaagctccatctgcctacgacaacagacctaaatc gctcattgcatactcttcaatcagccacatagccctcgtagtacagccattctcaccacaccc cctgaagcttcacccggcgagtcattctcataatgcccacgggcttatactctcattactattct gcctagcaaaactcaactacgaacgcactcacagtcgcataataatctctcctcaaggacttca aacttactcccactaatagctttttagtacttctagcaagcctcgtacacctcgccttaccctcc actaataactactgggagaactctctgtgctagttaaccacgttctctgatcaaatatcactctc ctacttacaggactcaacatactagtacagccctatactccctctacataatttaaccacaaca atggggtcactaccaccacattaaacataaaaaccttctacacagagaaaacacct catgttcatacacctatccccattctctctatccctcaaccccgacatcattaccgggtttcc tctt	45
<i>MORF4 L1</i>	NM_00126560 3.1	cggtgctccctggggcgggcgggcgaggggcggtgctgctggggggctgtgtgtggct ggagcagcgggtgcgcgggtgcgggtgctgtgaggtctgcgggcgtggcaaatccggcc	46

		caggatgtagagctggcagtgccctgacggcgctctgacgcggagttgggtgggtagag agtagggggcgtagtcgggggtggtgggagaaggaggaggcgcgcaatcacttataaat ggcgccgaagcaggaccggaagcctaaattccaggagggtgggatgaatgggtccggag agcagagtactcaatacgtggacaccaatttcagaaacagcgagaacttcaaaaagccaa tcaggagcagtatgcagagggaagatgagagggtgctcccaggaaagaagacatctg gtctgcaacagaaaaatgttgagtgaaaacgaaaaagaacaaacagaaaaacacctggaaa tggagatgtgtgacgtacagtgagaccctcagccctcctgggaagaaaaggcccggtgta gatcctactgttgaatgaggaacattcatgaacagagttgaagttaaagttaagattcctg aagagctaaaaccgtggctgtgtgactggacttaattaccaggcaaaaacagctctttat cttctgccaagaagaatgtggattcattcttgaggattatgcaaattacaagaatctctgg aaacacagataataaggagtgatcggttaataagttgtgagggataaaaagaatacttcaa cgtaatgtgggtaccagctactctataaattgagagaccacagatgctgaattcttgag atcatccgafgcacccatgtccaggtgtatggagcgccacatctctgagattattgtacg aattggagcaatgttgcttatacacctctggatgagaagagccttctttactcaattatct cacgatttctaaagtacctggcaagaattctgcaacttcttcagtgccagcgattatgaag ggctcctctgagtagcaccatggaaagctgtgtgagaggcactctcactcacttatgttgatct ccgtaaacacattttgttcttagtctatctgttacaacgatgtgttgaagatgttagtgata acaattgatgtttgttctgttgaatttaaacagagaaaaataaaagggggtatagctccttt ttcttcttcttttttttcaattcaaaattgtgctcagtggttcaatgatggacaacagagggata gctgtagagtggtttattgcctagttgacaagctgctttgaatgctggtgttcttcttgcac actacgcacttttataatcatgttaatgctatatgacaaaatgctctgattcctagtgccaaaggt tcaattcagtgatataaactgaacacactatccattgtgctttgtttttttatgtgtctaaagta aagagcccatccttgcagtgatccatgtgttacttaggcattttatcttggtcctaaattgtgaa gaatgggtggtgttcatggtttgttattgtgtctaatgcacgttttaacatgatagcgaatg cattgtgtagctagtttctggaaaagtcattcttttaggaattgttttcagatctcaataaattttt ctttaaatttcaaaagacaaaaaaacaaaaaa	
MRPL1 9	NM_014763.3	gtagcttgacgtgagctagctggcatggcgccctgcattgcagcggggcactgggctgcaa tgggcttagggcgaggttccaagccgacaggactctgctcccccccgccctctatcgcc tgcagggtccacgcggggcctgtccggcagcagagcactgggcttccgagcccggtgctg ttccaaccgcccgcgaacccggtcatctgtggaacagcaccgccccggtggaaccggaacgc agggtcttgagctcgaattcattcctcgaagggaagaaacagatcctctgaatttcaaataga aagaaaagatatgtagaagagagaaagtactccacattccagagttctatgttgaagtatt cttctgttactacagctgacctatagccagtggaataacagccagttctggggatttgcac tcagagatcaggaagaggacttggagctactttcactccttaggaatgttatcgaaggacaaggt gtcagagatttgccttgaactttataatcctcgggtccaggagattcaggtggtcaaatagagaa acggctggatgtagcttctatactacgagatgcccttctgaatfatagcactttttagtga tatgaagccagtagtacaagagcctaaccaaaaagtctctgttaatgagctgaagtaaaatg aagcctaagccctggtctaacgcgtgggaacgtccaaatttaataaaggaatcagatttga tctttgttaactgaacagcaaatgaaagaagctcagaagtggaaatcagccatgctgaatttga atatgatgagggaatatgatacttcaaaattgaagctgcaatatggaaggaaattgaagcgtc gaaaaggcttgattctgagaatgaatttgggtagttgcagaagatacatgtgctcctaaggat atatgtttagaccatftaatttcaattataagaacatagtaattaagtgaactaagcattcattgttt attaatacttttttcaaaataaaactgtacaccagtttattactctaaaaagagaattacacatgc caaatggaccaatgtccatttgcctatttgaggcgaagctacaatagaagtcagagcatcaca gaatggtctttaatgagcatggaacctgagcaagggaataggtgggatgaatttttttaatt gtgaaacaattcataagcacaatatgattacagaataataaacattcatgtaccactatcaggt taagaaatagaacatttataatgtaggaatgttaagaataaaacatttaataagatctcaga agactccagtaaatctgcaattgtatctctcctttttaaattgaatatcatcttgactgttaatta ttcccttgactttttagttactgccaacacatatatttcaacaatatatttaatttgaacaccc tgaaaaaaaacctgttagcaagtataaaggggcagttactattattgcatgaaggcttcaa	47

		gggaaacgttacagctcttgggtcatagctggtctcagctcctctgagagtttacagaggcca atfttgagcaaatcatggctaaggttatgagtgagttctgctaacagaaggtcaccacaag gtatctggcaggattatactgggtagctggatgtgcagaaatgtggttagaggaaagtaactg tttttgatgctcacagcatgatgaatcaactctgtatcttaggattagggttaaacaatacctttg gtatgatatgagtggttggctgacatgcagcatggattggaagctgggtataagcacac atgctaagaaaaacatgtaatttgggtccatactacctggatatactgttctcagggttaaaaa tacagtactatccataatcttgaaggcaactctcagcctatccattgagttacctcagatctgcc ctctggtccctagctgtcttgggactaactcttctcgtcgctcagctgttctggtacatgtttt ccattttatgagtactaactgttttctgcagcacatccttggtagcttctagaggaaagtttgg tggaggtaaaattttgagacctgtcatgtctcatgtttgattgatactttatacgtttaggtaggag gtaatttctcctcaggactttaaaaatattgttctccatttcttcttattgttattgagaatc caatgccattttgatttccccatcataaattcatgatgatgtgtcttgggtgggtctataattatcc atftgattgggttttaggtgaaccttccagatagtaactaattctgtcagttctgggaaacactt agcattgtgtgatgtatttctctgtctgttcttctcccaactattattggatgttggatccag cactgggtatctatttcttaccctccctccttgcacccagctctgttttttagctcttagctcaatc ttccaactcttctattgtattttaaaatcttaagaccttcttctgattgtagaagttcctttctac aaccaaaaagcctttatctatggattgttcacagataagggttatcaatatagtatttttttctc atttaaaattgttgcgcatctatttctcctcaaatcttctgtatttttttcttctatatttcagac tttccaggatctgataaacttggctgtcttctatgtgtgaaagagggtactaaaaagcttggga aagcctttgggttgggaagggtgtctttaggattatctgaatgggtcttttttgggagtcctcc tctccacatgaatattttgttctcagattccctagaatagaggcttccaatctcttctgga ggggtctgtccagggaaggagattgtctagggtgtctgcagacagcagcttctcagctacttctt gatcttttcaatattatatagtcatctactctgtcaacaagtaatagatactatctatcttca cttgttttagattttgtgagataacctctcaaaagaacctctcaaaataaaagggttaacaagag cctatacttataatttcttcttcttctgttgaagatagctatttaaacctgttcttcttctgtctg ataaacacacttcaatcttggtagaatgttagatgggacagatatttttaggacctaaagctctg caaatgtatgatcagctgttaagtacagggtctcaaaaacatgtaaacatcatgcttttactct gtaggaaatctttaaattcttgtgaattttccccaagaagtaaaagcaaatcttccccaagaata aaattaaatgtgcataatcaaaagcttttttttttattgtggtaggatataataaaacataattg ccattgtaaacattttaatttacaagtcagaggcatttaattacatcacaatgttgtgaattattac tactatttcaaaattttctatccccaaactgaaactctgtaactgttgagcaataacctcattc ctgtatctctcccaacccaggtaacctcaaatcttcttttcttctttagacaaaggtctcattctat cactcaggtaggagtgagtggtgtgatcatagctcattgcagcctcaaatctgggtctcaa gcaatctctctgagtagctaaactataggcacacattaaactgcgcctgggtgattttttttt tagagatgtggtctgtatgttcccatgctgtctttaggttcttggcctcaagcagctccttaag attcatccatgttggcatgtgtcagaattcattgtttttatgactaaataatattccattgtatgt atatacattttgtcatccatctctgtatgaacactgggatatgtctaccttttggctattgtgaataa tgctgcagtaaacattgacataacaagtatgtattgtattgctgttcttaagttcttttgggtatac atcttgagtagaattgctagataatgtcatgttttatttctctgtgatttcttctcagatccccgtgtg agtgtgttaatttctacatgtttatgaatttccactgtttttttgttattgatttccaagttcattcatt gtgattagagaagatacttagtatgattttaaatttttgagaattgtgtgtgtgcctgatagatgg tctgtctggagaatgttctcatacacttgagcaaaatattatcatgctattgttactgtatgtt ctatatgtctttaggtcaaggtgtttacaatgtgttaaggttctcttttttaaaaaatttttgcac agagtatcttttctatgtgtccatgtattgtgtctttggagctatagctctctttagacagcatatc actatctgtttttgttttttctgtccattctgccaattctgaccttttgattggaaaatttaaccat ttgcatttaagtaattaaaggaggacttcttctaccatttaacacttctctatatgtcatatactttt ttggccccctatttctcttattgaccttcttctgttttttttagtgaaactagctgattcttctcca ctcccccttgtgtatattgttagatgtttattgtgtgtgtctatgggattatagttacacactaca cttaaaaacatctaatftaaactgataccaatttacctcaatagcatacaaaatctactcctgta aagctctgccccctgccccctattgtattgatggcacaaattgcctaataaataattatagttatt	
--	--	--	--

		tgtatgagttgtcttttaaatcatttaggaaaataaaagtgaggtagtagaaaacagtatgatagtaa tactgaccttttataatttgcataatataattatcttatttggatccctatttctatfatagattttagtact gtctagtgcctcttcatttcggcccaaggaattccctatgcatttcttcaggggcaagtctaatt gtaataaaacctccagcctttgtttatctgagaatgtcttgatttccctatttttagtgataatt ttgccagatacatgaatttttggtaacagatattttcttcagcactttaaatgtcatccactacc ttctgacttcatggtttctcatgagatattagatgttataaaatttgaggatttccatttctgatgag tcagtttctgtcttattgtcttctgggatttgcagccttttgccttttgacagtttgattataacgcggct cagttgtgggtctctgagttatccacttagagtttggtagtttcttggagtcacagattatgtctt ttatcaaatttggacatafttggctatttatttctcaatttttctactgcttcttcttctcttgaat attctaatgtatatgttggctgttggatgctgtctcaccagtttcttaggctgtgttctcttggctct cagacttgattattgcagttgccctcttttatttttcaagttgttgattcttccctgttcagatc aactgttgaactcctctagtgaaatttattcagttactgtactttcagctccaagatttatcttgggt cctttttataacgctctgtgtcttattgatafttctatfttggctcatatgtcttcttcttctttagtcttgt ccatgttttctttagctcttgggcttatttaagacaattgtttaagcttctgcatagtaagtccaat gtctgttcttctcagggatgttcttatttgttttcaatgagccatacttctctgtcttcttgtat gctgtcttttgttgtgaaaactgtatgttgaacatcataacgtggtggccctgaaatcagata ttccccctctctgagagttagtttttatttatttgaagattgtagcagctattgtctacatgtgca gtcatttccaaactattttgcaaagactgtatttcttctgtgtgcatcactgaagctctgttctt agtttgtgtttaaafgttgacatagatttcttgaaggaggttaaaactagcagaaaaatctctct cccagcttctcagcttctttagattgttctgtgtctggcttctcattatacttagccaggtctg tactgagccctaacaatcaggcccaaaagcgtagggcttcttgcagatcttctgtgagcatgcttct tgtctgtatgcacgtagtttttaaatctcctgtatgtgtgtgaatattctaatttccaaaga aactccttctcagcttcttctcacagaacafatagattgttttggatatcttgaccatagcttctgcac ccaggtgttctgtgtgtgttagttcacttttcaagcattgcccactgcttacgatgagtg ctgttcaatcctttaaagtagcccaagacaggctaccagagacttaaaacagaattgttaaggttc tgtcagcttctctagaanaatgggatcagggtccaagacagaatgcagttgtctgatttcaaga ctgtgtcaacaccaggagcttgtgggggaagggaagcagagaatgtcacaaagcttctctg ccattttaaagttgctgttcttgaactcagcatttgccttcaattgctataaaacttttactgttttcagag ttctgataaaattggctatgcctgttctgtctttaaanaatatataatatttttagggatttgggtc tactatactgaccaggctgtgtcttgaacttctggcctcaagccatctctcatttcagcttccca aagtgtgtcaattacacgcgtgaaccaccacaccagccctgttcttcaatgtgcctact ccaccatgttgcacagatgtatatttctaactacctttagtgtgtgtgatgggaataaatcc ctgagcctttgaataactcagagagatcaaaaacttagttatctatttgaaggatttagaaaaa tgatatacttctcatttttcagggatagggctctcattagaaggctcctatgtgccgatgtgtac aagacatttcaatttctcttaattgtttacaacaagcttgttccaaggctgaattgaactcctggcc tcaaacgatctctccagctcagctctcaaaaagttgtgggatgtctggcccaactaatgactactt aactcttgttcttcaatgtttatgcttcttatttctttagactgattgtatgactatgtcttctagaacaat gttgaacagaaatggtagagcagacatccttgccttataatttaccattatataatgatgttaggt atagatttttctcacagatgcctttatcagattgaggaaatttatcttctacttggccgaagggtttt gtagtatgaggggggtctgaatttgcacaacacttttgcgtaataattgagatgattgttctgc agtcacgagatgtggatttctcttatttctgttctgtgagtgattacactggttgactaatgttaa aacaaccttacttccagggaataaacctattatctttttataca	
PSMC4	NM_153001.2	tgcgggtacggacagcgcgatgagcttatgttgaggggcggagccagaccagcccttctgctct atctgccccttcagcaectctcagccgtaactttaaactacacttccagaagcctctcagcc agggacttccgttctctcagcgggaagcgggtgacagatcatccaggccacacagaggccg gcttggtaactatgaggagataggcatcttggaggagaaggctcaggatgagatccagca ctgtccgtgtcccgccccagaccggcctgtccttctgggcccctgagcctgaggacctgga ggacctgtacagccgtacaaggaggaggtgaagcgaatccaaagcatcccgctgtgcatc ggacaatttctggaggctgtggatcagaataacagccatcgtgggtcttaccacaggtctcaac tattatgtgcgcacctctgagcaccatcgcggagctgtcctcaagcccaacccctcagtgccc 	48

		ctccacaagcacagcaatgcactgggtggacgtgctgccccgaagccgacagcagcatca tgatgctcacctcagaccagaagccagatgtgatgtacgaggacatcgaggcatggacatc cagaagcaggagggtgcccggaggccgtggagctcccgctcacgcatttcgagctctacaagc agatcggcacgatcccccgaggcgctcctcatgtatggcccacctggctgtgggaagacc atgttggcaagggcggtggcacatcacacaacagctgcattcatcgggctgtgggctcgga gtttgtacagaagtatctgggtgaggggccccgcatggtccggatgtgttccgcctggccaa ggagaatgcacctgcccatacttcatagacgagatggaatgccatgccaccaagagatcga tgcacagacaggggccgacaggagggttcagaggatcctgtgagctgctgaatcagatg gatggattgatacagaatgtcaatgtcaaggtaataatggtccacaacagagcagacacccgtg gatccggccctgctacggccaggacggctggaccgtaaaatgaatttcacttctgaccgc cgccagaagagattgatttctcactatcactagcaagatgaacctctctgaggaggttgactt ggaagactatgtggccggccagataagattcaggagctgataattaactcactctgcagga gagtggaatgttggtgtccgtgaaaaccgtacattgtcctgccaaggacttcgagaaagc atacaagactgtcatcaagaaggacgagcaggagcatgagtttacaagtgaaccttcccttc ctccaccacaccactcaggggctggggcttctctgcacccccagcacctctgtcccaaaa cctcattcccttttttaccaggattgggttcttcaataaataagataagatcgaatccatttaatt tctcttagaagtttaactccttggagaatgtgggcttgaaataggatcctctgggtccctttaa tctgacagatgagcagacgagggtcatggcctgggttcagcttgagagaacaaaatattc aaaccagatgacttcaaaatgtggggaaaggatgaaaatgaacctgagatggagtcctt aatcacgggataaagccctgtgcatctccctcatttctacaggtaaaagacagtaaaagaaatt cagggtcacaggcccttgggagttcataggaaaggagatgtccagtgtgtccagtagaacttt	
SF3A1	NM_005877.5	gggtccgggaagtgcgccagtcgtactctcgcgccgcaactcgtcggccggcccatcttg cgagctcgtcgtactgaccgagcggggaggctgtcttgaggcggcaccgctcaccgacacc gaggcggactggcagccctgagcgtcgcagtcacgcccggccgaccgctgagcgggtg cccccgccggcccggtgcccacggagcccaaacagcccacagaagaagaagcatctca aaggaggattctgcacttctaagccagttgtggggattattaccctccagaggctcagaa atattgtgacaagactgccagcttctgtggccagaacgggctgaatttgaagctaggatccg acagaacgagatcaacaaceccaagtccaacttctgaaccccaatgaccttaccatgacctac taccgccacaaggtcagcaggttcaagggaagggaaggtcaggagccgtccgcccatc cccaaggtcatgacagcagcagcagaccaccagcagcagctgcccagaaggtccaa gccaagtaataccaagagaccatctgcccgaaggcctcctcctgagtttgatttctg atcctccctctatctcagccttcgacttgatgtgtgaagctgacggctcagttgtggccagg aatggcgccagtttctgaccagctgatgcagaagagcagcgcactaccagtttgacttt ctcgcgccacagcacagccttcaactacttcacgaagctagtggaaacagtacaccaagatc ttgattccaccaaaaggtttatttcaagctcaagaagaggctgaaaacccccgagaagttt ggatcaggtgtgttaccaggtgggaatgggccaattccaggaaacgtgagagggaagga gaagaggagaaggagaaggagcgggtggcctatgctcagatcgaatggcatgttttgtgt gggtgaaacagtggaacttcaacccaatgagcaagggaacttccctccccaccacgcc gaggagctgggggcccgaatcctcattcaggagcgctatgaaaagtttggggagagtgagg aagttgagatggaggctcagctctgatgaggagatgacaacaggagaaggcgaggagc ctccttccagctggaccaggacaccaagttacaagatatggatgagggttcagatgatgaa gaagaaggcgagaaggtgccccacccccagagacacccatgcttccaccttgccecca actccagaccaagtcattgtccgcaaggattatgatccaaagcctccaagcccttgcctcca gcccctgctccagatgagtatctgtgtccccattactggggagaagatccccgccagcaaa atgcaggaaacacatgcgcattggacttcttgaccctcgtggctggagcagcgggacgctc catccgtgagaagcagagcgtatgatgggtgtacgccaccaggtctgatatattgagacagct tgaagcagttggctgagcggcgctactgacatcttcggtgtagaggaaacagccattgtgaag aagatcgggtgaggaggagatccagaagccagaggaaaaggtgacctgggatggccactca ggcagcatggccgggaccagcagcgtcccaggccaacatcacctccaggagcagatt gaggccattcacaaggccaaaggcctgtgagcagaggatgacactaaagagaagattggcc	49

		ccagcaagcccaatgaaafccctcaacagccaccgccaccatcttcagccaccaacatcccc agctcggctccaccatcacttcagtgccccgaccaccacacaatgccactccagttcgtact acagttgtctcgcagtagccctcatgccccggcccccaatggcatctgttggtccggctgccc ccaggctcagtagtgcctccatgcccgcctatccacgcgcccagaatcaacgttggtgccc catgctcctcggccccctctattatgccccccgcccacccccatgattgtgccaacagc ctttgtcctgctccactgtggcacctgtccagctccagccccaatgcccctgtgcatccc ccactcccagtggaagatgagccacctccaaaaactgaagacagaggacagccctcatgc cagaggaggagttcctgcgcagaaacaagggtccagtgctcatcaaatgccagtgcccaa catgcaggataagacgggaatgaaaactgaatgggcaggtgctgtcttccctccactca cggaccaggtctctgtcattaaggtagaattcatgaagccacaggtcatgctgcagggaaa cagaagctacagtagagggtatctcatcaaatccaaactcactggctactacaacatgg ccaatggcgcagtcacacactggccctcaaggagagaggcgaggaggaagtagacaa gaggaaacctgctgcaagtccctgccaatttgcctctctgctccaccctgccccagacc caggagccccctgaggctttgctgctgcatattgttgcctcttactcagtttggaattca aatgtcctgcagagggttccctgacctttcccatatggtaagagtagctgggtttct aagccactctcggaaatctcttggtagggctcgtgattgaggacattcattctcagcagccc attagcaactgagagcccagggtatgctacaggatagttcatagtgacaggtggcacttgg ctaataagaatatggctgatattgtcaaatcatttgccttgacatgggtgtctataaaactc ggaccttcttggaaatcagttaataagacttgcctgcctgacctgtgcccctgcccagactg aggcagtggttaacactgcacagtgctatgtggcttcttggaggattttgggtttgtaactaa ttctgtcgtccctcactattttagtagaatcatattcgtattgccctttaaacattgggatcc tccaaaggcctgcccctgatttaacagtaatacagggaagcatggcaggcaccatgcaaac caaggatggatggtgcagtcctgtgcagtgggcggtgttctcgtgcccctggaatcact catcactgattgattggctcgtggtcctgggcaggtgcccctcataggtgtgtggatagtagac gtttcttaaaatgtatgtatttaacaataacttaattgtattaaaggtagtagaaggatttgataa agtttaataaatttactctctacttttatccatttaccatttaactatgtaactcctcatgtgagtatt cctgttaacactgtagtaactgaggcacagagaacataagttgcatgcatagtcacacact gtgaaagtgaagagaatgtgtgcaaacacgtcacagtcctggttctgagtaaggcag gctgttatcttagaatcaagctatcacaggagataggcaatgctgtgggtgtggaggag gtgagagcctgtgtaacaatttctggttttaagctaaggctgattttatgggaagatctca catgtgtgtgcccctgagagttcccagtgctttatttgcagtccttcatttggacctctagc tgccccatcaggtcatctccagggtcagagggtgagaccatttccaaggtcacagaacc agctctctagtcaccacccctgctctccctcaccagagtcagtagcagtttatggctttatta caaatgctgggtcccctccattttcaacttgattgatgggatgtatcccttactgtctgacat ttgctctggtgctgtgctagaagtgtgcccaggggcgaagagtgaatttggcttctgag gtgggtttgtgtgtgctcctaaagtgcagccactactggtgtgtgctcatggtccaaacc agaaatccccctgagcactacctgggtctcattccaagaagggaagggtcaggagacctgg ggagtctcatattccaagtcttcttcttctgggagcagtggtgagttcatggtgttagggcac tcaccccccacagactggcaaacctgcaggacttccgtggctgaggtgtgacctggaggcc aggaaatgcctgtgggtggtgattgtgagtgaaatgggccccttggagctgcccctagagagcaaat ccagtttctggtgagctcctgaatgaatctgtactggctcgtcagatgcagaagctccattga ccatgaggcctgtgaacatcagtggtccacaggcccagtggtgctgtgtgacctgcactagtt aggacctgcagcatgtaggtagctcctagtggttataatacaagctgctctgcacagcttttc tgattcttctgcaatctcctgaggattatctgcccatttttaaacgaggtgggaatacccaagg tcatgtagccagtgagtgctctggaaagccaaagcagctcatcccttctggggaccacactg ctctgctcaccagaccacactatgaatagggaataagtgctcctgttgaggactgctggga aaacagggtgtgtgggacttaagtcaccataatttgaagacttgcagcagagggtcctcagg aattgtagacattgaaggaattcactttcagtttaccactactaagactgtcatgtactctta gaggaggccagtaatgatcagaaccattttacttttaataataatattgtattagagaatatatt aatgggtatattgggttataggatatatacttgaaatgaatacatgtactattagcaatcata	
--	--	---	--

		tttcattatccctgtaattagacaagaaagcataatagctctactcatgggtacacataccagtg gtataagatttttagaagtttactttttaaaaataaaagcaaaatgtaagatcttaaaaaaaaaa aaaaaa	
PUMI	NM_00102065 8.1	agtggccgccaatgtgtcggagtgaaaggtaaggaggagcgagagcgccagagagaga agatcggggggctgaaatccatctcatctaccgctccgctgttggtggaatgagcgtt gcatgtgtctgaagagaaaagcagtgcttggcaggactcttcagccccacctgaaacatc acctcaagaaccagctaataccaacatgctgtgttttgacatctggaacagggtcgaagc gcagccacaaccagctgcaaatcagggtcttgcagctgggactcactcagccctgtccag gatctataggagttgcaggccgttccaggacgacgctatgggtgactacttcttcaggaggc agcatgtgtgagcagcttggggaggagggaagtggaggaggcggtataataatgcaaac atcgtatggcctactggggataacatcatgcagaacatcagggtggttccatggatgaactga atcatgatttcaagcacttgcctggagggaagagcgtatgggagagcagctcttgcaggta aaaagtttgggaaacagatgaatccagcaaatgagcaaaagggaatatctcgtgggtgatc aatggcgagacagtgccctggggaacatcagatcattcagtttccagccaatcattggtcaga gaagacctggtcagagtttccatgtgaacagtgaagtcattctgtactgtccccagatcggg gagtgggggactaggcggttagcatggtgagtgatgtgtgagctcatccccggcgatctctg tctaagaaaaggaggatttggcccaaggatgcagacagtgaatgaacgacaaaaggtgaa aagaagaacaagggtacgtttgatggagataagctaggagattgaaggaggagggtgatgt gatggacaagaccaatgtttaccagtgcagaatgggattgatgcagacgtcaaaagttag ccgtaccctgttaattccagaaactctgtaataagtgatcttctgggtccaaaccagaat gggtctgagggttagccagctgaccagcacaatgggtccaagcctgtggaggatttctcc aacatggagtcaccagagtgtcccttggaccccatggaacatgtggcagtgagcctctca gtttgattatcaggcagcaggtacctgtggactcagcagcagaactgtggacttttgcact acaatttcaacaacagctgttccaaagacctaagtcgttgcgttccagcagttgacagctgc tcagcagcagcagtgatgcactggcagctgctcatcagccgcacatcggtttagctcccgtgc gtttgtcccaatccatacatcagcgtgctccccaggagcggacccctacacagctgg attggctgcagcagcgacactaggccagctgtgtgtccctcaccagtattatggagtactcc ctggggaggtctaccctgcccagctgttccagcagaagctgcccgtgcccgtgcagcaactaa ttcagctaatacaacagaccacccacaggtcagcaaggacagcagcagcttctccgtgga ggagccagccaagctccttggacccaaaccagaaccagcaggagcagcaaacggatccc ctgtggcagctgcagcagtgaaatctgccttgcatttggacaaggctgtgagcagcagcatg ccagggtatccgtgtgtgctcctgctgttactatgacaaactgggtcccctgtagtgaatgc aggcgcgagaaatgtgttggagctcctgttgcactgttagctcctgcccagtcattagtt cctcagctgcacaagcagctgttgcagcagccgcagcttcagcaaatggagcagctgtgtgt ctgtgtggaacaacaatggaccatttgcctttaggaacacagcagcctcagccccagccc cagcagcagcccaataacaacctggcatccagttcttctacggcaacaactctctgaacagc aatcacaagagcagctccccttctccagggctctgcccagcctgccaacacatccttgggat tcggaagtagcagttctctcgccgcccacccctgggacccgccccttggagggttggaaacgca gttgcacaactccaactggcagtgctcccgccgtgactccctgactggcagcagtgacctt tataagaggacatcgagcagcttgaccccatggacacagttttataacggccttagcttttc ctcctctctggacccgtgggcatgctctcctagtcaggggaccaggacattcacagacacc acctcttccctctcttccatggatccttcaagcttaaacctgggaggactcacgaatggca gtggaagatacatctctgctcctcagcgctgaagccaagtaccgagtgcaagcagcgc ctccagccttccagcccagcagcactctttcttctctctgttgcgatatggaatgtctgat gtcatgccttctggcaggagcaggttttgaagatttgaacaaccgggtaccccaatttac aactgcgggagattgtggacataataatggaatttccaagaccagcagtggtccagattcat tcagctgaaactggagcgtgccacaccagctgagcggccagcttcttcaatgaatcctcca ggctgcctaccaactcatggtggtgtgttggtaattacgtcattcagaagtcttgaatttggc agtcttgaacagaagctggttggcagaacgattcagaggccacgtcctgtcattggcacta cagatgtatggctgccgtgttaccagaagctcttgaatttattccttcagaccagcagtaatt	50

		aatgagatgggtcgggaactagatggccatgtcttgaagtgtgtgaaagatcagaatggcaat cacgtggttcagaaatgcattgaatgtgtacagccccagtccttgaatttatcatcgatgcgttt aaggacaggtatttgcctatccacacatcctatggctgcccagtgattcagagaatcctgg agcactgtctccctgaccagacactccctatttagaggagcttcaccagcacagagcagc ttgtacaggatcaatatggaaattatgtaaccaatgtactggagcacggctgctctgaggat aaaagcaaaattgtagcagaaatccgaggcaatgtactgtattgagtcagcacaatttgc gcaatgtgtggagaagtgtgttactcacgcctcacgtacggagcgcgtgtgtctatcgatg aggtgtgcacatgaacgacgggtcccccagtgccctatacaccatgatgaaggaccagtat gccaaactacgtgtgccaagaatgattgacgtggcgaggccaggccagcggaagatogtca tgcataagatccggccccacatcgcaactcttcgtaagtacacctatggcaagcacattctggc caagctggagaagtactacatgaagaacgggtgtgacttagggcccatctgtggccccctaa tggtatcatctgaggcagtgacccgctgttccctcattccgctgacctcactggcccactg gcaaatccaaccagcaaccagaaatgttctagtgtagagtcgtgagacggcgcaagtgtgtgtc caggtaactcctcctccaaaaaaggaaatcaaatccagagtggaagccttgttaaattta attttattacataacatgtactatttttaattgactaattgcccgtgtgttactgggtatagg atactgtacataggtaaccaatgtacatggaggccacataatttgcactgtgtatctatatt cacatgtggaaacttccagggtgtgtgttaacaaaaaaaaaagcttaaaaaaaaaaagaaa aaaaggaaaaggttttagctcatttgcctggccgcaagtttgcaaatagctcttcccacct cctcattttagtaaaaaacacaaaaacaaaaaacctgagaagtgtgaattgtagttaaatga ccccaaactggcatttaacactgtttataaaaaatataatataatataatataatgaaaaa ggtttcagagttgctaagcttcagttgtgacattaaattatgaaattcaaaaaatgcctttttg gagactatattatgctgaagaaggctgttctgtaggaggagatgcgagcaccagaacgctct ttgaggctggcggggtgtgtgttactgcctactggatttttctattaacattgaaagtaaa atctgattttagcatgagaaaaaaaaaaccactctgctttggctgtctctataaatatag tgtatacttgggtgtgacttgcataatacaaatgttagtatttctgtttgtatgtctaactgtat ctataatgtaccctagtcgaacatactttgattgtacaattgtacattgtataacctgtaatgt aatgtggagaagtgtgaatcaacataaacacgttttttggtaagaaaagagaattagccagccc tgtcattcagtgatatttcacactttatggctgtgcatataggtgtgtattgtaaattgtaatt caaccagaagtaatttttctttgaaggaaataaattgtctttatacagcctagttaattgtaaa agaaaaaaatagcttggttttttgtcatctagctcaagtatagcgagattcttcaatgtatt caagattgagttctactagttttttaatcctaaaaagtaattgtttgtgtacagtcaaa aggacgtgcaaaagtctagccttgcggagcttccctacaatcagagccctctcaccctgtg aagtgtgaatcgcccttccctttgtacagaagatgaactgtattttgcatttgtctactgtagt gaatgtaacatactgtcaatttcttgtttgaatatagaattgtaacactacagggtgtacattcc agagccctgtgtatattccaatgaactttttgcaagcacactgttaaccatatgtgtataataac aaacctgtgtatgtctatgcctgggcaactattttgttaactctgtgtgattgtcttaacaat gtgtgatctttatttgaataacagaactttggaatctgaaaaaaaaaaaaaaaaaaaaaa aaaaaa	
ACTB	NM_001101.4	gagtgagcggcggggccaatcagcgtgcgcgttcgaaagtgcctttatggctcgag cggccgcgcgcgccctataaaaccagcggcgcgacgcgccaccaccgcgagacc gcgtccgccccgcgagcacagagcctcgcctttgcccagtcgcccgcgtccacaccgcgc gccagctcaccatggatgatgatacgcgcgctcgtcgtcgacaacggctccgcatgtgc aaggccggcttcgggcgacgatccccccggcgccgtcttccctccatcgtggggcgcc ccaggcaccagggcgtgatggggcatgggtcagaaggattcctatgtggcgacgagg cccagagcaagagaggcatcctcaccctgaagtacccatcagacagcgcatcgtcaccaa ctgggacgacatggagaaatctggcaccacacctctacaatgagctcgtgtggctccg aggagcaccctgctgctgaccgaggccccctgaacccaaggccaaccgcgagaag atgaccagatcatgtttgagaccttcaaccccagccatgtacgttctatccaggctgtgct atccctgtacgcctctgcccgtaccactggcatcgtgtatggactcgggtgacggggcacc acactgtgcccatctacgagggtatgccctcccccatgccatcctgctgtgacctggctg	51

		gccccgacctgactgactacctcatgaagatcctaccgagcgcgctacagcttaccacc acggccgagcgaggaaatcgtgctgacattaaggagaagctgtgctacgtcgccctggactt cgagcaagagatggccacggctgcttccagctcctccctggagaagagctacgagctgcct gacggccaggtcatcaccattggcaatgagcggttcgctgcccctgagggcactcttccagcct tccttcctggcatggagctctgtggcatccacgaaactaccttcaactccatcatgaagtgtg acgtggacatccgcaagacctgtacgcaacacagtgctgtctggcggcaccacatgtac cctggcattggcgacaggatgcagaaggagatcactgcccctggcaccagcacaatgaaga tcaagatcattgctcctcctgagcgcaagtactccgtgtggatcgcggtccatcctggcctc gctgtccaccttcagcagatgtggatcagcaagcaggagatgacgagtcggccctcca tcgtccaccgcaaatgctttagggcgactatgactagtgtcggttacacctcttctgacaaaac ctaacttgcgcagaaaaacaagatgagattggcatggctttattgtttttgtttgtttgtttt ttttttttgtgctgactcaggttttaaaactggaaacgggtgaagggtgacagcagtcggttgag cgagcatcccccaagttcacaatgtggcgaggactttgattgcacattgtgttttttaatagt cattccaaatatgagatgcgtgttacaggaaagtccttgcctacctaagcccccacttct ctctaaggagaatggcccagctcttcccaagtcacacaggggagggtatagcattgtcttc gtgtaaatfatgtaatgcaaaatttttaattcttgccttaatactttttttgtttttatgtatg gagccttcgtgccccctctccccctttttgtcccccaactgagatgtatgaagccttttggct ccctgggagtggtggaggcagccagggttacctgtacactgacttgagaccagttgaata aaagtgcacaccttaaaatgaggaaaaaataaataaataaataaataaataaataaataaataa	
<i>GAPD</i>	NM_002046.6	gctctctgctcctcctgttcgacagtcagccgcatcttctttgctgcccagccgagccacatc gctcagacacatgggggaagggtgaaggctcgagtgcaacggatgtgctgattggcgccctg gtcaccagggtgcttttaactctgtgtaagtgatattgttccatcaatgaccccttcattgac ctcaactacatgggttaccatgttcaatatgattccaccatggcaaatccatggcaccgtcaa ggctgagaacgggaagctgtcatcaatggaaatccatcaccatcttccaggagcgagatc cctccaaaatcaagtggggcgatgctggcgctgagtagctgtgagtgccactggcgcttcca ccaccatggagaaggctggggctcatttgcaggggggagccaaaagggtcatcatctctgc cccctctgctgatgccccatgttctgcatgggtgtgaaccatgagaagtatgacaacagccctc aagatcatcagcaatgctcctcgcaccaccaactgcttagcaccctggccaaaggtcatccat gacaactttggtatcgtggaaggactcatgaccacagtcacgtccatcactgcccaccagaa actgtggatggccctccgggaaactgtggcgctgagtgccgcggggctctccagaacatcat cctgctcctactggcgctgccaaggctgtgggcaaggctatccctgagctgaacgggaag ctcactggcatggccttccgtgtcccactgccaacgtgtcagtggtgacctgacctgcccgt ctagaaaaacctgccaatatgatgacatcaagaagggtggtgaagcaggcgctcgaggggcc ccctcaagggtatcctgggtacactgagcaccaggtggtctcctctgacttcaacagcgaca cccactcctccactttgacgtggggctggcattgcccctcaacgaccactttgtcaagctcatt tctgtgatgacaacgaatttggctacagcaacagggtggtggacctcatggccacatggc ctccaaggagtaagaccctggaccaccagccccagcaagagcacaagagggaagagaga gaacctcactgctggggagtcctgccacactcagtcceccaccacactgaatctccctcct cacagtggccatgtagacccttgaagaggggaggggcctagggaagccgacacttgcattgt accatcaataaagtaccctgtgctcaaccagttaaaaaaaaaaaaaaaaaaaaaa	52
<i>GUSB</i>	NM_000181.3	gtcctcaaccaagatggcgcggtatggcttcaggcgcatcagacacggcgcgctacgcga cccgccctacgggcacctcccgcttttcttagcgccgcagacggtggccgagcggggga ccgggaagcatggcccgggggtcggcggttgcctggcgcgctcgggcggtgtgtgtg ggctgcgctgctgggctgcaggcggggatgctgtaccccgagagagcccgtcgcgga gtgcaaggagctggacggcctctggagcttcggcgccgacttctgtacaaccgacggcg ggcttcgaggagcagtggtaccggcgccgctgtgggagtcaggccccaccgtggacatg ccagtccctccagcttcaatgacatcagccaggactggcgctgtcggcattttgtcggctggg tgtgtacgaacgggagtgatcctgcccggagcgatggaccaggacctgcgcacaagag tggtgctgaggattggcagtgcccattcctatgcccctgtgtgggtgaatggggtgacacgc	53

		tagagcatgaggggctacctccctcggagggccgacatcagcaacctcgtggtccaggtggg gccccctgccccccggctccgaatcactatcgccatcaacaacacactcaccaccaccct gccaccaggggaccatccaatacctgactgacacctccaagatcccaagggttactttgtcca gaacacatattttgacttttcaactacgctggactgcagcggctctgtactctgtacacgacacc caccacctacatcgtgacatcacctgaccaccagcgtggagcaagacagtgggctgtgtg aattaccagatctctgtcaagggcagtaacctgttcaagttgggaagtgcgtcttttggatgcaga aaacaaagtcgtggcgaatgggactgggacccaggggccaacttaagggtgccaggtgtcagc ctctgtgtggccgtacctgatgcacgaacggccctgcctatctgtattcatggaggtgcagctga ctgcacagacgtcactggggcctgtgtctgacttctacacactccctgtggggatccgcactgt ggctgtcaccagagccagttcctcatcaatgggaaacctttctatttccacgggtgtcaacaag catgaggatgcggacatccgagggaaggcgcttcgactggccgctgtgtgtgaaggacttca acctgcttcgtcggcttgggtccaacgctttccgtaccagccactaccctatgcagagggaagt gatgcagatgtgtgaccgctatgggattgtgtgcatcgatgagtgtccggcgctgggctgtgc gctgcgcagttcttcaacaacgtttctctgcatcaccacatgcaggtgatggaagaagtgtgtg cgtagggacagaagaccaccccgcggtcgtgatgtgtctgtggccaacgagcctgtgcctcc acctagaatctgtcgtgctactactgaagatgtgtgacgtcacaccaaatccttgacccttc ccggcctgtgacctttgtgagcaactctaactatgcagcagacaagggggctccgtatgtggga tgtgatctgtttgaacagctactactcttggatcacgactacgggcacctgtgattgtatcagct gcagctggccaccagtttgagaactgggtatagaagatcagaagccattattcagagcga gtatggagcagaaaacgattgcagggtttcaccaggatccacctctgatgttactgaagagta ccagaaaagtctgctagagcagtaccatctgggtctgtgatcaaaaacgcagaaaatactgtg ttggagagctcatttgaattttccgatttcactgaacagtcaccgacgagagtgctggg gaataaaaaaggggatcttactcggcagagacaacaaaaagtgcagcgcttcttttgcgag agagatactgggaagattgccaatgaaaccagggtatccccactcagtagccaagtccaatgttt ggaaaacagccctgttacttgagcaagactgataccacctgcgtgtcccttccctcccgagtca gggcgacttccacagcagcagaacaagtgcctcctggactgttcacggcagaccagaacgtt tctggcctgggttttgtgtcatctattctagcagggaaactaaagggtggaataaaagatttct tattatggaaataaagagttggcatgaaagtggctactgaaaaaaaaaaaaaaaaaaaaa a	
RPLP0	NM_001002.3	gtctgacgggcgatggcgcagccaatagacaggagcgtatccgcggtttctgattggctac tttgttcgattataaaaaggcacgcgcggggcgcgaggcccttctctgccaggcgctcctgtg gaagtgcacatcgtctttaaacctgcgtggcaatccctgacgcaccgcctgtgatgccaggg aagacaggcgcgacctgggaagtccaactacttccctaagatcatccaactattggatgattacc gaaatgtttcattgtgggagcagacaatgtgggctcgaagcagatgcagcagatcccgatgtc ccttcgcgggaaggcgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt gggcacctggaaaacaaccagctctggagaaaactgctgccctatattccggggggaatgtgg gctttgtgttaccacaggagacctcactgagatcagggacatgtgtgtgtgtgtgtgtgtgtgtgt cagctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt gtctcggggcccgagaagacctccttttccaggcttttaggtatcaccactaaaatctccagggg caccattgaaatcctgagtgatgtgcagctgatcaagactggagacaaagtgggagccagcg aagccacgctgtgtgaacatgtcaacatctcccccttctccttttgggctgtgtgtgtgtgtgt gttcgacaatggcagcatctacaacctgaagtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt cgcttctggagggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt atcagtacccattctatcatcaacgggtacaacagagtgctgtgtgtgtgtgtgtgtgtgtgtgt tacaccttcccactgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt gccccgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt gccaaaggaaagtctggagagtgctggacgaggtatgggattgtgtgtgtgtgtgtgtgtgtgtgt aaaaagcaaccnaacttagccagtttttttgcacaaaacagggaataaaggcttacttcttaaaa agttaaaaaaaaaaaaaaaaaaaaaaaaaa	54

TFRC	NM_003234.3	agagcgtcgggatacgggtggcggctcgggacggagacgcgctagtgtagtgccgg cttctagaactacaccgaccctcgtgtccctccctcctcctcgtcggggctggctggagcggccg ctcgggtgctgtccagcagccataggagccgcacggggagcgggaaaagcggctcggc cccaggcggggcggccgggatggagcggggccgcgagcctgtgggaaagggcgtgtg cggcgcctcagcggctgcaggttcttctgtgtggcagttcagaatgatggatcaagctagat cagcattcttaactgttttgggtggagaaccattgtcatataccgggttcagcctgtcctggcaa gtagatggcgataacagtcattgtggagatgaaactgtctgtatgaagaagaaaatgtgac aataacacaaaggccaatgtcacaaaacaaaaagggtgtatggagatctgtctatgggact attgctgtgacgtcttttcttattgattgattgattggctacttggctattgtaaagggttaga accaaaaactgagtgtagagactggcaggaaaccgagtcctcagtgaggggaggagccagg agaggacttcctcgcagcacgtcgttatattgggatgacctgaagagaaaagtgtcggagaa actggacagcacagacttcacggcaccatcaagctgtgaatgaaaattcatatgtcctcgt gaggctggatctcaaaaagatgaaaatctgtgtgtatgtgaaaatcaatttctgttaatttaa ctcagcaaaagtctggcgtgatcaacatttgttaagattcaggtcaaaagacgcgtcaaaact cgggtgatcatagttgataagaacggtagactgtttacctgggtgagaatctgggggttatgtg gcgtatagtaaggctgcaacagttactggtaaaactggctcatgttaatttggactaaaaaga tttggagattatatacactcctgtgaatggatctatagtattgtcagagcagggaaaaatcacctt gcagaaaagggtgcaaatgtgaaagctaaatgcaattgtgtgtgtatatacatggaccaga ctaaatttccattgttaacgcagaacttcttcttggacatgtctatctggggacagggtgacc cttacacacctggatttcccttccatcaactcagtttccaccatctcgggtcatcaggtattgc ctaatacctgtccagacaatctccagagctgctgcagaaaagctgttgggaatattggaag gagactgtccctgtactggaaaacagactctacatgtaggatgttaacctcagaaaagcaaga atgtgaagctcactgtgagcaatgtgctgaaagagataaaaattcttaacatttggagtattta aaggctttgtagaaccagatcactatgtgtgtgtggggcccagagagatgcatggggccctg gagctgcaaaatcgggtgtaggcagcgtctcctattgaaactgtccagatgttctcagatat ggctttaaagatgggttccagccagcagaagcattatcttggcagttggagtgtcggagac ttggatcgggtgtccactgaatggctagagggataaccttctcctcgtcatttaaaggcttcc acttatattaatctggataaagcgggttctgtgtaccagcaactcaaggttctgccagccactg ttgtatagcttattgagaaaacaatgcaaaatgtgaagcctcgggttactgggcaatttctat caggacagcaactgggccagcaaaagtgtgaaaactcactttagacaatgtcgttcccttcc ttgcatattctggaatccagcagtttcttctgttttggcaggacacagattatcttattgggta ccaccatggacacctataaggaaactgattgagaggattcctgagttgaacaaagtgtgcagga gcagctgcagaggtcgtgtcagttcgtgttaaaactaaccatgatgtgaattgaacctgtg actatgagaggtacaacagccaactgcttctattgtgagggtatctgaaccaatacagagcag acataaaggaaatgggctgagttacagtggtgtattctgtcgtgagacttctcgtgct acttcagactaacaacagatttgggaatgtgagaaaacagacagatttgcataagaagaa ctcaatgatcgtgtcatgagagtggagtatcacttctctctccctacgtatctccaaaagagct ctttccgacatgtcttctgggctccggctctcacacgtctccagcttactggagaacttgaa actgcgtaaacaaaataacgggtgtttaaagaaacgtgttcagaaaccagttggctcagcta cttggactattcagggagctgcataatgcctctctgtgtgacgtttgggacattgacaatgagttt taaatgtgatacccatagcttccatgagaacagcagggtagtcgtgttctagactgtgtgctgat cgtgctaatttctagtagggctacaaaacctgatgttaaaatccatccatcttgggtactac tagatgtctttaggcagcagctttaaatacagggttagataacctgtacttcaagttaaagtgaata accacttaaaaatgtccatgaggaatttccctatctctagaatttgaagtgttgaatggg aactgcctcttctgtgtgttaataatgaaaatgtcagaaaccagttatgtgaatgtctctgaat cctaagggtgtgtctgtgaggtgtgaagtgtgtcgttactttagtgatcctccaacttcat ttgatgctaaataggagataccagggtgaaagaccttctccaaatgagatctaagccttccata aggaaatgtagctgttctcattcctgaaagaaacagtttaacttcaagagatgaggctgtgtt tcttccaatgaggtgtgaaatggaggtccttctgtgataaaatgaggttcaactgtgattg caggaaataggccttaatatgttaacctcaggtgtcatttatgaaaagaggggaccagaagcca	55
------	-------------	---	----

		aagacifagfatafittttcttctgtccctccccataagcctccatttagtcttfttattttgt tcttccaaagcacattgaaagagaaccagtttcaggtgttagtgcagactcagttgtcagac tttaagaataatagctgccaattttggccaaagtgttaatttagggagagcttctgtcctt ttggcactgagatattttattttatcagtgacagagttcactataaagggtgttttttaataga atataattatcggaagcagtgccctccataattatgacagttatactgtcgggttttttaataaaa gcagcatctgctaataaaacccaacagatactggaagttttgcafttatgtcaacacttaaggg tttagaaaacagccgtcagccaaatgtaattgaataaagttgaagctaagatttagagatgaat taaatfaattaggggttgcctaagaagcgagcactgaccagataagaatgctgttttccataat gcagtgaaftgtgaccaagttataaataatgtaacttaaaaggctgtgtagtactcctgcaaaa ttttatagctcagtttatccaaaggtgtaacttaattccattttgcaaaatttcagtaactttgtca caatcctaacacattatcgggagcagtgcttccataatgtataaagaacaaggtagttttacct accacagtgctgtatcgagacagtgatctccatagttacactaagggtgtaagtaattatcg ggaaacagtggttccataaattttctcatgcaatgacatcttcaagcttgaagctgttagtactt aacatgtatcccaactcctataatccctatcttttagtttagttgcagaacattttgtgtcatta agcattgggtgggtaaatcaaccactgtaaaatgaaattactacaaaatttgaatttagctgg gtttttgtacattatgttttctccaggtccttacttaagtagtagcatacattataatgttt gctattgacaagtcattttaactttatcacattattgcatgttacctcctataaacttagtgcggac aagtttaataccagaattgacctttgacttaagcagagggtactttgtatagaagggttggggg ctgtggggaaggagagtgccctgaaggtctgacacgtctgctaccattctgtgtgtaataat taaatgtaggtatgaataagttcgaagctcgtgagtgaaacatcattataaacgtgatgatcag ctgtttgtcatagggcagttggaacggcctcctagggaaaagtcatagggtccttctcaggttc ttagtgtcactttacagatttacagctcacttgatgtgtaactactcacagttctttaattctca gtttatctttaatctcctttttatcttgactgacatttagcgttagctaaatgaaaggtcatagct gagattcctgggttcgggtgttacgcacagctacttaaatgaaagcatgtggcagttcatcgtat aacacaatagataacagggcatgcaattttgcagcagtgagttcttcagaaaacctttctac agttagggttgagttacttctatcaagccagtagctgtaacaggctcaatattctgtaagtga atatcagactagtgacaagctcctggtgtgagatgtcttctcgttaaggagatgggctttgg aggtaaggataaaatgaatgagttctgtcatgattcactattctagaacttgcaggtacttact gtgttagctcttgaatgtctgaaattttagactttctgttaacaaatgatagtccttatcattgt ataaaagctgttatgtgcaacagtggtgagattcctgtctgatttaataaaataacttaaacactga aaaaaaaaa	
18S	X03205.1	tacctggtgacccgtccagtagcatatgctgtctcaaagattaagccatgcatgtctaagtagc cacggccggtacagtgaaactgcgaatggctcattaaatcagttatgggtcctttggctgctc ctcctctccacttggaataactgtgtaattctagagctaatacatgcccagggcgctgaccc ccttcgcggggggagtgctgcatattatcagatcaaaaccaacccggtcagccctctccgg ccccggcgggggggcgggcgccggcggtttggtgacttagataaactcggggcgatcg cacgcccccggtgcgggcgacgacccattcgaaactgtcgcctatcaactttcgatgtagtc gacctgacctaccatggtgaccacgggtgacgggggaatcagggttcgattccggagaggga gcctgagaacgggtaccacatccaagggaaggcagcagggcgcaaataccactccg accgggggaggttagtgacgaaaaataacaatacaggactcttccaggccctgtaattggaat gagtcactttaatctttaacgaggtaccattggaggggcaagtctggtgccagcagccgg gtaatccagctc caatagcgtatattaaagtctgcagttaaaaagctcgttagttggtcttg gagcgggcgggcggtccgcccggagcgagccaccgcccgcctccgcccctgctctc ggcgccccctcgtatctcttagctgagtggtccggcgggcgccgaagcgtttactttgaaaaa ttagagtgttcaaagcagggccgagccgctggataccgagctagggaataatggaatagga ccgcggttctattttgtgttttcggaactgaggccatgattagaggagcggcgccggggcat tcgtattgcgcgctagagggtgaaattcttgaccggcgcaagacggaccagagcgaagc attgccaaagatgtttcattaatcaagaacgaaagtcggaggttcgaagacgatcagatacc gtcgtagtccgaccataaacgatccgaccggcgatgcggcggtttatcccatgaccgg ccgggcagcttccgggaacaaagctttgggttccgggggagtagttgtcgaagctga	56

[illegible]

		cggctccctcgtgaccgaatcacgacctctccccagctgtatttccaaatgtcgttteta acaagctgacgctggacaagctggacgttaaagggaagcgggtcgttatgagagtcgacttc aatgttctatgaagaacaaccagataacaacaaccagaggattaaggctgctgtcccaagc atcaaattctgctggacaatggagccaagtcggtagtcttatgagccactagcgccgct gatggtgtgccatgacctgacaagtactcttagagccagttgctgtagaactcaatctctgct gggcaaggatgttctgttctgaaggactgtgtaggccagaagtgagaaagcctgtgcca accagctgctggtctgtcatcctgctggagaacctccgcttcatgtggaggaagaaggga agggaagatgttctgtgggaacaaggfitaagccgagccagccaaatagaagctttccga gttcaacttccaagctaggggatgtctatgtcaatgatgtttggcactgctcacagagccca cagctcatggttaggagtaactgtccacagaaggctggtgggtttgtatgaagaaggagct gaactacttggcaaggcctggagagccagagcgaccttctggtccactctggcgag ctaaagtgcagacaagatccagctcatcaataatgctggacaaagtcaatgagatgattatt ggtgtgtgaatggctttaccttccctaagggtgctcaacaatggagattggcacttctgttt gatgaaggagggaagcaagattgtcaagacctaatgtccaaagctgagaagaatggtgtgaa gattacctgtcctgttacttgtcactgctgacaagttgtatgagaatgccaagactgccaag ccactgtggtcttggcatacctgctggctggtggtggtgactgtggtctgaaagcagca agaagtatgtgaggtgtcactcgggtaagcagattgtgtgaatgtctgtgggggtatt tgaatgggaagctttgcccggggaaccaaagctctcatggtatggtgtgaagccacttc taggggtgctcatcacatcataggtgtgtgagacactgccacttgcgtgccaatggaca cggaggataaagtcagccatgtgagcactgggggtggtgccagtttgagctcctggaaggt aaagtccttctggtgtggtgtctcagcaataatttagtacttctgctttagttctgtgca cagcccctaagtcaacttagcatttctgcatctccacttggcattagctaaaccttccatgtca agattcagctagtggccaagagatgcagtgccaggaaccttaaacagtgtcacagcatctca gtcatcttactgcacctggattgtcatacttctcaagatcccatttgaatttttagtgacta aaccattgtgcattctagagtgcatatatttatatttgcctgttaaaaagaagtgaagcagtgta gcttagttctctttgatgtaggttattatgattagctttgtcactgttccactactcagcatggaac aagatgaatccattttaggtagttagacaaaattgatgcatcattagtaaacataaaaagt gtcattgaaaccgtgatttttttttctgtcatactttaggaagggtgagaatagaatctt gaggaaacggatcagatgtctatattgtgaatgcaagaagtggggcagcagcagtgagag atgggacaattagataaatgtccattcttatcaaggccctactttaggcagacattgtctagt gcttttattctaactttttttatcagttacacatgataaattaaaaagtcaggcttataacaa aaaagccccagcccattctccattcaagattccactcccagaggtagccactttcaactc ttgagttttcagggtatatacctccatgttctaaagtaatatgcttatattgttcaacttctttttttattt ttaaagaaatctattcataccatggagggaaggctctgttccacatataattccacttcttattctc cgggtatagtttgtcaattatagattagatcaaaagctcacaactaataacagctgagctatgt agtatgctatgattaaattacttatgtaaaaaaaaaaaaaaaaa	
RPL13A	NM_012423.3	cacttctgcccccctgtttcaagggaataagaaacctgacaaaacctctctttccaag cggctgccgaagatggcgaggtgcaggtcctggtgctgatggtcgaggccatctcctgg gccgcttggcgccatctgtgctaacagggtactgtggcggaagggtggtggtcgtacg ctgtgaaggcatcaacatttctgcaatttctacagaacaagttgaagtacctggtttctcc gcaagcggatgaacaccaaccttcccaggccctaccacttccgggccccagccgcct cttctggcgaccgtgtaggtatgtctgcccacaaaaccaagcgaggccaggccgctctg gaccgtctcaaggtgttgacggcatccaccgcccactacgacaagaaaaagcggatgtgtgt tctgtgctccctcaaggctgtgctgtgaagcctacaagaaagtgtgctatctggggcgctg gtcacgaggttggtggaagtaccaggcagtgacagccacctggaggagaagaggaaa gagaagccaagatccactaccggaagaagaacagctcatgaggctacggaacaggcc gagaagaacgtggagaagaaaattgacaatacacagaggtcctcaagaccacggactcc tggtctgagccaataaagactgttaattctcatgctgtgctgctccctctccattgttgcct ggaaatgtacgggaccaggggcagcagcagtcaggtgccagggcagccctgggacat aggaaagctgggagcaaggaaagggtcttagtctactgctcccgaaagttgctgaaagcactc	59

		ggagaattgtgcagggtgctatttatctatgaccaataggagagcaaccagttactatgagtga aaggaggagccagaagactgattggaggccctatcttggagtgaggccatctgttgactttcc acctgggtcatatactctgcagctgttagaattgtgcaagcacttggggacagcatgagctgtg ttgtacacaggggtatttctagaagcagaaatagactgggaagatgcacaaccaagggttaca ggcatcgcccatgctcctcacctgtatttgaatcagaaataattgcttttaagaaaaaaaa aaaaaaaa	
B2M	NM_004048.2	aatataagtgaggcgctgcgctggcgggcattcctgaagctgacagcattcgggcccagat gtctcgctcctggccttagctgtgctgcgctactctctcttctggcctggaggctatccagc gtactccaaagattcagggttactcacgtcatccagcagagaatggaaagtcaaatctcgaat tgctatgtgtctgggttccatccacgacattgaagttgacttactgaagaatggagagagaatt gaaaagtgaggcattcagactgtctttcagcaaggactggctttctatctctgttactacact gaattcaccctcactgaaaagatgagtatgctgctgctgaaccatgtgactttgtcacagc ccaagatagtaagtgggagcagacatgtaagcagcatcatggagggttgagaatgctgcat ttggattggatgaattcctcctgctgctgttttaataattgatatgcttatacacttacattta tgcacaaaatgtagggttataataatgttaacatggacatgctcttcttataattctactttgagt ctgtctcatgtttgagtgtatctgagcagggtgtctcacaggtagcttaggagggtgctggcaact tagagggtgggagcagagaattctctatccaacatcaacatcttggtcagattgaactctca atctctgctcactcaagctgttaagatagtttaagcgtgcataagtttaactccaattacatactct gcttagaattgggggaaaaattagaataataattgacaggattattggaattgttataatgaat gaaacattttgcatataagattcataattacttctatacatttgataaagtaaggcatgtgtgtgt taattctggtttattttgttcacaaagttaaataaatcataaaacttgatgtgttatctctta	60
YWHAZ	NM_003406.3	ctttctcttcccttcttccgggctcccgtctccgctcatcccggtctgtggcccactccca ccgcccagctggaaacctggggactacgacgtccctcaaaccttgcctctagaggatataaaag aacatccagtcattggataaaatgagctggttcagaaggccaaactggccgagcaggctga gcgatatgtatgacatggcagccctgcatgaagtctgttaactgagcaaggagctgaattatccaa tgaggagagggaattctctcagttgttataaaaattgttaggagcccgtaggtcatcttga gggtcgtctcaagtattgaacaaaagacgggaaggtgctgagaaaaacagcagatggctcg agaatacagagagaaaattgagacggagcagtaagagatatctgcaatgatgtactgtctctttg gaaaagtcttgatcccaatgcttcacaaagcagagcaaaagtcttctatttgaaaatgaaag gagattactaccgttacttggctgagggtgcccgtggtgatgacaagaaagggttgcgataca gtcacaacaagcataccaagaagctttgaaatcagcaaaaagggaatgcaaccacacatc ctatcagactgggtctgccccttaacttctctgtgttctattatgagattctgaactccccagaga aagcctgctctcttgcacaaagacagcttttgatgaagccattgctgaactgatacatgaagtga gagtcatacaaaagacagcagcctaataatgcaattactgagagacaactgacattgtggacat cggataccacaaaggagacgaagctgaagcaggagaaggaggggaaaatfaaccgcttcc aactttgtctgctcctcattctaaaatttacacagtagaccatttgcacatgctgtccacaaata gtttttgtttacgattatgacaggttatgttacttctatttgaaattctataatttccatgtggtttat gtttaattataggaggtagagccagtttaacatttagggagttatctgttttcatcttgagggtgc caatatgggagtggaattttatacaagttataagtttggcatagtacttttgatcattgtg cttcaaaaggggcagtgtaaaactgcttccatgtctaaagcaaaagaaactgctacatactgggt ttgtcctggcggggaataaaagggtcattgttccagtcacaggtgtagtaattgtgggtactt taaggtttggagcacttacaaaggctgtgtagaatcataccccatggataccacataattaaacc atgtatatctgtggaatactcaatgtgtacacctttgactacagctgcagaaggttctcttagac aaagttgtgaccattttactctggataagggcagaaacgggttcacattccattttgtaaaagt acctgtgttagctttcattattttgtctacactatftttgtattttaaattgtttaggcaacctaaag aacaatgtaaaagtaagatgcaggaaaaatgaattgttggtatctacttcatgtatatca agcacagcagtaaaacaaaaaccatgtattttaacttttttaggattttgtctttgtattttttt tttgatacttgcctaacatgcatgtgctgttaaaatagtttaacagggaataacttgagatgatg gctagctttgttaattgtcttatgaaattttcatgaacaatccaagcataattgttaagaacacgtgt	61

		attaaattcatgtgaagtggaataaaaagtftttatgaatggacacttttcaactactttctctacagccttttc atgtaaattagctctgtgtctgaaactctctaaaggaaattgtacatttttggaaatttattcctttatc cctctgtgagctaatgggctcttaccagtttaacacaaaatttatcatacaaaaaatactact aatataactactgtttcctgcatcccatgatccctctctctcccccacccgtaaaaaatgagttc ctatttttctgggagagggggggattgattagaaaaaatgtagtgtgtccattttaaatttgg catatggcattttctaacttaggaagcccaaatgttctggcccatcatgacattgggtagcatta actgtaaatttctgtctccaatacacttttgggttttaagaatttcttgaatacttataagcctgcct caattttgatcccttattcttctatttctcaggtgcacaaagattaccttctgttttagccttctgtctt gtcaccaaccacttctacttgggtggccatgtacttggaaaaaggccgcatgatcttctggctcc actcagtgctaaaggcaccctgtcttctgttgcacccacagactatttccctcatctatttac tgcagcaaatctctcttagttgatgagactgtgtttatctccctttaaaccctacattctcgaat ggtctgtctattgtcgtctttaaataccttctcttctctctcttattcttaataatgattgggg ctaagttatacccaaggctcacttttacaataatttctcagtaacttctgacagaaaacaccaaaaa aatgtccattttaaanaagggtgtatttttctttagaattgaagctctcaaggagcaggggacaat gtttctgtatgttctattgtgcctagtacactgtaaatgtcaataaataatgafatggaggagca gtgagttctgtatgataagggtgagaaactgaaatcccaaacactgttttctgtctgtttattatg acctcagattaaattgggaaatattggcccttttgaataattgtcccaaatattacattcaataaa agtgcaatggagaaaaaanaaa	
SDHA	NM_004168.3	actgcagccccgctcgcactccggcgtgtgtgcgcaggcgcgggtatccccctccccgccag ctgcaccccggtgtgtgtgcgcaggcgcagctctgcgcaggggactggcgggactgcgcggc ggcaacagcagacatgtcgggggtccggggcctgtgcgcggctgtgagcgtctggcgct ggcgtgtgccaaggcgtgtgccaacagtggtgcaaacaggaaaccgaggtttcacttcatgt ttgatgggaacaaggggcatctgctaaagtgtcagattccatttctgtcagtafcagtagtg gatcatgaatttgatgagtggtgtgtaggcgctggaggggcaggcgttgcagagctgcatttggc ctttctgagcgagggtttaatacagcatgtgttaccagctgtttcctaccaggctcacacatgtt gtcacacaggggagggaataatgctgtctctgggggaacatggaggacacactggaggtgg catttctacgacaccgtgaagggtccgactggctgggggacaggaggtccatccactacat gacggagcaggcccccgccgctgtgtcgcagctagaaaaattatggcatgcccgtttagcaga actgaagatgggaagatttatcagcgtgcatttgggtgacagagcctcaagtttggaaagggc gggcaggcccacgggtgtctgtgtgtgtgatcggactggccactcgtattgacacctta tatggaagggtctctgcgatataaccagctatttgtgagatatttgccttggatctcctgatgg agaattggggagtgccgtgtgtgtcatcgcactgtgcatagaggaggggtccatccatgcata agagcaaaagaacactgtgttggccacaggaggctacgggcgcacctacttctcagctgcacgtc tgcacacaccagcactggcgacggcacggccatgatccaggggcaggccttctctgccag gacctagagttgttcagtccaccctacaggcctatatgtgtgtgtgtgtctcattacgggaagg atgtctgtggagaggggaggcattctcattaacagtcaggcgaaaggtttatggagcgcatacg cccctgtcgcgaaggacctggcgtctagagatgtgtgtgtctcgttccatgactctgagagatc ggaagggaagaggctgtggccctgagaagaatcactgttactcagctgcagctgcacccactacct ccagagcagctgtggccacggcctgtccttggcatttcagagacagccatgatcttctgtgtgcgt ggacgtcacgaaggagccgaacctgtctctccccaccgtgcattataacatggggcggtatc ccaccaactacaaggggcaggctctgaggcacgtgaatggccaggatcagattgtgtcccg cctgtacgcctgtggggaggccgctgtgtcctcgggtacatgtgtccaaaccgctcggggca aactcgtcttggacctgtgtgttcttgggtcgggcatgtgcctgagcatcgaagagtcagca ggccctggagataaagtccctccaattaaaccaaacgctggggaagaatctgtcatgaattctg acaaatgagattgtctgatggaagcataagaacatcggaactgcgactcagcatgcagaagt caatgcaaaatcatgctgcgtgttccgtgtgtgggaagcgtgttgaagaagggtgtgggaaaa tcagcaagctctatggagacctaaagcacctgaagacgttgcaccggggaatgtgttgaac acggacctgtgtgagacctgtgagctgcagaacctgatctgtgtgtcgtcgtgcagaccatca cggagcagaggcacgggaaggagtcacggggcgccgcatgccagggaagactcaagggtg cggattgatgaatfaccattactccaagcccatccaaegggcaacagaagaaccccttaaggga	62

[illegible]

	caaggacagaafectaalgccacttttggtaggttcaaaaattgtggcctccatgtgggat agtcttggagaggagcaaaaacagggtatataagaggaaaactgaggctgccaagaaagagt atctgaaggcactggctgcttacaagaacaggagtgtaggcccactgtggaacagtg gaattggatccagcaccaccatcacaaactccttccacctcctatggctactgttgaccag catctccagcaccagcttcaatagagccccctgccccctgcccattgtgttaactccacc cttcatcctatgtggcaaacaggcatcttctggagctgggggtcagcccaatcaccaaggt tgattattaccaaaacaatgttgcctcttctattactatgtctcaaggagggtatgttactgtatc ccagccacagtgtgtgacctccgggggtcctcaactaggccaaccagtcagctactatcca gcccagtcacaagcccagattgtcactcgggtcagtggttcaggcagcagcagctgctgctg ctgctgcttctatgcaactgcctcaccctgactacagccccctccattacaacagatgccaca gccccgactcagcagcaagttaccattctgcagcagcctcctccactccaggccatgcaac agcctccacctcagaaagttcgaaatcaattacagcaacagcctcctcctctgcagatcaagag tgtcctctaccactttgaaaatgcagactaccttagtccaccaactgtggaagtagtctg agcggcctatgaacaacagccctgaggcccatagtgaggcacccttctctgagactatct gtgagatgacacagatgtagtctctgagggtgagtccttctcagatggatgtgaattggtga gtgggtctcctgtggcactctcaccagcctcgatgtgtgagggtctggtgtgagaacctcc cattgtgagtaaggactgggacaatgaatactgcagcaatgagtggtgtgaagcactgca gggatgtattcttggcctgggtagcctctagaaatcaaacacagtggtgttgtgaaatagtc ttcctgttctcaagccagtgaaaggtatctgctgggaaagtgtccaaagagcctgttttgaaa cacaagctgggcttctgtgtgctcctatcacacccatgatggctgttcatgtttcaccctttt cttcttcagcagaggccaggctatggagcaggccactgaatttgcgtgaatctggagatgc ttttactttcaaccataagcggtaatagcagaggaaagggtgaaggagctgtgggcaagcaa agcatagagatgtgggtgtgtgtgggtggaagaaactgtgtgtataattgtcatagact tgccataaatattatataaataacgggaggtgtactcagctttgagcctagagaaaatgccactg tgtgcatcacttttaagggttcctcataaaaaatgtattcccatatcacatcagtcactg ctttgaaaacaaaacttttcaacatgggcatactgggtcactatggaaaatgacatcacccagga gtgatttctcttatataatattttctgcagttaccatccttatctgagtatcacagttcatgaatcta agaggcggaaactctacatcattagtaagggttcaccaaagtctaaagtgtattcactgtgtgt tgatgaactatctttaaagaccataggtctatcattatttcttagacataatctaaagaaaaacag actagagaagccacctggtgtacagaataagcagaagttacagcatgatagtcgaagtgg tgataactttaataaaaactcaaattttactgtttgttagacaggaaatgctgtcctagagaacctcc tctcaaccagctacgtacatagttttatcctatgcattcctgttttctgtgttttttttttttt tttttttttgagacagagtcctgctgtcaccaggctggagtgagtggtgagacctcagct cactgaaacctctgctcctccgggttcaagcgattctcctgcacagcctcccgagtagctagg attacaggcggccgactacgcccagctaattgtgtgttttttagtagagacagggttcacc atgttggccaggctgtctcgaactcctgacctcatgacgcccgccttgacctccaaagtgt ctgggattacaggcatgagccaccgcacccagcctgcatcctgttttttaattgttttggagg gtagcagtagagatgggtctcactatgttcccagctagtcttgaactcctgggtacagtta ccctcctacctggcttccaaagtgtcctggattacaggtgtgagccactgtgcctagcctata atgatcattttaattgttccatgcactcatfttagttgaaccttcacagcaaccaatfaggtaat actcccattcacatataatactgagagatgaggtgcacaagattatacactgttaagtagcaga gccagaatggacttcagaatcccaactacaatacaaatgtttattaaataaagaagaaagctat tgtacaaatcactctcagggttagcttacagagccatggctatggattcttagctctgtaagg	
--	---	--

		aagtgcttctataaattcttaggttttagagatgataccatctgggtaccttctgaacccgtgcaa ccacatctgggtctagtaggtggatccatccagttggttccaagggtgatcctgaacagtg taaaaggaggggcacaaccagaaatctggaaatagagggttaataattgttaaaaaatgcatac caaatgaagactgacctatcatcatatacaaatatgccaattctaaaaagagcttaacattagaata gtatatgtagaattactagttcagaattggcatagattctgggtgtaaaatagactggatctgtat tatctgagggttagtaactaatgcttagccaggcctgcttcacagagttgctaccaggggagtatt cttgggataagcaaaatgctagcagcatgtgtttaagctctgttaagggggtgaaagatgtaatta ttgacagattaaatagataactcgttaaccaccagggggcagattcaatacatcacagaatggc tgagggaagatccctgggttggaagagagtagaaaccctaggggagcagtgctttgggtccta gaacctgttgagtttctaataatgtagaattctcataaaacagtttaatacaagcttaagtg gcttatgaatcctgtgaagctcatttatggactagtgtaaaacaatgtgaagctctactaagtct gtccttaatacataataatagccccttgaggactagcctgttctctggtcacctaccagttgggt tgcacattgtgtggtcgtccaaataactcaatcttgcgagtgccaggagatagctttcaatcat gccatagattcatctggttatgactggtggaacgaacctaggaaataaaaactagctgctttti aagttacacaagaaaaaa	
TPTI	NM_00128627 2.1	cttctgcccacgtcaccgcctgctgcttccggaggcgcagcgggagtagacgttagagg acgtgccctctatagagggtggggagcggctgagtcggcctttccgcccgtccccctcc ccccgagcgcgctccggctgcaccgcgctgctcggagtctcaggtcgtgctaagctagc ggcgtcgtcgtcctcctcagtcgccatcatgattatctaccgggacctcatcagccacgatga gatgttctccgacatctacaagatccgggagatcgggacgggtgtgctgaggtggagg ggaaagatggtcagtaggacagaaggtaacattgatgactcgtcattggtgaaatgctccg ctgaaggccccgaggcggaagggtaccgaaagcacagtaatacactggtgctgattgtcatg aaccatcacctgcaggaaacaagttcacaaaagaagcctacaagaagtacatcaagattac atgaatcaatcaaaagggaacttgaaacagagaccagaagagtaaaacctttatgaca ggggctgcagaacaatcaagcacatccttcttaattcaaaaactaccagttcttattgtga aaacatgaatccagatggcatggtgtctctattggactaccgtgaggatggtgtgacctcata atgattttcttaaggatggtttagaatggaaaaatgtgatcaaaagaagaatccctgctg tttctgtctgtcttggggggccagattgaattgggaatacatcttagcctggaaatgtagg ctgcatgttaatgtaatgtaactttgcagtgtaatgtttgaaaaatattatgattttgtttta cagtaacaaatgtggcaattatttggatctatcacctgtcatcataactggctctgtgtcatc cacacaacaccaggacttaagacaatgggactgatgtcatcttgagctcttcattatttgcact gtgatttatttggagtgaggcattgttttaagaaaaacatgtcatgtagggtgtctaaaaataaa atgcatttaaaactcatttgagagaatgcttttagtttaatgcatatttaaaactaaattgatcctgtag tgttctgggagaagctagagcctgattgtaggctactactatcaatcaactctacagtgagga ctacttctgggactggaatataaaaaagaatcaaaaggtctgattttaggtgcaataaaggga agaccatgctcatagcagtgccaacatctgaagtgtggagccttaccattcatcacctaca cggagtagttaactggaagagattaccaagagaataaaaagagactcattcagtggaagca actttgtctcagcttatttcacataaagagagcgaagcttttgggatgaatttaataaactccc tggttaactagaacagggactggcaactagcctatctgaccacctgtttgtacactttaagggtg gttgggttgccttttaaatggttgaggggaaaagaatacctgtgggatatggaaatttaagttcga gtccagttttattggaacgtggctatgcttattcattatggattgactgtggctgtgtcagtgcat gagcagagttgtgttaacagactagagcctgcaagtttccagcccctgatttaaaagatga aggtacacagaatgtgggctggctggtgggcaagggggtaaaaatgttctctatattgtatctg	65

		aaaagatgggtgtctgaafaagaaaatgcatctatttgacagacctggagcagttgctatctg ctgctatgggttcaccacagatgcaagaagaacatgtccttgcgcttccgtctgctaatgtg gcagctgagattgaafagagggaatacaggaggaaaaaagcgggaagagttttgaggcag gtcgggtcaccaggctgttagtgagtgccacaagcaactcactgcattctctgcacctgtgc tcaagccatttccacctcagtcactagttgctgggactgcaggcatgcacctatgccc agctaattttgtagagaccgagatcgcttagttgccagggtggtctcaactcctgggctcaa ggagatctgcccacctcagcctccaaagtgcaggcctagcctgggagggaattttcaaaa cgtgagttttgggaatagctatcagccctacctggttgattacacttgtaaaagaagattaaa agcaggccagtgactctggctcgtctgaacatgtgaatgtagtggttgagcaatctggagttg ccctagtgtcaaatccagactgtccatagtgctcaaaacctgaggcagatactaatgttaacc ccagcaccctggtattggaacaacctaatacgtattgggaacttaataagcaatttaagcat tctgatagattttttagggatgggtcatgcatgtgcccaggctggtctgaaaactctggc ctcaagtatctcaagcttggccttcaaaagtgtgggattacagggtgtaggcaatgcacctg gcttagcgtctgattgacattgtaataaaaagtgtgagtcctatcacaggccctttgtccct gaaatgatagcagggaagggaatttcaggcagtggtcaaaagctggggaaccaggatagtg aagaaggccttgaggtgagagatggaagctaattggtgaactagccttgggaagcctgaaca gacaagtagcaatfcagagactttgtgggtccactgctccaactgttttgaaagtattcagttct gcagaagagggtatttcccagttgtctttcagtgctcttagctgttttcccaactccagatcca atcaaggctgggacatagcattttatcatgtctatttaagtcagaagtgatgaacccagctgtt acctatggttaacctttgaagattccaggtagaatcttccagacttgaagactgtctcatttta tatcttttctgcttattcctagggtcaagacgttttgggcaagaataaggatgtgaacatcagaa agctcataaactttgtttgatgctaagttaacaaaggcatgcttttagtagcctgtgggcccta gggtttgttaagtgtggagaacaactgagtgaggcaagaggacttttctagggaaggtcctgt aatgtgacatttgaacaaatgaagggtgtggaagtaggccatgtggatagcaggacaaccca ttccaggccaagacaacagcagttagtctggagtgatgtgttctgggaaaaaagtggccac tttctaaccacaagaagacagggaagggtgtgaagcagtgaggagtggtcaagggaaggaga ccagacctcaaggaaaccacaggcgctctgagcagaagagttacatgatatgactcaaatttt aaaggatcactttggctgcccagggtggcagggtaaaagcatagaataattgtgtataatgtgtt taaggcaagatagtgcttagtctagggttagtagactgagggtgtaggaaatgaagataga gacaacaggatagctgggtgaggatgggattaatgttgatacaagtattttgctgagcgt tttgaagaaagtgtgactgaggtgggaagtcgagtttagtttttagttttgagtggttaagt ttgagatgctgattctcagagaagtcataagctggagaactatagagagtggaagataaca atagacattgaagccatgatacaggataaggtcatttggagagaggatagactgcattccaa catgagattggttgacaaagagaacccaacaaaggtaattaaagggtgctcccactgcacttg tactcagaaggctgaggtaggtgttagaggccagcctgggcaccacaggagagacccat ctctaaaatttagccagggaaccatggctcatgctgtagccccagggaatttggaggctgagt ggggaggatcgttgaggtcagggtttgagaccagcctgggcaacataggagaccta aaaattaattgggcatctgtagtccagctactcaggcggctgagctgagaggatggcttgag tccgagagattgagggtcagtgagctgtgatcataccactgcactccagcctggcgagcag tgagacactatctgaaaaaagtftaaaaattftaaaaaagaaggaaactgccctgaggtaagaa ccaaggaggaggcctccagaggtcagggtggaaaaagtfttaggaaggagggaagtgtcaa cagggttacctgttgcaaggtacttaagtaatatgagcctgafagtggttaacttgactaccgt tggattcactagtgagggaaggaaagtctaattaaatgactcaagagactaacagtcgagg	
--	--	--	--

		catgaaatacaafacagggtacatgggtttttattatgtgtgcatctgcttcagtaatagggtgaatt actcatttggatcattaggaggttcaaaatctagttaaactagattttgtgatgtaaattctgt cattctgaactgcagggtgtcagtaactgaactgaactaaactgggtgataattatggtaaa attgcaagacgagcaataaatctcaaccaactgagagaactgataa	
--	--	--	--

Definitions

[00126] The articles “a” and “an” are used in this disclosure to refer to one or more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[00127] The term “and/or” is used in this disclosure to mean either “and” or “or” unless indicated otherwise.

[00128] As used herein, the terms “polynucleotide” and “nucleic acid molecule” are used interchangeably to mean a polymeric form of nucleotides of at least 10 bases or base pairs in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide, and is meant to include single and double stranded forms of DNA. As used herein, a nucleic acid molecule or nucleic acid sequence that serves as a probe in a microarray analysis preferably comprises a chain of nucleotides, more preferably DNA and/or RNA. In other embodiments, a nucleic acid molecule or nucleic acid sequence comprises other kinds of nucleic acid structures such as for instance a DNA/RNA helix, peptide nucleic acid (PNA), locked nucleic acid (LNA) and/or a ribozyme. Hence, as used herein the term “nucleic acid molecule” also encompasses a chain comprising non-natural nucleotides, modified nucleotides and/or non-nucleotide building blocks which exhibit the same function as natural nucleotides.

[00129] As used herein, the terms “hybridize,” “hybridizing,” “hybridizes,” and the like, used in the context of polynucleotides, are meant to refer to conventional hybridization conditions, such as hybridization in 50% formamide/6XSSC/0.1% SDS/100 µg/ml ssDNA, in which temperatures for hybridization are above 37 degrees centigrade and temperatures for washing in 0.1 XSSC/0.1% SDS are above 55 degrees C, and preferably to stringent hybridization conditions.

[00130] As used herein, the term “normalization” or “normalizer” refers to the expression of a differential value in terms of a standard value to adjust for effects which arise from technical variation due to sample handling, sample preparation, and measurement methods rather than biological variation of biomarker concentration in a sample. For example, when measuring the

expression of a differentially expressed protein, the absolute value for the expression of the protein can be expressed in terms of an absolute value for the expression of a standard protein that is substantially constant in expression.

[00131] The terms "diagnosis" and "diagnostics" also encompass the terms "prognosis" and "prognostics", respectively, as well as the applications of such procedures over two or more time points to monitor the diagnosis and/or prognosis over time, and statistical modeling based thereupon. Furthermore, the term diagnosis includes: a. prediction (determining if a patient will likely develop aggressive disease (hyperproliferative/invasive)), b. prognosis (predicting whether a patient will likely have a better or worse outcome at a pre-selected time in the future), c. therapy selection, d. therapeutic drug monitoring, and e. relapse monitoring.

[00132] "Accuracy" refers to the degree of conformity of a measured or calculated quantity (a test reported value) to its actual (or true) value. Clinical accuracy relates to the proportion of true outcomes (true positives (TP) or true negatives (TN)) versus misclassified outcomes (false positives (FP) or false negatives (FN)), and may be stated as a sensitivity, specificity, positive predictive values (PPV) or negative predictive values (NPV), or as a likelihood, odds ratio, among other measures.

[00133] The term "biological sample" as used herein refers to any sample of biological origin potentially containing one or more biomarkers. Examples of biological samples include tissue, organs, or bodily fluids such as whole blood, plasma, serum, tissue, lavage or any other specimen used for detection of disease.

[00134] The term "subject" as used herein refers to a mammal, preferably a human. In some embodiments, the subject has at least one prostate cancer symptom. In some embodiments, the subject has a predisposition or familial history for developing a prostate cancer. The subject could also be previously diagnosed with a prostate cancer and is tested for cancer recurrence. In some embodiments, the subject has benign prostate hyperplasia.

[00135] "Treating" or "treatment" as used herein with regard to a condition may refer to preventing the condition, slowing the onset or rate of development of the condition, reducing the risk of developing the condition, preventing or delaying the development of symptoms associated with the condition, reducing or ending symptoms associated with the condition, generating a complete or partial regression of the condition, or some combination thereof.

[00136] Biomarker levels may change due to treatment of the disease. The changes in biomarker levels may be measured by the present disclosure. Changes in biomarker levels may be used to monitor the progression of disease or therapy.

[00137] "Altered", "changed" or "significantly different" refer to a detectable change or difference from a reasonably comparable state, profile, measurement, or the like. Such changes may be all or none. They may be incremental and need not be linear. They may be by orders of magnitude. A change may be an increase or decrease by 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 100%, or more, or any value in between 0% and 100%. Alternatively, the change may be 1-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold or more, or any values in between 1-fold and 5-fold. The change may be statistically significant with a p value of 0.1, 0.05, 0.001, or 0.0001.

[00138] The term "stable disease" refers to a diagnosis for the presence of a prostate cancer, however the prostate cancer has been treated and remains in a stable condition, i.e. one that is not progressive, as determined by imaging data and/or best clinical judgment.

[00139] The term "progressive disease" refers to a diagnosis for the presence of a highly active state of a prostate cancer, i.e. one has not been treated and is not stable or has been treated and has not responded to therapy, or has been treated and active disease remains, as determined by imaging data and/or best clinical judgment.

[00140] The term "neoplastic disease" refers to any abnormal growth of cells or tissues being either benign (non-cancerous) or malignant (cancerous). For example, the neoplastic disease can be a prostate cancer.

[00141] The term "neoplastic tissue" refers to a mass of cells that grow abnormally.

[00142] The term "non-neoplastic tissue" refers to a mass of cells that grow normally.

[00143] The term "immunotherapy" can refer to activating immunotherapy or suppressing immunotherapy. As will be appreciated by those in the art, activating immunotherapy refers to the use of a therapeutic agent that induces, enhances, or promotes an immune response, including, e.g., a T cell response while suppressing immunotherapy refers to the use of a therapeutic agent that interferes with, suppresses, or inhibits an immune response, including, e.g., a T cell response. Activating immunotherapy may comprise the use of checkpoint inhibitors. Activating immunotherapy may comprise administering to a subject a therapeutic agent that activates a stimulatory checkpoint molecule. Stimulatory checkpoint molecules include, but are not limited to, CD27, CD28, CD40, CD122, CD137, OX40, GITR and ICOS. Therapeutic agents

that activate a stimulatory checkpoint molecule include, but are not limited to, MEDI0562, TGN1412, CDX-1127, lipocalin.

[00144] The term "antibody" herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity. An antibody that binds to a target refers to an antibody that is capable of binding the target with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting the target. In one embodiment, the extent of binding of an anti-target antibody to an unrelated, non-target protein is less than about 10% of the binding of the antibody to target as measured, e.g., by a radioimmunoassay (RIA) or biacore assay. In certain embodiments, an antibody that binds to a target has a dissociation constant (K_d) of $< 1 \mu\text{M}$, $< 100 \text{ nM}$, $< 10 \text{ nM}$, $< 1 \text{ nM}$, $< 0.1 \text{ nM}$, $< 0.01 \text{ nM}$, or $< 0.001 \text{ nM}$ (e.g. 10^8 M or less, e.g. from 10^8 M to 10^{13} M , e.g., from 10^9 M to 10^{13} M). In certain embodiments, an anti-target antibody binds to an epitope of a target that is conserved among different species.

[00145] A "blocking antibody" or an "antagonist antibody" is one that partially or fully blocks, inhibits, interferes, or neutralizes a normal biological activity of the antigen it binds. For example, an antagonist antibody may block signaling through an immune cell receptor (e.g., a T cell receptor) so as to restore a functional response by T cells (e.g., proliferation, cytokine production, target cell killing) from a dysfunctional state to antigen stimulation.

[00146] An "agonist antibody" or "activating antibody" is one that mimics, promotes, stimulates, or enhances a normal biological activity of the antigen it binds. Agonist antibodies can also enhance or initiate signaling by the antigen to which it binds. In some embodiments, agonist antibodies cause or activate signaling without the presence of the natural ligand. For example, an agonist antibody may increase memory T cell proliferation, increase cytokine production by memory T cells, inhibit regulatory T cell function, and/or inhibit regulatory T cell suppression of effector T cell function, such as effector T cell proliferation and/or cytokine production.

[00147] An "antibody fragment" refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')₂;

diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments.

[00148] Administering chemotherapy to a subject can comprise administering a therapeutically effective dose of at least one chemotherapeutic agent. Chemotherapeutic agents include, but are not limited to, 13-cis-Retinoic Acid, 2-CdA, 2-Chlorodeoxyadenosine, 5-Azacitidine, 5-Fluorouracil, 5-FU, 6-Mercaptopurine, 6-MP, 6-TG, 6-Thioguanine, Abemaciclib, Abiraterone acetate, Abraxane, Accutane, Actinomycin-D, Adcetris, Ado-Trastuzumab Emtansine, Adriamycin, Adrucil, Afatinib, Afinitor, Agrylin, Ala-Cort, Aldesleukin, Alemtuzumab, Alecensa, Alectinib, Alimta, Alitretinoin, Alkaban-AQ, Alkeran, All-transretinoic Acid, Alpha Interferon, Altretamine, Alunbrig, Amethopterin, Amifostine, Aminoglutethimide, Anagrelide, Anandron, Anastrozole, Apalutamide, Arabinosylcytosine, Ara-C, Aranesp, Aredia, Arimidex, Aromasin, Arranon, Arsenic Trioxide, Arzerra, Asparaginase, Atezolizumab, Atra, Avastin, Avelumab, Axicabtagene Ciloleucel, Axitinib, Azacitidine, Bavencio, Bcg, Beleodaq, Belinostat, Bendamustine, Bendeka, Besponsa, Bevacizumab, Bexarotene, Bexxar, Bicalutamide, Bicnu, Blenoxane, Bleomycin, Blinatumomab, Blincyto, Bortezomib, Bosulif, Bosutinib, Brentuximab Vedotin, Brigatinib, Busulfan, Busulfex, C225, Cabazitaxel, Cabozantinib, Calcium Leucovorin, Campath, Camptosar, Camptothecin-11, Capecitabine, Caprelsa, Carac, Carboplatin, Carfilzomib, Carmustine, Carmustine Wafer, Casodex, CCI-779, Ccnu, Cddp, Ceenu, Ceritinib, Cerubidine, Cetuximab, Chlorambucil, Cisplatin, Citrovorium Factor, Cladribine, Clofarabine, Clolar, Cobimetinib, Cometriq, Cortisone, Cosmegen, Cotellic, Cpt-11, Crizotinib, Cyclophosphamide, Cytamza, Cytadren, Cytarabine, Cytarabine Liposomal, Cytosar-U, Cytosan, Dabrafenib, Dacarbazine, Dacogen, Dactinomycin, Daratumumab, Darbepoetin Alfa, Darzalex, Dasatinib, Daunomycin, Daunorubicin, Daunorubicin Cytarabine (Liposomal), daunorubicin-hydrochloride, Daunorubicin Liposomal, DaunoXome, Decadron, Decitabine, Degarelix, Delta-Cortef, Deltasone, Denileukin Diftitox, Denosumab, DepoCyt, Dexamethasone, Dexamethasone Acetate, Dexamethasone Sodium Phosphate, Dexasone, Dexrazoxane, Dhad, Dic, Diodex, Docetaxel, Doxil, Doxorubicin, Doxorubicin Liposomal, Droxia, DTIC, Dtic-Dome, Duralone, Durvalumab, Eculizumab, Efudex, Ellence, Elotuzumab, Eloxatin, Elspar, Eltrombopag, Emcyt, Empliciti, Enasidenib, Enzalutamide, Epirubicin, Epoetin Alfa, Erbitux, Eribulin, Erivedge, Erleada, Erlotinib, Erwinia L-asparaginase, Estramustine, Ethyol, Etopophos, Etoposide, Etoposide Phosphate, Eulexin, Everolimus, Evista, Exemestane, Fareston, Farydak,

Faslodex, Femara, Filgrastim, Firmagon, Floxuridine, Fludara, Fludarabine, Fluoroplex, Fluorouracil, Fluorouracil (cream), Fluoxymesterone, Flutamide, Folinic Acid, Folutyn, Fudr, Fulvestrant, G-Csf, Gazyva, Gefitinib, Gemcitabine, Gemtuzumab ozogamicin, Gemzar, Gilotrif, Gleevec, Gleostine, Gliadel Wafer, Gm-Csf, Goserelin, Granix, Granulocyte - Colony Stimulating Factor, Granulocyte Macrophage Colony Stimulating Factor, Halaven, Halotestin, Herceptin, Hexadrol, Hexalen, Hexamethylmelamine, Hmm, Hycamtin, Hydrea, Hydrocort Acetate, Hydrocortisone, Hydrocortisone Sodium Phosphate, Hydrocortisone Sodium Succinate, Hydrocortone Phosphate, Hydroxyurea, Ibrance, Ibritumomab, Ibritumomab Tiuxetan, Ibrutinib, Iclusig, Idamycin, Idarubicin, Idelalisib, Idhifa, Ifex, IFN-alpha, Ifosfamide, IL-11, IL-2, Imbruvica, Imatinib Mesylate, Imfinzi, Imidazole Carboxamide, Imlygic, Inlyta, Inotuzumab Ozogamicin, Interferon-Alfa, Interferon Alfa-2b (PEG Conjugate), Interleukin-2, Interleukin-11, Intron A (interferon alfa-2b), Ipilimumab, Iressa, Irinotecan, Irinotecan (Liposomal), Isotretinoin, Istodax, Ixabepilone, Ixazomib, Ixempra, Jakafi, Jevtana, Kadcyla, Keytruda, Kidrolase, Kisqali, Kymriah, Kyprolis, Lanacort, Lanreotide, Lapatinib, Lartruvo, L-Asparaginase, Lbrance, Lcr, Lenalidomide, Lenvatinib, Lenvima, Letrozole, Leucovorin, Leukeran, Leukine, Leuprolide, Leurocristine, Leustatin, Liposomal Ara-C, Liquid Pred, Lomustine, Lonsurf, L-PAM, L-Sarcolysin, Lupron, Lupron Depot, Lynparza, Marqibo, Matulane, Maxidex, Mechlorethamine, Mechlorethamine Hydrochloride, Medralone, Medrol, Megace, Megestrol, Megestrol Acetate, Mekinist, Mercaptopurine, Mesna, Mesnex, Methotrexate, Methotrexate Sodium, Methylprednisolone, Meticorten, Midostaurin, Mitomycin, Mitomycin-C, Mitoxantrone, M-Prednisol, MTC, MTX, Mustargen, Mustine, Mutamycin, Myleran, Mylocel, Mylotarg, Navelbine, Necitumumab, Nelarabine, Neosar, Neratinib, Nerlynx, Neulasta, Neumega, Neupogen, Nexavar, Nilandron, Nilotinib, Nilutamide, Ninlaro, Nipent, Niraparib, Nitrogen Mustard, Nivolumab, Nolvadex, Novantrone, Nplate, Obinutuzumab, Octreotide, Octreotide Acetate, Odomzo, Ofatumumab, Olaparib, Olaratumab, Omacetaxine, Oncospar, Oncovin, Onivyde, Ontak, Onxal, Opdivo, Oprelvekin, Orapred, Orasone, Osimertinib, Otrexup, Oxaliplatin, Paclitaxel, Paclitaxel Protein-bound, Palbociclib, Pamidronate, Panitumumab, Panobinostat, Panretin, Paraplatin, Pazopanib, Pediapred, Peg Interferon, Pegaspargase, Pegfilgrastim, Peg-Intron, PEG-L-asparaginase, Pembrolizumab, Pemetrexed, Pentostatin, Perjeta, Pertuzumab, Phenylalanine Mustard, Platinol, Platinol-AQ, Pomalidomide, Pomalyst, Ponatinib, Portrazza, Pralatrexate, Prednisolone, Prednisone, Prelone,

Procarbazine, Procrit, Proleukin, Prolia, Prolifeprospan 20 with Carmustine Implant, Promacta, Provenge, Purinethol, Radium 223 Dichloride, Raloxifene, Ramucirumab, Rasuvo, Regorafenib, Revlimid, Rheumatrex, Ribociclib, Rituxan, Rituxan Hycela, Rituximab, Rituximab Hyalurodinase, Roferon-A (Interferon Alfa-2a), Romidepsin, Romiplostim, Rubex, Rubidomycin Hydrochloride, Rubraca, Rucaparib, Ruxolitinib, Rydapt, Sandostatin, Sandostatin LAR, Sargramostim, Siltuximab, Sipuleucel-T, Soliris, Solu-Cortef, Solu-Medrol, Somatuline, Sonidegib, Sorafenib, Sprycel, Sti-571, Stivarga, Streptozocin, SU11248, Sunitinib, Sutent, Sylvant, Synribo, Tafinlar, Tagrisso, Talimogene Laherparepvec, Tamoxifen, Tarceva, Targretin, Tassigna, Taxol, Taxotere, Tecentriq, Temodar, Temozolomide, Temsirolimus, Teniposide, Tespa, Thalidomide, Thalomid, TheraCys, Thioguanine, Thioguanine Tabloid, Thiophosphoamide, Thioplex, Thiotepa, Tice, Tisagenlecleucel, Toposar, Topotecan, Toremifene, Torisel, Tositumomab, Trabectedin, Trametinib, Trastuzumab, Treanda, Trelstar, Tretinoin, Trexall, Trifluridine/Tipiricil, Triptorelin pamoate, Trisenox, Tspa, T-VEC, Tykerb, Valrubicin, Valstar, Vandetanib, VCR, Vectibix, Velban, Velcade, Vemurafenib, Venclexta, Venetoclax, VePesid, Verzenio, Vesanoid, Viadur, Vidaza, Vinblastine, Vinblastine Sulfate, Vincasar Pfs, Vincristine, Vincristine Liposomal, Vinorelbine, Vinorelbine Tartrate, Vismodegib, Vlb, VM-26, Vorinostat, Votrient, VP-16, Vumon, Vyxeos, Xalkori Capsules, Xeloda, Xgeva, Xofigo, Xtandi, Yervoy, Yescarta, Yondelis, Zaltrap, Zanosar, Zarxio, Zejula, Zelboraf, Zevalin, Zinecard, Ziv-aflibercept, Zoladex, Zoledronic Acid, Zolinza, Zometa, Zydelig, Zykadia, Zytiga, or any combination thereof.

[00149] The terms “effective amount” and “therapeutically effective amount” of an agent or compound are used in the broadest sense to refer to a nontoxic but sufficient amount of an active agent or compound to provide the desired effect or benefit.

[00150] The term “benefit” is used in the broadest sense and refers to any desirable effect and specifically includes clinical benefit as defined herein. Clinical benefit can be measured by assessing various endpoints, e.g., inhibition, to some extent, of disease progression, including slowing down and complete arrest; reduction in the number of disease episodes and/or symptoms; reduction in lesion size; inhibition (i.e., reduction, slowing down or complete stopping) of disease cell infiltration into adjacent peripheral organs and/or tissues; inhibition (i.e., reduction, slowing down or complete stopping) of disease spread; decrease of auto-immune response, which may, but does not have to, result in the regression or ablation of the disease

lesion; relief, to some extent, of one or more symptoms associated with the disorder; increase in the length of disease-free presentation following treatment, e.g., progression-free survival; increased overall survival; higher response rate; and/or decreased mortality at a given point of time following treatment.

[00151] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Included in this definition are benign and malignant cancers. Examples of cancer include but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers include adrenocortical carcinoma, bladder urothelial carcinoma, breast invasive carcinoma, cervical squamous cell carcinoma, endocervical adenocarcinoma, cholangiocarcinoma, colon adenocarcinoma, lymphoid neoplasm diffuse large B-cell lymphoma, esophageal carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, acute myeloid leukemia, brain lower grade glioma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, mesothelioma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma, paraganglioma, prostate adenocarcinoma, rectum adenocarcinoma, sarcoma, skin cutaneous melanoma, stomach adenocarcinoma, testicular germ cell tumors, thyroid carcinoma, thymoma, uterine carcinosarcoma, uveal melanoma. Other examples include breast cancer, lung cancer, lymphoma, melanoma, liver cancer, colorectal cancer, ovarian cancer, bladder cancer, renal cancer or gastric cancer. Further examples of cancer include neuroendocrine cancer, non-small cell lung cancer (NSCLC), small cell lung cancer, thyroid cancer, endometrial cancer, biliary cancer, esophageal cancer, anal cancer, salivary, cancer, vulvar cancer or cervical cancer.

[00152] The term "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The terms "cancer," "cancerous," "cell proliferative disorder," "proliferative disorder" and "tumor" are not mutually exclusive as referred to herein.

[00153] As used herein, the term "about" when used in conjunction with numerical values and/or ranges generally refers to those numerical values and/or ranges near to a recited numerical value and/or range. In some instances, the term "about" can mean within $\pm 10\%$ of the recited value. For

example, in some instances, “about 100 [units]” can mean within $\pm 10\%$ of 100 (e.g., from 90 to 110).

Examples

[00154] The disclosure is further illustrated by the following examples, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure and/or scope of the appended claims.

[00155] EXAMPLE 1. Derivation of a 38-marker gene panel

[00156] Two microarray datasets (E-GEOD-46691 and E-GEOD-46602, Table 2) were used as derivation cohorts ($n = 595$ samples). Random Forest algorithm was applied to each dataset to identify the most important sets of transcripts that are predictive of phenotypic diversity within each set. Each microarray dataset comprised 22,011 and 54,675 probe sets, respectively. The Random Forest-driven marker selection algorithm identified $n = 129$ transcripts as predictive of disease progression across the two datasets. Of these $n = 30$ exhibited high Predictive Importance scores in both datasets (FIGs. 1A-1B). Three microarray datasets (E-GEOD-62116, E-GEOD-62667, E-GEOD-72220, Table 2) were then used to validate the putative Prostate Cancer signature. For each transcript across the validation cohort ($n = 564$ samples) Predictive Importance and Kruskal-Wallis p-values were obtained and averaged across the three datasets (FIG. 2). Examination of the literature identified the ARv7 variant, the ERG-TRMS22 fusion gene and AR1/AR2 signaling as additional gene sets to include and evaluate.

[00157] Evaluation of transcripts in a preliminary dataset of blood samples from prostate cancer ($n = 20$) and matched normal blood ($n = 20$) confirmed expression of the 37 genes as markers of PCA (Table 3). These genes were demonstrated to be highly expressed in PCA tumor tissue compared to normal prostate and this could be used to effectively differentiate tumor from control (FIG. 3). They also differentiated seven different PCA cell lines, 22Rv1 and E006AA-hT (localized); VCaP; PC-3; LNCaP; DU145 and MDA PCa2b (all metastatic) from two normal prostate epithelial lines: PWR-1E and RWPE-1 (FIG. 4). These data demonstrate the candidate

target transcripts are produced by neoplastic transformed prostate epithelial cell and are detectable in blood.

[00158] An artificial intelligence model of prostate cancer disease was built using normalized gene expression of these 37 markers in whole blood from Controls ($n=100$), and PCA ($n=21$) samples. The dataset was randomly split into training and testing partitions for model creation and validation respectively. Twelve algorithms were evaluated (XGB, RF, glmnet, cforest, CART, treebag, knn, nnet, SVM-radial, SVM-linear, NB and mlp). The top performing algorithm (XGB – “gradient boosting”) best predicted the training data. In the test set, XGB produced probability scores that predicted the sample. Each probability score reflects the “certainty” of an algorithm that an unknown sample belongs to either “Control” or “PCA” class. For example, an unknown sample S1 can have the following probability vector [Control = 20%, PCA = 80%]. This sample would be considered a PCA sample.

[00159] Table 2. Summary of all public microarray datasets that were used to derived Prostate Cancer specific gene signature.

Accession Number	Sample Count	Dataset Description
E-GEOD-46691	545	Gleason Score 5 - 10
		Score 5 (n=3)
		Score 6 (n = 60)
		Score 7 (n = 271)
		Score 8 (n = 68)
		Score 9 (n = 134)
E-GEOD-46602	50	Score 10 (n = 9)
		Benign Prostate Glands (n = 14) Prostate Tumor (n = 36)
E-GEOD-62116	235	Gleason Score 5 - 10
		Score 5 (n = 1)
		Score 6 (n = 17)
		Score 7 (n = 119)
		Score 8 (n = 39)
		Score 9 (n = 58)
E-GEOD-62667	182	Score 10 (n = 1)
		Gleason Score 6 - 9
		Score 6 (n = 25)
		Score 7 (n = 112)
		Score 8 (n = 23)
E-GEOD-72220	147	Score 9 (n = 22)
		Normal Tissue (n = 90) Tumor Tissue (n = 57)

[00160] Table 3: 37 PCA marker gene panel (not including the housekeeping gene)

Prostate Cancer Biomarker Gene		NCBI Chromosome Location	UniGene ID	RefSeq	Exon Boundary	Assay Location	Amplicon Length
Symbol	Name						
AAMP	Angio-associated migratory cell protein	Chr.2: 218264129 - 218270209	Hs.83347	NM_001087.4	2 - 3	395	58
ANO7	Anoctamin 7	Chr.2: 241188509 - 241239602	Hs.163909	NM_001001891.3	5 - 6	686	60
AR	androgen receptor	Chr.X: 67544032 - 67730619	Hs.76704	NM_000044.3	2 - 3	2882	144
AR-V7	androgen receptor transcript variant 7	AR truncation					73
C16orf89	chromosome 16 open reading frame 89	Chr.16: 5042772 - 5066145	Hs.11782	NM_001098514.2	5 - 6	995	75
CHTOP	chromatin target of PRMT1	Chr.1: 153633982 - 153646306	Hs.611057	NM_001206612.1	2 - 3	445	66
COL1A1	collagen type I alpha 1	Chr.17: 50184096 - 50201648	Hs.172928	NM_000088.3	1 - 2	230	66
EDC4	enhancer of mRNA decapping 4	Chr.16: 67873023 - 67884514	Hs.75682	NM_014329.4	27 - 28	4089	72
FGFR2	fibroblast growth factor receptor 2	Chr.10: 121478330 - 121598656	Hs.533683	NM_000141.4	13 - 14	2516	74
FXYD7	FXYD domain containing ion transport regulator 7	Chr.19: 35143250 - 35154302	Hs.134729	NM_022006.1	5 - 6	300	89
FYCO1	FYVE and coiled-coil domain containing 1	Chr.3: 45917899 - 45995824	Hs.200227	NM_024513.3	11 - 12	3651	59
HNRNP U	heterogeneous nuclear ribonucleoprotein U	Chr.1: 244842123 - 244864720	Hs.106212	NM_004501.3	8 - 9	1773	79
HPN	hepsin	Chr.19: 35040506 - 35066573	Hs.182385	NM_002151.2	10 - 11	1052	89
KRT15	keratin 15	Chr.17: 41513745 - 41522413	Hs.654570	NM_002275.3	7 - 8	1461	81

KRT23	keratin 23	Chr.17: 40922696 - 40937643	Hs.9029	NM_0012 82433.1	5 - 6	1045	90
MAN2B 2	mannosidase alpha class 2B member 2	Chr.4: 6575174 - 6622403	Hs.188464	NM_0012 92038.1	5 - 6	716	55
MAX	MYC associated factor X	Chr.14: 65006101 - 65102695	Hs.285354	NM_0013 20415.1	3 - 4	377	61
MRPS2 5	mitochondrial ribosomal protein S25	Chr.3: 15042251 - 15065337	Hs.657764	NM_0224 97.4	2 - 3	380	80
NDUFS 2	NADH:ubiquinone oxidoreductase core subunit S2	Chr.1: 161197377 - 161214395	Hs.173611	NM_0011 66159.1	3 - 4	632	80
PPARG CIA	PPARG coactivator 1 alpha	Chr.4: 23792021 - 24472975	Hs.527078	NM_0132 61.3	7 - 8	998	83
PPRC1	peroxisome proliferator- activated receptor gamma, coactivator- related 1	Chr.10: 102132994 - 102150333	Hs.533551	NM_0012 88727.1	1 - 2	224	55
RAD23 A	RAD23 homolog A, nucleotide excision repair protein	Chr.19: 12945814 - 12953643	Hs.643267	NM_0012 70362.1	1 - 2	203	74
REPIN1	replication initiator 1	Chr.7: 150368228 - 150374044	Hs.647086	NM_0134 00.3	3 - 4	474	70
SDR39 U1	short chain dehydrogenase/redu ctase family 39U member 1	Chr.14: 24439766 - 24442905	Hs.643552	NM_0201 95.2	4 - 5	358	91
SETBP1	SET binding protein 1	Chr.18: 44680173 - 45068510	Hs.435458	NM_0011 30110.1	2 - 3	882	70
SLC14 A1	solute carrier family 14 member 1 (Kidd blood group)	Chr.18: 45724123 - 45752520	Hs.101307	NM_0011 28588.3	7 - 8	1057	80
SLC18 A2	solute carrier family 18 member A2	Chr.10: 117241073 - 117279430	Hs.596992	NM_0030 54.4	15 - 16	1605	145
SMC4	structural maintenance of chromosomes 4	Chr.3: 160399304 - 160434962	Hs.58992	NM_0010 02800.2	5 - 6	1134	91
SPARC	secreted protein acidic and cysteine rich	Chr.5: 151661096 - 151687054	Hs.111779	NM_0013 09443.1	6 - 7	650	76

SQLE	squalene epoxidase	Chr.8: 124998478 - 125022283	Hs.71465	NM_0031 29.3	9 - 10	2368	109
STRIP1	striatin interacting protein 1	Chr.1: 110031577 - 110054641	Hs.584996	NM_0012 70768.1	12 - 13	1303	64
STX12	syntaxin 12	Chr.1: 27773183 - 27824452	Hs.523855	NM_1774 24.2	1 - 2	248	70
TMPRS S2_1	TMPRSS2-ERG fusion	TMPRSS2 exon 1 and ERG exon 4 fusion		DQ20477 2.1		49	106
TMPRS S2_2	TMPRSS2-ERG fusion			OM_TMP RSS2- ERG_T2E 4_COSF2 8.0		58	88
TRIM29	tripartite motif containing 29	Chr.11: 120111286 - 120138179	Hs.504115	NM_0121 01.3	2 - 3	1025	62
UNC45 A	unc-45 myosin chaperone A	Chr.15: 90929980 - 90954093	Hs.389461	NM_0010 39675.1	20 - 21	3095	62
XPC	XPC complex subunit, DNA damage recognition and repair factor	Chr.3: 14145147 - 14178672	Hs.475538	NM_0046 28.4	2 - 3	403	104

[00161] EXAMPLE 2. Clinical Utility

[00162] The ProstaTest scores were significantly ($p < 0.001$) elevated in PCA ($63 \pm 19\%$) compared to men with benign prostate hyperplasia ($17 \pm 13\%$) and controls ($8 \pm 9\%$) (FIG. 5). There was no difference in levels between controls and hyperplasia. The data (receiver operator curve analysis and metrics) for the utility of the test to differentiate patients with prostate cancer ($n=125$) from controls ($n=201$) in the validation is included in FIG. 6. The score exhibited an area under the curve (AUROC) of 0.97. The metrics are: sensitivity: 92% and specificity: 99% (FIG. 7). The Youden index J is 0.94 and the Z-statistic for differentiating controls was 38.9.

[00163] A Probit-risk assessment plot identified a ProstaTest score >30 was 50% accurate for predicting PCA in a blood sample (FIG. 8). This was increased to 60% at a ProstaTest score ≥ 32 and was $>80\%$ at a score >34 . The tool can therefore accurately differentiate between controls and prostate cancer disease.

[00164] The ProstaTest scores were significantly ($p < 0.001$) elevated in high grade (Gleason score ≥ 7 : $70 \pm 19\%$) compared to low grade (Gleason 5+6) PCA ($41 \pm 7\%$). The data (receiver operator

cure analysis and metrics) for the utility of the test to differentiate high from low grade scores is included in FIG. 9. The score exhibited an area under the curve (AUROC) of 0.98. The metrics are: sensitivity: 100% and specificity: 88%. The Youden index J is 0.87. PSA levels, in comparison, exhibited an AUROC of 64%. The sensitivity and specificity were 54% and 87% respectively. The Z-statistic for differentiating the ProstaTest from PSA was 3.05 ($p=0.002$).

[00165] Specific evaluation of a PCA cohort before and after surgery identified that complete removal of a tumor and no evidence of disease was associated with a significant decrease ($p<0.0001$) in the ProstaTest (FIG. 10). Levels were not significantly different to controls or those with prostate hyperplasia. Evaluation of separate cohort identified that patients who underwent and responded to therapy exhibited a significant lower score ($p<0.001$) than those diagnosed with disease (FIG. 11). Therapies included hormone and chemotherapy. The tool can therefore accurately identify treatment response in prostate cancer disease.

[00166] References:

[00167] Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer*. 2013; 49: 1374-403. doi: 10.016/j.ejca.2012.12.027. Epub 3 Feb 26.

[00168] Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, Ward EM. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. *JAMA*. 2015; 314: 2054-61. doi: 10.1001/jama.2015.14905.

[00169] Nam RK, Satkunavisam R, Chin JL, Izawa J, Trachtenberg J, Rendon R, Bell D, Singal R, Sherman C, Sugar L, Chagin K, Kattan WM. Next-generation prostate cancer risk calculator for primary care physicians. *Can Urol Assoc J*. 2017; 1.

[00170] The Molecular Taxonomy of Primary Prostate Cancer. *Cell*. 2015; 163: 1011-25. doi: 10.6/j.cell.2015.10.025.

[00171] Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. *Lancet Oncol*. 2014; 15: 1521-32. doi: 10.016/S470-2045(14)71021-6. Epub 2014 Nov 13.

[00172] Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, et al. Exome sequencing

identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. *Nat Genet.* 2012; 44: 685-9. doi: 10.1038/ng.2279.

[00173] Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science.* 2005; 310: 644-8. doi: 10.1126/science.1117679.

[00174] Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. *Cancer Epidemiol Biomarkers Prev.* 2012; 21: 1497-509. doi: 10.158/055-9965.EPI-12-0042. Epub 2012 Jun 26.

[00175] Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. *JAMA Oncol.* 2015; 1: 582-91. doi: 10.1001/jamaoncol.2015.1341.

[00176] Velonas VM, Woo HH, dos Remedios CG, Assinder SJ. Current status of biomarkers for prostate cancer. *Int J Mol Sci.* 2013; 14: 11034-60. doi: 10.3390/ijms140611034.

[00177] Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Maattanen L, Lilja H, Denis LJ, Recker F, Paez A, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. *Lancet.* 2014; 384: 2027-35. doi: 10.1016/S0140-6736(14)60525-0. Epub 2014 Aug 6.

[00178] Schroder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, Roobol MJ. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. *Eur Urol.* 2008; 53: 468-77. doi: 10.1016/j.eururo.2007.10.047. Epub Nov 5.

[00179] Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. *J Urol.* 2005; 173: 1938-42. doi: 10.097/01.ju.0000158155.33890.e7.

[00180] Troyer DA, Lucia MS, de Bruine AP, Mendez-Meza R, Baldewijns MM, Dunscomb N, Van Engeland M, McAskill T, Bierau K, Louwagie J, Bigley JW. Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent

positive biopsies. *Cancer Epidemiol Biomarkers Prev.* 2009; 18: 2717-22. doi: 10.1158/055-9965.EPI-09-0068. Epub 2009 Sep 15.

[00181] Van Neste L, Partin AW, Stewart GD, Epstein JI, Harrison DJ, Van Criekinge W. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. *Prostate.* 2016; 76: 1078-87. doi: 10.02/pros.23191. Epub 2016 Apr 28.

[00182] Stewart GD, Van Neste L, Delvenne P, Delree P, Delga A, McNeill SA, O'Donnell M, Clark J, Van Criekinge W, Bigley J, Harrison DJ. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. *J Urol.* 2013; 189: 1110-6. doi: 10.016/j.juro.2012.08.219. Epub Oct 8.

[00183] Day JR, Jost M, Reynolds MA, Groskopf J, Rittenhouse H. PCA3: from basic molecular science to the clinical lab. *Cancer Lett.* 2011; 301: 1-6. doi: 10.1016/j.canlet.2010.10.019. Epub Nov 18.

[00184] Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, Moller H, Scardino P, Warren JD, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. *Lancet Oncol.* 2011; 12: 245-55. doi: 10.1016/S1473-0245(10)70295-3.

[00185] Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. *PLoS One.* 2013; 8: e66855. doi: 10.1371/journal.pone.0066855. Print 2013.

[00186] Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. *J Urol.* 2013; 190: 2047-53. doi: 10.1016/j.juro.2013.06.017. Epub Jun 11.

[00187] Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, Watson D, Falzarano SM, Magi-Galluzzi C, Klein EA, Quale C. Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. *BMC Genomics.* 2013; 14:690. doi: 10.1186/1471-2164-14-690.

[00188] Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, et al. A 17-gene

assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. *Eur Urol.* 2014; 66: 550-60. doi: 10.1016/j.eururo.2014.05.004. Epub May 16.

[00189] Zhao SG, Evans JR, Kothari V, Sun G, Larm A, Mondine V, Schaeffer EM, Ross AE, Klein EA, Den RB, Dicker AP, Karnes RJ, Erho N, et al. The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. *Clin Cancer Res.* 2016; 22: 1777-86. doi: 10.158/078-0432.CCR-15-1250. Epub 2015 Dec 2.

[00190] Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, et al. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. *Lancet Oncol.* 2016; 17: 1612-20. doi: 10.016/S470-2045(16)30491-0. Epub 2016 Oct 12.

[00191] Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. *Lancet Oncol.* 2012; 13: 1105-13. doi: 10.016/S470-2045(12)70263-2. Epub 2012 Oct 9.

[00192] Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G, Fleisher M, Reid AH, Castro E, Sandhu SK, Barwell L, Oommen NB, Carreira S, et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. *Lancet Oncol.* 2012; 13: 1114-24. doi: 10.016/S470-2045(12)70372-8. Epub 2012 Oct 9.

[00193] Danila DC, Anand A, Schultz N, Heller G, Wan M, Sung CC, Dai C, Khanin R, Fleisher M, Lilja H, Scher HI. Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. *Eur Urol.* 2014; 65: 1191-7. doi: 10.016/j.eururo.2013.07.006. Epub Jul 26.

[00194] Wang L, Gong Y, Chippada-Venkata U, Heck MM, Retz M, Nawroth R, Galsky M, Tsao CK, Schadt E, de Bono J, Olmos D, Zhu J, Oh WK. A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. *BMC Med.* 2015; 13:201. doi: 10.1186/s12916-015-0442-0.

[00195] Kohli M, Young CY, Tindall DJ, Nandy D, McKenzie KM, Bevan GH, Donkena KV. Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in

castration-resistant prostate cancer. *Onco Targets Ther.* 2015; 8:1915-22.: 10.2147/OTT.S86637. eCollection 2015.

[00196] Diaz-Uriarte R, Alvarez de Andres S. Gene selection and classification of microarray data using random forest. *BMC Bioinformatics.* 2006; 7: 3. doi: 10.1186/1471-2105-7-3.

Equivalents

[00197] While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

Claims:

1. A method for detecting a prostate cancer in a subject in need thereof, the method comprising:

determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYP7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SOLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene;

normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYP7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SOLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYP7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SOLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*;

inputting each normalized expression level into an algorithm to generate a score;

comparing the score with a first predetermined cutoff value; and

identifying the presence of a prostate cancer in the subject when the score is equal to or greater than the first predetermined cutoff value or identifying the absence of a prostate cancer in the subject when the score is less than the first predetermined cutoff value.

2. A method for determining whether a prostate cancer in a subject is stable or progressive, the method comprising:

determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYP7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLP*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene;

normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYP7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLP*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYP7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLP*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*;

inputting each normalized expression level into an algorithm to generate a score; comparing the score with a first predetermined cutoff value; and

identifying that the prostate cancer is progressive when the score is equal to or greater than the first predetermined cutoff value or identifying that the prostate cancer is stable when the score is less than the first predetermined cutoff value.

3. A method for determining whether a prostate cancer in a subject is low or high grade, the method comprising:

determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYP7*,

FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, XPC, and a housekeeping gene;

normalizing the expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A*, and *XPC*;

inputting each normalized expression level into an algorithm to generate a score; comparing the score with a first predetermined cutoff value; and

identifying that the prostate cancer is high grade when the score is equal to or greater than the first predetermined cutoff value or identifying that the prostate cancer is low grade when the score is less than the first predetermined cutoff value.

4. A method for determining the completeness of surgery in a subject having a prostate cancer, the method comprising:

determining the expression level of at least 38 biomarkers from a test sample from the subject after the surgery by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the 38 biomarkers comprise *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, XPC*, and a housekeeping gene;

normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYP7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYP7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*;

inputting each normalized expression level into an algorithm to generate a score;
comparing the score with a first predetermined cutoff value; and

identifying that the prostate cancer is not completely removed when the score is equal to or greater than the first predetermined cutoff value or identifying that the prostate cancer is completely removed when the score is less than the first predetermined cutoff value.

5. A method for differentiating benign prostate hyperplasia from a prostate cancer in a subject having an enlarged prostate, the method comprising:

determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYP7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene;

normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXYP7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*,

TMPRSS2_1, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXVD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*;

inputting each normalized expression level into an algorithm to generate a score;
comparing the score with a first predetermined cutoff value; and

identifying the presence of a prostate cancer in the subject when the score is equal to or greater than the first predetermined cutoff value or identifying the presence of benign prostate hyperplasia in the subject when the score is less than the first predetermined cutoff value.

6. A method for evaluating the response of a subject having a prostate cancer to a first therapy, the method comprising:

(1) at a first time point:

(a) determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXVD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene;
(b) normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXVD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*,

COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC;

(c) inputting each normalized expression level into an algorithm to generate a first score;

(2) at a second time point, wherein the second time point is after the first time point and after the administration of the first therapy to the subject:

(d) determining the expression level of the at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers;

(e) normalizing the expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP, ANO7, AR, AR-V7, C16orf89, CHTOP, COL1A1, EDC4, FGFR2, FXYD7, FYCO1, HNRNPU, HPN, KRT15, KRT23, MAN2B2, MAX, MRPS25, NDUFS2, PPARGC1A, PPRC1, RAD23A, REPIN1, SDR39U1, SETBP1, SLC14A1, SLC18A2, SMC4, SPARC, SQLE, STRIP1, STX12, TMPRSS2_1, TMPRSS2_2, TRIM29, UNC45A, and XPC*;

(f) inputting each normalized expression level into an algorithm to generate a second score;

(3) comparing the first score with the second score; and

(4) identifying the subject as responsive to the first therapy when the second score is significantly decreased as compared to the first score or identifying the subject as not responsive to the first therapy when the second score is not significantly decreased as compared to the first score.

7. A method for treating a prostate cancer in a subject in need thereof, the method comprising:

determining the expression level of at least 38 biomarkers from a test sample from the subject by contacting the test sample with a plurality of agents specific to detect the expression of the at least 38 biomarkers, wherein the at least 38 biomarkers comprise *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, *XPC*, and a housekeeping gene;

normalizing the expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC* to the expression level of the housekeeping gene, thereby obtaining a normalized expression level of each of *AAMP*, *ANO7*, *AR*, *AR-V7*, *C16orf89*, *CHTOP*, *COL1A1*, *EDC4*, *FGFR2*, *FXD7*, *FYCO1*, *HNRNPU*, *HPN*, *KRT15*, *KRT23*, *MAN2B2*, *MAX*, *MRPS25*, *NDUFS2*, *PPARGC1A*, *PPRC1*, *RAD23A*, *REPIN1*, *SDR39U1*, *SETBP1*, *SLC14A1*, *SLC18A2*, *SMC4*, *SPARC*, *SQLE*, *STRIP1*, *STX12*, *TMPRSS2_1*, *TMPRSS2_2*, *TRIM29*, *UNC45A*, and *XPC*;

inputting each normalized expression level into an algorithm to generate a score;

comparing the score with a first predetermined cutoff value; and

administering at least a first therapy to the subject when the score is equal to or greater than the first predetermined cutoff value or identifies the absence of a prostate cancer in the subject when the score is less than the first predetermined cutoff value.

8. The method of claim 1, wherein the housekeeping gene is selected from the group consisting of *ALG9*, *SEPN*, *YWHAQ*, *VPS37A*, *PRRC2B*, *DOPEY2*, *NDUFB11*, *ND4*, *MRPL19*, *PSMC4*, *SF3A1*, *PUM1*, *ACTB*, *GAPD*, *GUSB*, *RPLP0*, *TFRC*, *MORF4L1*, *18S*, *PPIA*, *PGK1*, *RPL13A*, *B2M*, *YWHAZ*, *SDHA*, *HPRT1*, *TOX4* and *TPT1*.

9. The method of claim 8, wherein the housekeeping gene is *TOX4*.
10. The method any of claims 1-5 or 7, wherein the first predetermined cutoff value is at least 33% on a scale of 0-100%.
11. The method of claim 10, wherein the first predetermined cutoff value is at least 50% on a scale of 0 to 100%.
12. The method of any of claims 1-7, having a sensitivity of at least 92%.
13. The method of any of claims 1-7, having a specificity of at least 95%.
14. The method any of claims 1-13, wherein at least one of the at least 38 biomarkers is RNA, cDNA, or protein.
15. The method of claim 14, wherein when the biomarker is RNA, the RNA is reverse transcribed to produce cDNA, and the produced cDNA expression level is detected.
16. The method of claim 14, wherein the expression level of the biomarker is detected by forming a complex between the biomarker and a labeled probe or primer.
17. The method of any of claims 1-16, wherein the first predetermined cutoff value is derived from a plurality of reference samples obtained from subjects not having or not diagnosed with a neoplastic disease.
18. The method of claim 17, wherein the neoplastic disease is prostate cancer.
19. The method of claim 1-16, wherein the test sample is blood, serum, plasma, or neoplastic tissue.

20. The method of claim 17, wherein each reference sample is blood, serum, plasma, or non-neoplastic tissue.
21. The method of claim 1-5, further comprising treating the subject identified as having a prostate cancer by administering at least one therapy, wherein the at least one therapy comprises active surveillance, surgery, radiation therapy, cryotherapy, hormone therapy, chemotherapy, vaccine treatment, bone-directed treatment, or a combination thereof.
22. The method of claim 21, wherein when the at least one therapy comprises hormone therapy, the hormone therapy comprises androgen suppression therapy.
23. The method of claim 21, wherein when the at least one therapy comprises chemotherapy, the chemotherapy comprises docetaxel, cabazitaxel, mitoxantrone, estramustine, or a combination thereof.
24. The method of claim 21, wherein when the at least one therapy comprises vaccine treatment, the vaccine treatment comprises Sipuleucel-T.
25. The method of claim 21, wherein when the at least one therapy comprises bone-directed treatment, the bone-directed treatment comprises a bisphosphonate, denosumab, a corticosteroid, or a combination thereof.
26. The method of any of claims 1-25, wherein the algorithm is XGB, RF, glmnet, cforest, CART, treebag, knn, nnet, SVM-radial, SVM-linear, NB, or mlp.
27. The method of claim 26, wherein the algorithm is XGB.
28. The method of claim 6, wherein the first time point is prior to the administration of the first therapy to the subject.

29. The method of claim 6, wherein the first time point is after the administration of the first therapy to the subject.
30. The method of any one of claims 6, wherein the second score is significantly decreased as compared to the first score when the second score is at least 25% less than the first score.
31. The method of any of claims 6 or 28-30, further comprising, continuing to administer the first therapy to the subject when the second score is significantly decreased as compared to the first score.
32. The method of any of claims 6 or 28-30, further comprising, discontinuing administration of the first therapy to the subject when the second score is not significantly decreased as compared to the first score.
33. The method of any of claims 6, 30 or 32, further comprising administering a second therapy to the subject when the second score is not significantly decreased as compared to the first score.